A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
provide for the regulation of in vitro clinical tests, and 
for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE; TABLE OF CONTENTS. 
3
(a) SHORT TITLE.—This Act may be cited as the 
4
‘‘Verifying Accurate Leading-edge IVCT Development Act 
5
of 2021’’ or the ‘‘VALID Act of 2021’’. 
6
(b) TABLE OF CONTENTS.—The table of contents of 
7
this Act is as follows: 
8
Sec. 1. Short title; table of contents. 
Sec. 2. Definitions. 
Sec. 3. Regulation of in vitro clinical tests. 
02:14 Jul 08, 2021
H4128
2 
•HR 4128 IH
‘‘SUBCHAPTER J—IN VITRO CLINICAL TESTS 
‘‘Sec. 587. Definitions. 
‘‘Sec. 587A. Applicability. 
‘‘Sec. 587B. Premarket review. 
‘‘Sec. 587C. Breakthrough in vitro clinical tests. 
‘‘Sec. 587D. Technology certification. 
‘‘Sec. 587E. Mitigating measures. 
‘‘Sec. 587F. Regulatory pathway redesignation. 
‘‘Sec. 587G. Advisory committees. 
‘‘Sec. 587H. Request for informal feedback. 
‘‘Sec. 587I. Registration and listing. 
‘‘Sec. 587J. Test design and quality requirements. 
‘‘Sec. 587K. Labeling requirements. 
‘‘Sec. 587L. Adverse event reporting. 
‘‘Sec. 587M. Corrections and removals. 
‘‘Sec. 587N. Restricted in vitro clinical tests. 
‘‘Sec. 587O. Appeals. 
‘‘Sec. 587P. Accredited persons. 
‘‘Sec. 587Q. Recognized standards. 
‘‘Sec. 587R. Investigational use. 
‘‘Sec. 587S. Collaborative communities for in vitro clinical tests. 
‘‘Sec. 587T. Comprehensive test information system. 
‘‘Sec. 587U. Preemption. 
‘‘Sec. 587V. Adulteration. 
‘‘Sec. 587W. Misbranding. 
‘‘Sec. 587X. Postmarket surveillance. 
‘‘Sec. 587Y. Electronic format for submissions. 
‘‘Sec. 587Z. Postmarket remedies. 
Sec. 4. Enforcement and other provisions. 
Sec. 5. Transition. 
Sec. 6. Emergency use authorization. 
Sec. 7. Antimicrobial susceptibility tests. 
Sec. 8. Combination products. 
Sec. 9. Resources. 
SEC. 2. DEFINITIONS. 
1
(a) IN GENERAL.—Section 201 of the Federal Food, 
2
Drug, and Cosmetic Act (21 U.S.C. 321) is amended— 
3
(1) by adding at the end the following: 
4
‘‘(ss)(1) The term ‘in vitro clinical test’— 
5
‘‘(A) means a test intended by its developer (as 
6
defined in section 587) to be used in the collection, 
7
preparation, analysis, or in vitro clinical examination 
8
02:14 Jul 08, 2021
H4128
3 
•HR 4128 IH
of specimens taken or derived from the human body 
1
for the purpose of— 
2
‘‘(i) identifying or diagnosing a disease or 
3
condition; 
4
‘‘(ii) providing information for diagnosing, 
5
screening, measuring, detecting, predicting, 
6
prognosing, analyzing, or monitoring a disease 
7
or condition, including by making a determina-
8
tion of an individual’s state of health; or 
9
‘‘(iii) selecting, monitoring, or informing 
10
therapy or treatment for a disease or condition; 
11
and 
12
‘‘(B) may include— 
13
‘‘(i) a test protocol or laboratory test pro-
14
tocol; 
15
‘‘(ii) an instrument (as defined in section 
16
587(11)); 
17
‘‘(iii) a specimen receptacle; 
18
‘‘(iv) software, excluding software that is 
19
excluded by section 520(o) from the definition 
20
of a device under section 201(h), and excluding 
21
modifications that are exempt in accordance 
22
with section 587A(l)(2)(A); and 
23
‘‘(v) subject to subparagraph (2), a compo-
24
nent or part of a test, a test protocol, an instru-
25
02:14 Jul 08, 2021
H4128
4 
•HR 4128 IH
ment, an article, or software described in any of 
1
clauses (A) through (D) of such subparagraph, 
2
whether alone or in combination, including re-
3
agents, calibrators, and controls. 
4
‘‘(2) Notwithstanding subparagraph (1)(v), an article 
5
intended to be used as a component or part of an in vitro 
6
clinical test described in subparagraph (1) is excluded 
7
from the definition in subparagraph (1) if the article con-
8
sists of any of the following: 
9
‘‘(A) Blood, blood components, or human cells 
10
or tissues, from the time of acquisition, donation, or 
11
recovery of such article, including determination of 
12
donor eligibility, as applicable, until such time as the 
13
article is released as a component or part of an in 
14
vitro clinical test by the establishment that collected 
15
such article. 
16
‘‘(B) An article used for invasive sampling, a 
17
needle, or a lancet, except to the extent such article, 
18
needle, or lancet is an integral component of an arti-
19
cle for holding, storing, or transporting a specimen. 
20
‘‘(C) General purpose laboratory equipment, in-
21
cluding certain pre-analytical equipment, as deter-
22
mined by the Secretary. 
23
02:14 Jul 08, 2021
H4128
5 
•HR 4128 IH
‘‘(D) An article used solely for personal protec-
1
tion during the administering, conducting, or other-
2
wise performing of test activities.’’; 
3
(2) by adding at the end of section 201(g) the 
4
following: 
5
‘‘(3) The term ‘drug’ does not include an in vitro clin-
6
ical test.’’; and 
7
(3) in section 201(h), by striking ‘‘section 
8
520(o)’’ and inserting ‘‘section 520(o) or an in vitro 
9
clinical test’’. 
10
(b) EXCLUSION FROM DEFINITION OF BIOLOGICAL 
11
PRODUCT.—Section 351(i)(1) of the Public Health Serv-
12
ice Act (42 U.S.C. 262(i)(1)) is amended— 
13
(1) by striking ‘‘(1) The term ‘biological prod-
14
uct’ means’’ and inserting ‘‘(1)(A) The term ‘biologi-
15
cal product’ means’’; and 
16
(2) by adding at the end the following: 
17
‘‘(B) The term ‘biological product’ does not in-
18
clude an in vitro clinical test as defined in section 
19
201(ss) of the Federal Food, Drug, and Cosmetic 
20
Act.’’. 
21
(c) IN VITRO CLINICAL TEST DEFINITION.—In this 
22
Act, the term ‘‘in vitro clinical test’’ has the meaning given 
23
such term in section 201(ss) of the Federal Food, Drug, 
24
and Cosmetic Act, as added by subsection (a). 
25
02:14 Jul 08, 2021
H4128
6 
•HR 4128 IH
SEC. 3. REGULATION OF IN VITRO CLINICAL TESTS. 
1
The Federal Food, Drug, and Cosmetic Act (21 
2
U.S.C. 301 et seq.) is amended— 
3
(1) by amending the heading of chapter V to 
4
read as follows: ‘‘DRUGS, DEVICES, AND IN 
5
VITRO CLINICAL TESTS’’; and 
6
(2) by adding at the end of chapter V the fol-
7
lowing: 
8
‘‘Subchapter J—In Vitro Clinical Tests 
9
‘‘SEC. 587. DEFINITIONS. 
10
‘‘In this subchapter: 
11
‘‘(1) ANALYTICAL VALIDITY.— 
12
‘‘(A) The term ‘analytical validity’ means, 
13
with respect to an in vitro clinical test, the abil-
14
ity of the in vitro clinical test, to— 
15
‘‘(i) sufficiently identify, measure, de-
16
tect, calculate, or analyze one or more 
17
analytes, biomarkers, substances, or other 
18
targets intended to be identified, measured, 
19
detected, calculated, or analyzed by the 
20
test; or 
21
‘‘(ii) as applicable, assist in such iden-
22
tification, measurement, detection, calcula-
23
tion, or analysis. 
24
‘‘(B) For an article for taking or deriving 
25
specimens from the human body described in 
26
02:14 Jul 08, 2021
H4128
7 
•HR 4128 IH
section 201(ss)(1)(B)(iii), the term ‘analytical 
1
validity’ means that such article performs as in-
2
tended and will support the analytical validity 
3
of an in vitro clinical test with which it is used. 
4
‘‘(2) APPLICABLE STANDARD.—The term ‘ap-
5
plicable standard’, with respect to an in vitro clinical 
6
test, means a reasonable assurance of analytical and 
7
clinical validity, except that such term— 
8
‘‘(A) with respect to test instruments, 
9
means a reasonable assurance of analytical va-
10
lidity; and 
11
‘‘(B) with respect to articles for taking or 
12
deriving specimens from the human body for 
13
purposes described in clause (i) or (ii) of section 
14
201(ss)(1)(A) means a reasonable assurance of 
15
analytical validity and, where applicable, safety. 
16
‘‘(3) CLINICAL
USE.—The term ‘clinical use’ 
17
means the operation, application, or functioning of 
18
an in vitro clinical test in connection with human 
19
specimens, including patient, consumer, and donor 
20
specimens, for the purpose for which it is intended 
21
as described in section 201(ss)(1)(A). 
22
‘‘(4) CLINICAL
VALIDITY.—The term ‘clinical 
23
validity’ means the ability of an in vitro clinical test 
24
02:14 Jul 08, 2021
H4128
8 
•HR 4128 IH
to achieve the purpose for which it is intended as de-
1
scribed in section 201(ss)(1)(A). 
2
‘‘(5) CROSS-REFERENCED
TEST.—The term 
3
‘cross-referenced test’ means an in vitro clinical test 
4
that references in its labeling the name or intended 
5
use of another medical product that is not an in 
6
vitro clinical test. 
7
‘‘(6) DEVELOP.—The term ‘develop’, with re-
8
spect to an in vitro clinical test, means— 
9
‘‘(A) 
designing, 
validating, 
producing, 
10
manufacturing, remanufacturing, propagating, 
11
or assembling an in vitro clinical test; 
12
‘‘(B) importing an in vitro clinical test; 
13
‘‘(C) modifying an in vitro clinical test ini-
14
tially developed by a different person in a man-
15
ner that— 
16
‘‘(i) changes any of the listing ele-
17
ments that define indications for use speci-
18
fied 
in 
paragraph 
(10), 
performance 
19
claims, or, as applicable, the safety of such 
20
in vitro clinical test; or 
21
‘‘(ii) affects the analytical or clinical 
22
validity of the in vitro clinical test as in-
23
tended by the developer; or 
24
02:14 Jul 08, 2021
H4128
9 
•HR 4128 IH
‘‘(D) adopting, using, or disseminating for 
1
use as an in vitro clinical test an article not 
2
previously intended for clinical use. 
3
‘‘(7) DEVELOPER.—The term ‘developer’ means 
4
a person who engages in an activity described in 
5
paragraph (6) for clinical use. 
6
‘‘(8) FIRST-OF-A-KIND.—The term ‘first-of-a- 
7
kind’ means, with respect to an in vitro clinical test, 
8
a test that has an intended use and a combination 
9
of the elements specified in paragraph (10) that dif-
10
fer from the intended use and such elements of 
11
other in vitro clinical tests that already are legally 
12
available in the United States. 
13
‘‘(9) HIGH-RISK.— 
14
‘‘(A) IN
GENERAL.—Subject to subpara-
15
graph (B), the term ‘high-risk’, with respect to 
16
an in vitro clinical test or category of in vitro 
17
clinical tests— 
18
‘‘(i) means that, when used as in-
19
tended by the developer, an undetected in-
20
accurate result from such test or cat-
21
egory— 
22
‘‘(I) presents unreasonable risk 
23
for serious or irreversible harm or 
24
death to a patient or patients, or 
25
02:14 Jul 08, 2021
H4128
10 
•HR 4128 IH
would otherwise cause serious harm to 
1
the public health; or 
2
‘‘(II) is potentially likely to result 
3
in the absence, significant delay, or 
4
discontinuation of life-supporting or 
5
life-sustaining medical treatment; and 
6
‘‘(ii) shall account for the degree to 
7
which the technology for the intended use 
8
of an in vitro clinical test or tests is well- 
9
characterized and the criteria for perform-
10
ance of the test or tests are well-estab-
11
lished for the intended use, the clinical cir-
12
cumstances under which the in vitro clin-
13
ical test is used, and the availability of 
14
other tests (such as confirmatory or ad-
15
junctive tests). 
16
‘‘(B) EXCEPTION.—The term ‘high-risk’ 
17
does not include an in vitro clinical test de-
18
scribed in subparagraph (A) if— 
19
‘‘(i) mitigating measures are estab-
20
lished to prevent, detect, or otherwise miti-
21
gate the risk of inaccurate results as de-
22
scribed in subparagraph (A), or 
23
‘‘(ii) an exemption from the definition 
24
of such term applies under section 587A. 
25
02:14 Jul 08, 2021
H4128
11 
•HR 4128 IH
‘‘(10) INDICATIONS FOR USE.—The term ‘indi-
1
cations for use’ means one or more in vitro clinical 
2
tests that have all of the following notification ele-
3
ments in common: 
4
‘‘(A) Substance or substances measured by 
5
the in vitro clinical test, such as an analyte, 
6
protein, or pathogen. 
7
‘‘(B) Test method. 
8
‘‘(C) Test purpose or purposes, as de-
9
scribed in section 201(ss)(1)(A). 
10
‘‘(D) Diseases or conditions for which the 
11
in vitro clinical test is intended for use, includ-
12
ing intended patient populations. 
13
‘‘(E) Context of use, such as in a clinical 
14
laboratory, in a health care facility, prescription 
15
home use, over-the-counter use, or direct-to- 
16
consumer testing. 
17
‘‘(11) INSTRUMENT.—The term ‘instrument’ 
18
means an in vitro clinical test that is hardware in-
19
tended by the hardware’s developer to be used with 
20
one or more in vitro clinical tests to generate a clin-
21
ical test result, including software used to effectuate 
22
the hardware’s functionality. 
23
‘‘(12) INSTRUMENT FAMILY.—The term ‘instru-
24
ment family’ means more than one instrument for 
25
02:14 Jul 08, 2021
H4128
12 
•HR 4128 IH
which the developer demonstrates and documents, 
1
with respect to all such instruments, that all— 
2
‘‘(A) have the same basic architecture, de-
3
sign, and performance characteristics, such as 
4
tolerance limits and signal range; 
5
‘‘(B) have the same intended use or uses 
6
and function; 
7
‘‘(C) share the same measurement prin-
8
ciples, detection methods, and reaction condi-
9
tions; and 
10
‘‘(D) produce the same or similar analyt-
11
ical results from samples of the same specimen 
12
type or types. 
13
‘‘(13) LABORATORY
OPERATIONS.—The term 
14
‘laboratory operations’— 
15
‘‘(A) means the conduct of a laboratory ex-
16
amination or other laboratory procedure on ma-
17
terials derived from the human body, including 
18
the conduct of an in vitro clinical test and asso-
19
ciated activities within or under the oversight of 
20
a laboratory and not related to the design of an 
21
in vitro clinical test; and 
22
‘‘(B) includes— 
23
02:14 Jul 08, 2021
H4128
13 
•HR 4128 IH
‘‘(i) performing pre-analytical and 
1
post-analytical processes for an in vitro 
2
clinical test; 
3
‘‘(ii) conducting standard operating 
4
procedures; and 
5
‘‘(iii) preparing reagents or other test 
6
materials that do not meet the definition of 
7
a in vitro clinical test for clinical use under 
8
section 201(ss). 
9
‘‘(14) LOW-RISK.—The term ‘low-risk’, with re-
10
spect to an in vitro clinical test or category of in 
11
vitro clinical tests, means that an undetected inac-
12
curate result from such in vitro clinical test, or such 
13
category of in vitro clinical tests, when used as in-
14
tended by the developer— 
15
‘‘(A) would cause minimal or no harm, or 
16
minimal or no disability, or immediately revers-
17
ible harm, or would lead to only a remote risk 
18
of adverse patient impact or adverse public 
19
health impact, taking into account the degree to 
20
which the technology for the intended use of an 
21
in vitro clinical test or category of tests is well- 
22
characterized and the criteria for performance 
23
of the test or category of tests are well-estab-
24
lished for the intended use, the clinical cir-
25
02:14 Jul 08, 2021
H4128
14 
•HR 4128 IH
cumstances under which the in vitro clinical 
1
test or category of tests is used, and the avail-
2
ability of other tests (such as confirmatory or 
3
adjunctive tests); or 
4
‘‘(B) would cause a serious adverse health 
5
consequence, harm that is reversible, a delay in 
6
necessary treatment that is not life-supporting 
7
or life-sustaining, or would lead to a serious 
8
risk of adverse patient experience or adverse 
9
public health impact, but applied mitigating 
10
measures have the capacity to ensure the test 
11
meets the standard described in subparagraph 
12
(A). 
13
‘‘(15) 
MITIGATING
MEASURES.—The 
term 
14
‘mitigating measures’— 
15
‘‘(A) means controls, standards, or require-
16
ments that the Secretary determines, based on 
17
available evidence— 
18
‘‘(i) are necessary for an in vitro clin-
19
ical test, or a category of in vitro clinical 
20
tests, to meet the applicable standard; or 
21
‘‘(ii) to mitigate the risk of harm en-
22
suing from an inaccurate result such that 
23
a test or category of tests subject to such 
24
mitigating measures does not meet the def-
25
02:14 Jul 08, 2021
H4128
15 
•HR 4128 IH
inition of high risk, or such that a test or 
1
category of tests subject to such mitigating 
2
measures is low risk; and 
3
‘‘(B) includes, as appropriate, applicable 
4
requirements regarding labeling, conformance 
5
to performance standards or guidance, perform-
6
ance testing, submission of clinical data, adver-
7
tising, website posting of information, clinical 
8
studies, postmarket surveillance, user com-
9
prehension studies, training, and availability of 
10
confirmatory laboratory or clinical findings. 
11
‘‘(16) 
SPECIMEN
RECEPTACLE.—The 
term 
12
‘specimen receptacle’ means an in vitro clinical test 
13
specifically intended for the holding, storing, or 
14
transporting of specimens derived from the human 
15
body or for in vitro examination for purposes de-
16
scribed in clause (i) or (ii) of section 201(ss)(1)(A). 
17
‘‘(17) TECHNOLOGY.—The term ‘technology’— 
18
‘‘(A) means a developer’s grouping of in 
19
vitro clinical tests that do not significantly dif-
20
fer in control mechanisms, energy sources, or 
21
operating principals and for which design, de-
22
velopment, and manufacturing, including ana-
23
lytical and clinical validation as applicable, of 
24
02:14 Jul 08, 2021
H4128
16 
•HR 4128 IH
the tests would be addressed in a similar man-
1
ner or through similar procedures; and 
2
‘‘(B) may include clot detection, colori-
3
metric 
(non-immunoassay), 
electrochemical 
4
(non-immunoassay), 
enzymatic 
(non- 
5
immunoassay), flow cytometry, fluorometry 
6
(non-immunoassay), immunoassay, mass spec-
7
trometry or chromatography (such as HPLC), 
8
microbial culture, next generation sequencing 
9
(also known as ‘NGS’), nephlometric or turbi-
10
dimetric (non-immunoassay), singleplex or mul-
11
tiplex non-NGS nucleic acid analysis, single- 
12
based technology, spectroscopy, and any other 
13
technology, as the Secretary determines appro-
14
priate. 
15
‘‘(18) TEST.—The term ‘test’, unless otherwise 
16
provided, means an in vitro clinical test. 
17
‘‘(19) VALID SCIENTIFIC EVIDENCE.—The term 
18
‘valid scientific evidence’— 
19
‘‘(A) means, with respect to an in vitro 
20
clinical test, evidence— 
21
‘‘(i) that has been generated and eval-
22
uated by persons qualified by training or 
23
experience to do so, using procedures gen-
24
02:14 Jul 08, 2021
H4128
17 
•HR 4128 IH
erally accepted by other persons so quali-
1
fied; and 
2
‘‘(ii) from which it can be fairly and 
3
responsibly concluded by qualified experts 
4
whether the applicable standard has been 
5
met by the in vitro clinical test for its in-
6
tended use; and 
7
‘‘(B) may include evidence described in 
8
subparagraph (A) consisting of— 
9
‘‘(i) peer-reviewed literature; 
10
‘‘(ii) clinical guidelines; 
11
‘‘(iii) reports of significant human ex-
12
perience with an in vitro clinical test; 
13
‘‘(iv) bench studies; 
14
‘‘(v) case studies or histories; 
15
‘‘(vi) clinical data; 
16
‘‘(vii) consensus standards; 
17
‘‘(viii) reference standards; 
18
‘‘(ix) data registries; 
19
‘‘(x) postmarket data; 
20
‘‘(xi) real world data; 
21
‘‘(xii) clinical trials; and 
22
‘‘(xiii) data collected in countries 
23
other than the United States if such data 
24
are demonstrated to be adequate for the 
25
02:14 Jul 08, 2021
H4128
18 
•HR 4128 IH
purpose of making a regulatory determina-
1
tion under the applicable standard in the 
2
United States. 
3
‘‘(20) WELL-CHARACTERIZED.—The term ‘well- 
4
characterized’, with respect to an in vitro clinical 
5
test, means well-established and well-recognized by 
6
the scientific or clinical community, if adequately 
7
evidenced by one or more of the following: 
8
‘‘(A) Peer-reviewed literature. 
9
‘‘(B) Practice guidelines. 
10
‘‘(C) Consensus standards. 
11
‘‘(D) Recognized standards of care. 
12
‘‘(E) Technology in use for many years. 
13
‘‘(F) Scientific publication by multiple 
14
sites. 
15
‘‘(G) Adoption by the scientific or clinical 
16
community. 
17
‘‘(H) Real world data. 
18
‘‘SEC. 587A. APPLICABILITY. 
19
‘‘(a) IN GENERAL.— 
20
‘‘(1) APPLICABILITY OF THIS SUBCHAPTER.— 
21
‘‘(A) IN
GENERAL.—An in vitro clinical 
22
test shall be subject to the requirements of this 
23
subchapter, except as otherwise provided this 
24
subchapter. 
25
02:14 Jul 08, 2021
H4128
19 
•HR 4128 IH
‘‘(B) INTERSTATE
COMMERCE.—Any in 
1
vitro clinical test that is offered for clinical use 
2
in the United States is deemed to be introduced 
3
into interstate commerce for purposes of enforc-
4
ing the requirements of this Act. 
5
‘‘(C) NON-APPLICABLE
REQUIREMENT.— 
6
Subject to any exemption or exclusion in this 
7
section, an in vitro clinical test shall not be sub-
8
ject to any provision or requirement of this Act 
9
other than this subchapter unless such other 
10
provision or requirement— 
11
‘‘(i) applies expressly to in vitro clin-
12
ical tests; or 
13
‘‘(ii) describes the authority of the 
14
Secretary when regulating such in vitro 
15
clinical tests or subset of in vitro clinical 
16
tests, with respect to— 
17
‘‘(I) all articles regulated by the 
18
Secretary pursuant to this Act; or 
19
‘‘(II) a subset of such articles 
20
that includes in vitro clinical tests. 
21
‘‘(2) LABORATORIES AND BLOOD AND TISSUE 
22
ESTABLISHMENTS.— 
23
‘‘(A) RELATION TO LABORATORY CERTIFI-
24
CATION
PURSUANT
TO
SECTION
353
OF
THE 
25
02:14 Jul 08, 2021
H4128
20 
•HR 4128 IH
PHSA.—Nothing in this subchapter shall be 
1
construed to modify the authority of the Sec-
2
retary with respect to laboratories or clinical 
3
laboratories under section 353 of the Public 
4
Health Service Act. 
5
‘‘(B) AVOIDING DUPLICATION.—In imple-
6
menting this subchapter, the Secretary shall 
7
avoid issuing or enforcing regulations that are 
8
duplicative of regulations under section 353. 
9
‘‘(C) BLOOD
AND
TISSUE.—Nothing in 
10
this subchapter shall be construed to modify the 
11
authority of the Secretary with respect to lab-
12
oratories, establishments, or other facilities to 
13
the extent they are engaged in the propagation, 
14
manufacture, or preparation, including filling, 
15
testing, labeling, packaging, and storage, of 
16
blood, blood components, human cells, tissues, 
17
or tissue products under this Act or section 351 
18
or 361 of the Public Health Service Act. 
19
‘‘(3) PRACTICE OF MEDICINE.— 
20
‘‘(A) IN GENERAL.—Nothing in this sub-
21
chapter shall be construed to limit or interfere 
22
with the authority of a health care practitioner 
23
to prescribe or administer any legally marketed 
24
in vitro clinical test for any condition or disease 
25
02:14 Jul 08, 2021
H4128
21 
•HR 4128 IH
within a health care practitioner-patient rela-
1
tionship pursuant to applicable Federal or State 
2
law. 
3
‘‘(B) RULES OF CONSTRUCTION.— 
4
‘‘(i) SALE, 
DISTRIBUTION, 
LABEL-
5
ING.—Nothing in this paragraph shall be 
6
construed to limit the authority of the Sec-
7
retary to establish or enforce restrictions 
8
on the sale, distribution, or labeling of an 
9
in vitro clinical test under this Act. 
10
‘‘(ii) PROMOTION
OF
UNAPPROVED 
11
USES.—Nothing in this paragraph shall be 
12
construed to alter any prohibition on the 
13
promotion of unapproved uses of legally 
14
marketed in vitro clinical tests. 
15
‘‘(4) SPECIAL RULE.— 
16
‘‘(A) PREMARKET REVIEW APPLICABLE.— 
17
Notwithstanding the exemptions from pre-
18
market review under section 587B set forth in 
19
subsections (b), (c), (d), (e), (f), (g), (h), (j), 
20
and (k) of such section, an in vitro clinical test 
21
(including any article for taking or deriving 
22
specimens) shall be subject to the requirements 
23
of section 587B if the Secretary determines, in 
24
accordance with subparagraph (B), that— 
25
02:14 Jul 08, 2021
H4128
22 
•HR 4128 IH
‘‘(i)(I) there is insufficient valid sci-
1
entific evidence to support the analytical 
2
validity or the clinical validity of such in 
3
vitro clinical test; and 
4
‘‘(II) such in vitro clinical test is 
5
being offered by its developer with materi-
6
ally deceptive or fraudulent analytical or 
7
clinical claims; 
8
‘‘(ii) it is reasonably possible that 
9
such in vitro clinical test will cause serious 
10
adverse health consequences; or 
11
‘‘(iii) in the case of specimen recep-
12
tacles, there is sufficient valid scientific 
13
evidence indicating that a specimen recep-
14
tacle did not perform as intended, will not 
15
support the analytical validity of tests with 
16
which it is used, or as applicable, is not 
17
safe for use. 
18
‘‘(B) PROCESS.— 
19
‘‘(i) REQUEST FOR INFORMATION.—If 
20
the Secretary has valid scientific evidence 
21
indicating that the criteria listed in sub-
22
paragraph (A) apply to an in vitro clinical 
23
test, the Secretary may request that the 
24
developer of the test submit information— 
25
02:14 Jul 08, 2021
H4128
23 
•HR 4128 IH
‘‘(I) pertaining to such criteria; 
1
and 
2
‘‘(II) establishing the basis for 
3
any claimed exemption from pre-
4
market review. 
5
‘‘(ii) DEADLINE FOR SUBMITTING IN-
6
FORMATION.—The developer of an in vitro 
7
clinical test shall submit the information 
8
requested pursuant to clause (i) within 30 
9
days of receipt of such request. 
10
‘‘(iii) REVIEW DEADLINE.—Upon re-
11
ceiving a submission under clause (ii), the 
12
Secretary shall— 
13
‘‘(I) review the submitted infor-
14
mation within 60 calendar days of 
15
such receipt; and 
16
‘‘(II) determine whether the cri-
17
teria listed in subparagraph (A) apply 
18
to the in vitro clinical test. 
19
‘‘(iv) 
PREMARKET
REVIEW
RE-
20
QUIRED.— 
21
‘‘(I) IN
GENERAL.—If the Sec-
22
retary finds that the criteria listed in 
23
subparagraph (A) apply to the in vitro 
24
clinical test, the developer shall— 
25
02:14 Jul 08, 2021
H4128
24 
•HR 4128 IH
‘‘(aa) promptly, and not 
1
later than 90 days after the date 
2
of receipt of such information, 
3
submit an application for pre-
4
market review of the test under 
5
section 587B; or 
6
‘‘(bb) cease to market the 
7
test. 
8
‘‘(II) 
EXTENSION.—The 
Sec-
9
retary may grant an extension to a 
10
developer of the 90-day time period 
11
under subclause (I)(aa), as appro-
12
priate. 
13
‘‘(v) CONTINUED
MARKETING.—Dur-
14
ing the period beginning on the date of a 
15
request for information under clause (ii) 
16
and ending on the date of the disposition 
17
of an application for premarket review of 
18
the in vitro clinical test under section 
19
587B, the developer of the test may con-
20
tinue to market the test for clinical use, 
21
unless the Secretary issues an order to the 
22
developer under clause (vi) to immediately 
23
cease distribution of the test. 
24
02:14 Jul 08, 2021
H4128
25 
•HR 4128 IH
‘‘(vi) ORDER
TO
CEASE
DISTRIBU-
1
TION.— 
2
‘‘(I) IN GENERAL.—If the devel-
3
oper of an in vitro clinical test fails to 
4
submit an application for premarket 
5
review of the test by the deadline ap-
6
plicable under clause (iv), or the Sec-
7
retary finds that the criteria listed in 
8
subparagraph (A) apply to an in vitro 
9
clinical test and that it is in the best 
10
interest of the public health, the Sec-
11
retary may issue an order, within 10 
12
calendar days of the applicable dead-
13
line or finding by the Secretary, re-
14
quiring the developer of such in vitro 
15
clinical test, and any other appro-
16
priate person (including a distributor 
17
or retailer of the in vitro clinical test) 
18
to immediately— 
19
‘‘(aa) cease distribution of 
20
the test pending approval of an 
21
application for premarket review 
22
of the test under section 587B; 
23
and 
24
02:14 Jul 08, 2021
H4128
26 
•HR 4128 IH
‘‘(bb) notify health profes-
1
sionals and other user facilities of 
2
the order to cease distribution 
3
and advise health care profes-
4
sionals to cease use of such in 
5
vitro clinical test. 
6
‘‘(II) HEARING
AND
REVIEW.— 
7
An order under subclause (I) shall 
8
provide the person subject to the 
9
order with an opportunity for an in-
10
formal hearing, to be held not later 
11
than 10 days after the date of the 
12
issuance of the order, on the actions 
13
required by the order and on whether 
14
the order should be amended to re-
15
quire a recall of such in vitro clinical 
16
test. If, after providing an opportunity 
17
for such a hearing, the Secretary de-
18
termines that inadequate grounds 
19
exist to support the actions required 
20
by the order, the Secretary shall ter-
21
minate the order within 30 days of 
22
the hearing. Upon terminating an 
23
order, the Secretary shall provide 
24
02:14 Jul 08, 2021
H4128
27 
•HR 4128 IH
written notice of such termination to 
1
the developer. 
2
‘‘(vii) AMENDMENT TO REQUIRE RE-
3
CALL.—If the Secretary determines that 
4
an order issued under clause (vi) should be 
5
amended to include a recall of the in vitro 
6
clinical test with respect to which the order 
7
was issued, the Secretary shall amend the 
8
order to require a recall. In such amended 
9
order, the Secretary shall specify a time-
10
frame in which the in vitro clinical test re-
11
call will occur and shall require periodic re-
12
ports to the Secretary describing the 
13
progress of the recall. Upon termination of 
14
the recall, the Secretary shall provide writ-
15
ten notice of such termination to the devel-
16
oper. 
17
‘‘(viii) EFFECT OF TEST APPROVAL.— 
18
Any order issued under this paragraph 
19
with respect to an in vitro clinical test 
20
shall cease to be in effect if such test is 
21
granted approval under section 587B, pro-
22
vided that the in vitro clinical test is devel-
23
oped and offered for clinical use in accord-
24
ance with such approval. 
25
02:14 Jul 08, 2021
H4128
28 
•HR 4128 IH
‘‘(5) EMERGENCY USE.— 
1
‘‘(A) IN GENERAL.—In the case of a deter-
2
mination under section 319(a) of the Public 
3
Health Service Act or a declaration under sec-
4
tion 564(b) of this Act, an in vitro clinical test 
5
is exempt from the requirements of this sub-
6
chapter and may be lawfully marketed in ac-
7
cordance with subparagraph (B). 
8
‘‘(B) CRITERIA.—An in vitro clinical test 
9
is exempt from the requirements of this sub-
10
chapter and may be lawfully marketed in ac-
11
cordance with the exemption described in sub-
12
paragraph (A) if— 
13
‘‘(i) such test— 
14
‘‘(I) is submitted for emergency 
15
use 
authorization 
under 
section 
16
564(b); or 
17
‘‘(II) is developed and used in 
18
laboratories for which a certificate is 
19
in effect under section 353 of the 
20
Public Health Service Act to conduct 
21
high-complexity testing and the devel-
22
oper; and 
23
‘‘(ii) the developer— 
24
02:14 Jul 08, 2021
H4128
29 
•HR 4128 IH
‘‘(I) validates such in vitro clin-
1
ical test prior to use; 
2
‘‘(II) notifies the Secretary of the 
3
assay validation; and 
4
‘‘(III) submits an emergency use 
5
authorization application under sec-
6
tion 564 within 15 calendar days of 
7
marketing the test. 
8
‘‘(C) DISPOSITION OF PRODUCT.—With re-
9
spect to a previously unapproved in vitro clin-
10
ical test or an in vitro clinical test with an un-
11
approved use, for which an emergency use au-
12
thorization under section 564(b) ceases to be 
13
effective, the Secretary shall consult with the 
14
manufacturer of such product with respect to 
15
the appropriate disposition of the product. 
16
‘‘(D) STREAMLINING OF APPLICATION RE-
17
VIEW.—A developer may include any data or in-
18
formation already submitted to the Secretary 
19
within the emergency use authorization as a 
20
part of a premarket application under section 
21
587B or a technology certification application 
22
under section 587D. 
23
‘‘(6) EFFECT ON OTHER LAWS.—Any in vitro 
24
clinical test that is lawfully marketed under this Act, 
25
02:14 Jul 08, 2021
H4128
30 
•HR 4128 IH
including tests that are approved under section 
1
587B, cleared pursuant to an active technology cer-
2
tification order under section 587D, or exempt from 
3
premarket review under an exemption in this sec-
4
tion, shall be eligible for introduction into interstate 
5
commerce except as otherwise provided in this sub-
6
chapter. 
7
‘‘(b) COMPONENTS AND PARTS.— 
8
‘‘(1) EXEMPTION.— 
9
‘‘(A) IN
GENERAL.—Subject to subpara-
10
graph (B), a component, part, or raw material 
11
described in section 201(ss)(1)(B)(v) is exempt 
12
from the requirements of this subchapter if it 
13
is— 
14
‘‘(i) intended for further development 
15
as described in paragraph (2); or 
16
‘‘(ii) otherwise to be regulated based 
17
on its risk when used as intended by the 
18
developer, notwithstanding its subsequent 
19
use by a developer as a component, part, 
20
or raw material of another in vitro clinical 
21
test. 
22
‘‘(B) 
INAPPLICABILITY
TO
OTHER 
23
TESTS.—Notwithstanding subparagraph (A), an 
24
in vitro clinical test that is described in section 
25
02:14 Jul 08, 2021
H4128
31 
•HR 4128 IH
201(ss)(1)(B) and that uses a component or 
1
part described in such subparagraph shall be 
2
subject to the requirements of this subchapter, 
3
unless the test is otherwise exempt under this 
4
section. 
5
‘‘(2) FURTHER DEVELOPMENT.—A component, 
6
part, or raw material (as described in paragraph 
7
(1)(A)) is intended for further development (for pur-
8
poses of such paragraph) if— 
9
‘‘(A) it is intended solely for use in the de-
10
velopment of another in vitro clinical test; and 
11
‘‘(B) in the case of such a test that is in-
12
troduced or delivered for introduction into 
13
interstate commerce after the date of enactment 
14
of the Verifying Accurate Leading-edge IVCT 
15
Development Act of 2021, the labeling of such 
16
test bears the following statement: ‘This prod-
17
uct is intended solely for further development of 
18
an in vitro clinical test and is exempt from 
19
FDA regulation. This product must be evalu-
20
ated by the in vitro clinical test developer if it 
21
is used with or in the development of an in vitro 
22
clinical test.’. 
23
‘‘(c) GRANDFATHERED TESTS.— 
24
02:14 Jul 08, 2021
H4128
32 
•HR 4128 IH
‘‘(1) EXEMPTION.—An in vitro clinical test that 
1
meets the criteria set forth in paragraph (2) is ex-
2
empt from the requirements of this subchapter, ex-
3
cept as provided under subsection (a)(4), the reg-
4
istration and listing requirements under section 
5
587I, and the adverse reporting requirements under 
6
section 587L, and may be lawfully marketed subject 
7
to the other applicable requirements of this Act, if— 
8
‘‘(A) each test report template for the test 
9
bears a statement of adequate prominence that 
10
reads as follows: ‘This in vitro clinical test was 
11
developed and first introduced prior to the date 
12
of enactment of the Verifying Accurate Lead-
13
ing-edge IVCT Development Act of 2021 and 
14
has not been reviewed by the Food and Drug 
15
Administration.’; and 
16
‘‘(B) the developer of the test— 
17
‘‘(i) maintains documentation dem-
18
onstrating that the test meets and con-
19
tinues to meet the criteria set forth in 
20
paragraph (2); and 
21
‘‘(ii) makes such documentation avail-
22
able to the Secretary upon request. 
23
02:14 Jul 08, 2021
H4128
33 
•HR 4128 IH
‘‘(2) CRITERIA FOR EXEMPTION.—An in vitro 
1
clinical test is exempt as specified in paragraph (1) 
2
if the test— 
3
‘‘(A)(i) was first offered for clinical use by 
4
such laboratory before the date of enactment of 
5
the Verifying Accurate Leading-edge IVCT De-
6
velopment Act of 2021; 
7
‘‘(ii) was developed by a clinical laboratory 
8
for which a certificate was in effect under sec-
9
tion 353 of the Public Health Service Act that 
10
meets the requirements under such section 353 
11
for performing high-complexity testing; and 
12
‘‘(iii) is performed— 
13
‘‘(I) in the same clinical laboratory in 
14
which it was developed; 
15
‘‘(II) by another clinical laboratory for 
16
which a certificate is in effect under sec-
17
tion 353 within the same corporate organi-
18
zation and having common ownership by 
19
the same parent corporation; or 
20
‘‘(III) by a laboratory within a public 
21
health laboratory network coordinated or 
22
managed by the Centers for Disease Con-
23
trol and Prevention; 
24
02:14 Jul 08, 2021
H4128
34 
•HR 4128 IH
‘‘(B) does not have in effect an approval 
1
under section 515, a clearance under section 
2
510(k), 
an 
authorization 
under 
section 
3
513(f)(2), or an exemption under section 
4
520(m); and 
5
‘‘(C) is not modified on or after the date 
6
of enactment of the Verifying Accurate Lead-
7
ing-edge IVCT Development Act of 2021 by its 
8
initial developer (or another person) in a man-
9
ner such that the test is a new in vitro clinical 
10
test under subsection (l). 
11
‘‘(3) MODIFICATIONS.—In the case of a modi-
12
fication to an in vitro clinical test that is exempt as 
13
specified in paragraph (1) or such modification is 
14
otherwise not subject to premarket review pursuant 
15
to section 587A(l), the test continues to qualify for 
16
such exemption if the person modifying such test— 
17
‘‘(A) documents each such modification 
18
and maintains a summary of the basis for such 
19
determination; and 
20
‘‘(B) provides such documentation and 
21
summary to the Secretary upon request or in-
22
spection. 
23
‘‘(d) TESTS EXEMPT FROM SECTION 510(k).— 
24
02:14 Jul 08, 2021
H4128
35 
•HR 4128 IH
‘‘(1) EXEMPTION.—An in vitro clinical test is 
1
exempt from premarket review under section 587B 
2
and may be lawfully marketed subject to the other 
3
applicable requirements of this Act, if the in vitro 
4
clinical test— 
5
‘‘(A)(i) was offered for clinical use prior to 
6
the date of enactment of the Verifying Accurate 
7
Leading-edge IVCT Development Act of 2021; 
8
and 
9
‘‘(ii) immediately prior to such date of en-
10
actment was exempt pursuant to subsection (l) 
11
or (m)(2) of section 510 from the requirements 
12
for submission of a report under section 510(k); 
13
or 
14
‘‘(B)(i) was not offered for clinical use 
15
prior to such date of enactment; 
16
‘‘(ii) is not a test platform; and 
17
‘‘(iii) falls within a category of tests that 
18
was exempt from the requirements for submis-
19
sion of a report under section 510(k) as of such 
20
date of enactment (including class II devices 
21
and excluding class I devices described in sec-
22
tion 510(l)). 
23
‘‘(2) EFFECT ON SPECIAL CONTROLS.—For any 
24
in vitro clinical test, or category of in vitro clinical 
25
02:14 Jul 08, 2021
H4128
36 
•HR 4128 IH
tests, that is exempt from premarket review based 
1
on the criteria in paragraph (2), any special control 
2
that applied to a device within a predecessor cat-
3
egory immediately prior to the date of enactment of 
4
Verifying Accurate Leading-edge IVCT Development 
5
Act of 2021 shall be deemed a mitigating measure 
6
applicable under section 587E to an in vitro clinical 
7
test within the successor category, except to the ex-
8
tent such mitigating measure is withdrawn or 
9
changed in accordance with section 587E. 
10
‘‘(3) NEAR-PATIENT TESTING.—Not later than 
11
1 year after the date of enactment of the Verifying 
12
Accurate Leading-edge IVCT Development Act of 
13
2021, the Secretary shall issue draft guidance indi-
14
cating categories of tests that shall be exempt from 
15
premarket review under section 587B when offered 
16
for near-patient testing (point of care), which were 
17
not exempt from submission of a report under sec-
18
tion 510(k) pursuant to subsection (l) or (m)(2) of 
19
section 510 and regulations imposing limitations on 
20
exemption for in vitro devices intended for near-pa-
21
tient testing (point of care). 
22
‘‘(e) LOW-RISK TESTS.— 
23
‘‘(1) EXEMPTION.—An in vitro clinical test is 
24
exempt from premarket review under section 587B 
25
02:14 Jul 08, 2021
H4128
37 
•HR 4128 IH
and may be lawfully marketed subject to the other 
1
applicable requirements of this Act, including section 
2
587I(b)(6), if such test meets the definition of low- 
3
risk under section 587. 
4
‘‘(2) LIST OF LOW-RISK TESTS.— 
5
‘‘(A) IN
GENERAL.—The Secretary shall 
6
maintain, and make publicly available on the 
7
website of the Food and Drug Administration, 
8
a list of in vitro clinical tests, and categories of 
9
in vitro clinical tests, that are low-risk in vitro 
10
clinical tests for purposes of the exemption 
11
under this subsection. 
12
‘‘(B) INCLUSION.—The list under subpara-
13
graph (A) shall consist of— 
14
‘‘(i) all in vitro clinical tests and cat-
15
egories of in vitro clinical tests that are ex-
16
empt from premarket review pursuant to 
17
subsection (d)(1) or (d)(3); and 
18
‘‘(ii) all in vitro clinical tests and cat-
19
egories of in vitro clinical tests that are 
20
designated by the Secretary pursuant to 
21
subparagraph (C) as low-risk for purposes 
22
of this subsection. 
23
‘‘(C) DESIGNATION
OF
TESTS
AND
CAT-
24
EGORIES.—Without regard to subchapter II of 
25
02:14 Jul 08, 2021
H4128
38 
•HR 4128 IH
chapter 5 of title 5, United States Code, the 
1
Secretary may designate, in addition to the 
2
tests and categories described in subparagraph 
3
(B)(i), additional in vitro clinical tests, and cat-
4
egories of in vitro clinical tests, as low-risk in 
5
vitro clinical tests for purposes of the exemption 
6
under this subsection. The Secretary may make 
7
such a designation on the Secretary’s own ini-
8
tiative or in response to a request by any per-
9
son. In making such a designation for a test or 
10
category of tests, the Secretary shall consider— 
11
‘‘(i) whether the test, or category of 
12
tests, is low-risk; and 
13
‘‘(ii) such other factors as the Sec-
14
retary determines to be relevant to the pro-
15
tection of the public health. 
16
‘‘(f) MANUAL TESTS.— 
17
‘‘(1) EXEMPTION.—An in vitro clinical test is 
18
exempt from all requirements of this subchapter if 
19
the output of such in vitro clinical test is the result 
20
of direct, manual observation, without the use of 
21
automated instrumentation or software for inter-
22
mediate or final interpretation, by a qualified labora-
23
tory professional, and such in vitro clinical test— 
24
02:14 Jul 08, 2021
H4128
39 
•HR 4128 IH
‘‘(A) is designed, manufactured, and used 
1
within a single clinical laboratory for which a 
2
certificate is in effect under section 353 of the 
3
Public Health Service Act that meets the re-
4
quirements under section 353 for performing 
5
high-complexity testing; 
6
‘‘(B) is not a high-risk test, or is a high- 
7
risk test that the Secretary has determined 
8
meets at least one condition in paragraph (2) 
9
and is otherwise appropriate for this exemption; 
10
and 
11
‘‘(C) is not intended for testing donors, do-
12
nations, and recipients of blood, blood compo-
13
nents, human cells, tissues, cellular-based prod-
14
ucts, or tissue-based products. 
15
‘‘(2) HIGH-RISK TEST LIMITATION OR CONDI-
16
TION.—A high-risk test may be exempt under para-
17
graph (1) from the requirements of this subchapter 
18
only if— 
19
‘‘(A) no component or part of such test, in-
20
cluding any reagent, is introduced into inter-
21
state commerce under the exemption under sub-
22
section (b)(1) (relating to components or parts 
23
intended for further development), and any ar-
24
ticle for taking or deriving specimens from the 
25
02:14 Jul 08, 2021
H4128
40 
•HR 4128 IH
human body used in conjunction with the test 
1
remains subject to the requirements of this sub-
2
chapter; or 
3
‘‘(B) the test has been developed in accord-
4
ance with the applicable test design and quality 
5
requirements under section 587J. 
6
‘‘(g) HUMANITARIAN TEST EXEMPTION.— 
7
‘‘(1) IN GENERAL.—An in vitro clinical test is 
8
exempt from premarket review under section 587B 
9
and may be lawfully marketed subject to the other 
10
applicable requirements of this Act, if— 
11
‘‘(A) such in vitro clinical test is intended 
12
for use for a disease or condition for which no 
13
more than 10,000 (or such other number deter-
14
mined by the Secretary) individuals would be 
15
subject to negative or positive diagnosis by such 
16
test in the United States per year; and 
17
‘‘(B) the developer of the test— 
18
‘‘(i) maintains documentation (which 
19
may include literature citations in special-
20
ized medical journals, textbooks, special-
21
ized medical society proceedings, govern-
22
mental statistics publications, or, if no 
23
such studies or literature citations exist, 
24
credible conclusions from appropriate re-
25
02:14 Jul 08, 2021
H4128
41 
•HR 4128 IH
search or surveys) demonstrating that such 
1
test meets and continues to meet the cri-
2
teria described in this paragraph; and 
3
‘‘(ii) makes such documentation avail-
4
able to the Secretary upon request. 
5
‘‘(2) CROSS-REFERENCED TESTS.—In order to 
6
be eligible for an exemption under this subsection, 
7
the developer of a cross-referenced test shall submit 
8
a request under section 587H for informal feedback. 
9
‘‘(h) CUSTOM TESTS AND LOW-VOLUME TESTS.—An 
10
in vitro clinical test is exempt from premarket review 
11
under section 587B, the quality requirements under sec-
12
tion 587J, and the notification requirements under section 
13
587I, and may be lawfully marketed subject to the other 
14
applicable requirements of this Act, if— 
15
‘‘(1) such in vitro clinical test— 
16
‘‘(A) is a low-volume test performed in a 
17
laboratory in which it was developed or devel-
18
oped in a laboratory within the same corporate 
19
organization with the laboratory in which such 
20
test is performed and is administered to no 
21
more than 5 patients per year, unless otherwise 
22
determined by the Secretary; or 
23
‘‘(B) is a custom test developed or modi-
24
fied to diagnose a unique pathology or physical 
25
02:14 Jul 08, 2021
H4128
42 
•HR 4128 IH
condition of a specific patient for which no 
1
other in vitro clinical test is commercially avail-
2
able in the United States, and is— 
3
‘‘(i) not intended for use with respect 
4
to other patients; and 
5
‘‘(ii) after the development of the cus-
6
tom test, not included in any test menu, 
7
template test report, or other promotional 
8
materials, and not otherwise advertised; 
9
and 
10
‘‘(2) the developer of the test— 
11
‘‘(A) 
maintains 
documentation 
dem-
12
onstrating that such test meets and continues 
13
to meet the applicable criteria described in 
14
paragraph (1); 
15
‘‘(B) makes such documentation, such as a 
16
prescription order requesting the custom test 
17
for an individual patient, available to the Sec-
18
retary upon request; and 
19
‘‘(C) informs the Secretary, on an annual 
20
basis, in a manner prescribed by the Secretary 
21
by guidance, that such test was introduced into 
22
interstate commerce. 
23
‘‘(i) PUBLIC HEALTH SURVEILLANCE ACTIVITIES.— 
24
02:14 Jul 08, 2021
H4128
43 
•HR 4128 IH
‘‘(1) IN GENERAL.—The provisions of this sub-
1
chapter shall not apply to a test intended by the de-
2
veloper to be used solely for public health surveil-
3
lance activities, including the collection and testing 
4
of information or biospecimens, conducted, sup-
5
ported, requested, ordered, required, or authorized 
6
by a public health authority. 
7
‘‘(2) LIMITATION.—The public health surveil-
8
lance activities described in paragraph (1)— 
9
‘‘(A) are limited to activities necessary to 
10
allow a public health authority to identify, mon-
11
itor, assess, or investigate potential public 
12
health signals, onsets of disease outbreaks, or 
13
conditions of public health importance (includ-
14
ing trends, risk factors, patterns in diseases, 
15
and increases in injuries from using consumer 
16
products); and 
17
‘‘(B) include activities associated with pro-
18
viding timely situational awareness and priority 
19
setting during the course of a threat to the pub-
20
lic health (including natural or man-made dis-
21
asters and deliberate attacks on the United 
22
States). 
23
‘‘(3) EXCLUSION.—An in vitro clinical test is 
24
not excluded from the provisions of this subchapter 
25
02:14 Jul 08, 2021
H4128
44 
•HR 4128 IH
if such test is intended for use in making clinical de-
1
cisions for individual patients. 
2
‘‘(j) LAW ENFORCEMENT OR EMPLOYER TESTING.— 
3
An in vitro clinical test that is intended solely for use in 
4
forensic analysis, law enforcement activity, or employment 
5
purposes is exempt from the requirements of this Act. An 
6
in vitro clinical test that is intended for use in making 
7
clinical decisions for individual patients, or whose individ-
8
ually identifiable results may be reported back to an indi-
9
vidual patient or the patient’s health care provider, even 
10
if also intended for law enforcement or employment testing 
11
purposes, is not intended solely for use in law enforcement 
12
or employment testing for purposes of this subsection. 
13
‘‘(k) IN VITRO CLINICAL TESTS UNDER A TECH-
14
NOLOGY CERTIFICATION ORDER.—An in vitro clinical test 
15
that is within the scope of a technology certification order, 
16
as described in section 587D(a), is exempt from premarket 
17
review under section 587B. 
18
‘‘(l) MODIFIED TESTS.— 
19
‘‘(1) IN
GENERAL.—An in vitro clinical test 
20
that is modified, by the initial developer of the test 
21
or a different person, is a new in vitro clinical test 
22
subject to the requirements of this subchapter if the 
23
modification— 
24
02:14 Jul 08, 2021
H4128
45 
•HR 4128 IH
‘‘(A) affects the analytical or clinical valid-
1
ity of such test; 
2
‘‘(B) causes the test to no longer comply 
3
with applicable mitigating measures under sec-
4
tion 587E or restrictions under section 587N; 
5
or 
6
‘‘(C) as applicable, affects the safety of an 
7
article for taking or deriving specimens from 
8
the human body for a purpose described in sec-
9
tion 201(ss)(1). 
10
‘‘(2) 
EXEMPTIONS.—Notwithstanding 
para-
11
graph (1), an in vitro clinical test that is modified 
12
by the initial developer of the test or a different per-
13
son is not a new in vitro clinical test if the modifica-
14
tion— 
15
‘‘(A) is a software update that does not 
16
have an adverse effect on the analytical or clin-
17
ical validity or result in an increased risk to pa-
18
tients and consumers; 
19
‘‘(B) is made pursuant to methods or cri-
20
teria included in the change protocol premarket 
21
submission, amendment, or supplement ap-
22
proved by the Secretary for the in vitro clinical 
23
test being modified; 
24
02:14 Jul 08, 2021
H4128
46 
•HR 4128 IH
‘‘(C) is a labeling change that is appro-
1
priate to address patient or user harm; or 
2
‘‘(D) is a specimen-related modification 
3
that— 
4
‘‘(i) is made to extend specimen sta-
5
bility; or 
6
‘‘(ii) aligns with the data and infor-
7
mation submitted in an approved applica-
8
tion for premarket review under section 
9
587B or a technology certification order 
10
issued under section 587D. 
11
‘‘(3) DOCUMENTATION.—When a person modi-
12
fies an in vitro clinical test that was developed by 
13
another person, such modified test is exempt from 
14
the requirements of this subchapter provided that 
15
such person— 
16
‘‘(A) documents the modification that was 
17
made and the basis for determining that the 
18
modification, considering the changes individ-
19
ually and collectively, was not a type of modi-
20
fication described in paragraph (1); and 
21
‘‘(B) provides such documentation to the 
22
Secretary upon request or inspection. 
23
02:14 Jul 08, 2021
H4128
47 
•HR 4128 IH
‘‘(m) INVESTIGATIONAL USE.—An in vitro clinical 
1
test for investigational use is exempt from the require-
2
ments of this Act, except as provided in section 587R. 
3
‘‘(n) TRANSFER OR SALE OF IN VITRO CLINICAL 
4
TESTS.— 
5
‘‘(1) TRANSFER
AND
ASSUMPTION
OF
REGU-
6
LATORY OBLIGATIONS.—If ownership of an in vitro 
7
clinical test is sold or transferred in such manner 
8
that the developer transfers the regulatory submis-
9
sions and obligations applicable under this sub-
10
chapter with respect to the test, the transferee or 
11
purchaser becomes the developer of the test and 
12
shall have all regulatory obligations applicable to 
13
such a test under this subchapter. The transferee or 
14
purchaser shall update the registration and listing 
15
information under section 587I for the in vitro clin-
16
ical test. 
17
‘‘(2) TRANSFER OR SALE OF PREMARKET AP-
18
PROVAL.— 
19
‘‘(A) NOTICE REQUIRED.—If a developer 
20
of an in vitro clinical test transfers or sells the 
21
approval of the in vitro clinical test, the trans-
22
feror or seller shall— 
23
‘‘(i) submit a notice of the transfer or 
24
sale to the Secretary and update the reg-
25
02:14 Jul 08, 2021
H4128
48 
•HR 4128 IH
istration and listing information under sec-
1
tion 587I for the in vitro clinical test; and 
2
‘‘(ii) submit a supplemental applica-
3
tion if required under section 587B(h). 
4
‘‘(B) EFFECTIVE
DATE
OF
APPROVAL 
5
TRANSFER.—A transfer or sale described in 
6
subparagraph (A) shall become effective upon 
7
completion of a transfer or sale described in 
8
paragraph (1) or the approval of a supple-
9
mental application under section 587B(h) if re-
10
quired, whichever is later. The transferee or 
11
purchaser shall update the registration and list-
12
ing information under section 587I for the in 
13
vitro clinical test within 15 calendar days of the 
14
effective date of the transfer or sale. 
15
‘‘(3) TRANSFER OR SALE OF TECHNOLOGY CER-
16
TIFICATION.— 
17
‘‘(A) REQUIREMENTS FOR TRANSFER OR 
18
SALE
OF
TECHNOLOGY
CERTIFICATION.—An 
19
unexpired technology certification can be trans-
20
ferred or sold if the transferee or purchaser— 
21
‘‘(i) is an eligible person under section 
22
587D(b)(1); and 
23
‘‘(ii) maintains, upon such transfer or 
24
sale, the site, test design and quality re-
25
02:14 Jul 08, 2021
H4128
49 
•HR 4128 IH
quirements, 
processes 
and 
procedures 
1
under the scope of technology certification, 
2
and scope of the technology certification 
3
identified in the applicable technology cer-
4
tification order. 
5
‘‘(B) NOTICE REQUIRED.—If a developer 
6
of an in vitro clinical test transfers or sells a 
7
technology certification order that has not ex-
8
pired, the transferor or seller shall submit a no-
9
tice of the transfer or sale to the Secretary and 
10
shall update the registration and listing infor-
11
mation under section 587I for all in vitro clin-
12
ical tests covered by the technology certifi-
13
cation. 
14
‘‘(C) EFFECTIVE
DATE
OF
TECHNOLOGY 
15
CERTIFICATION TRANSFER.—The transfer of a 
16
technology certification shall become effective 
17
upon completion of a transfer or sale described 
18
in subparagraph (A). The transferee or pur-
19
chaser shall update the registration and listing 
20
information under section 587I for the in vitro 
21
clinical test within 30 calendar days of the ef-
22
fective date of the technology certification 
23
transfer. 
24
02:14 Jul 08, 2021
H4128
50 
•HR 4128 IH
‘‘(D) NEW
TECHNOLOGY
CERTIFICATION 
1
REQUIRED.—If the requirements of subpara-
2
graph (A)(ii) are not met, the technology cer-
3
tification order may not be transferred and the 
4
transferee or purchaser of an in vitro clinical 
5
test is required to submit an application for 
6
technology certification and obtain a technology 
7
certification order prior to offering the test for 
8
clinical use. 
9
‘‘(o) GENERAL LABORATORY EQUIPMENT.—Any in-
10
strument that does not produce an analytical result, and 
11
that functions as a component of pre-analytical procedures 
12
related to in vitro clinical tests, is not subject to the re-
13
quirements of this subchapter, provided that— 
14
‘‘(1) the instrument is operating in a clinical 
15
laboratory that is certified under section 353 of the 
16
Public Health Service Act; and 
17
‘‘(2) the instrument can be serviced by the 
18
manufacturer of such instrument or, if that manu-
19
facturer is no longer in business, a third party with 
20
the ability to service such instrument. 
21
‘‘(p) INSTRUMENT FAMILIES.—In the case of an in-
22
strument family, premarket approval under section 
23
587B(d) of one version of the in vitro clinical test is re-
24
quired, and previous and updated versions of the same test 
25
02:14 Jul 08, 2021
H4128
51 
•HR 4128 IH
within such instrument family shall be deemed to be sub-
1
ject to the approval pursuant to that section, unless the 
2
Secretary determines otherwise, as set forth in guidance. 
3
‘‘(q) GENERAL EXEMPTION AUTHORITY.—The Sec-
4
retary may, by order published in the Federal Register 
5
following notice and an opportunity for comment, exempt 
6
a class of persons from any section under this subchapter 
7
upon a finding that such exemption is appropriate for the 
8
protection of the public health and other relevant consider-
9
ations. 
10
‘‘(r) REGULATIONS.—The Secretary may issue regu-
11
lations to implement this subchapter. 
12
‘‘SEC. 587B. PREMARKET REVIEW. 
13
‘‘(a) IN GENERAL.—No person shall introduce or de-
14
liver for introduction into interstate commerce any in vitro 
15
clinical test, unless— 
16
‘‘(1) an approval of an application filed pursu-
17
ant to subsection (c) or (d) is effective with respect 
18
to test; or 
19
‘‘(2) the test is exempt under section 587A 
20
from premarket review under this section. 
21
‘‘(b) TRANSPARENCY AND PREDICTABILITY.— 
22
‘‘(1) PRE-SUBMISSION
MEETING
OR
REQUEST 
23
FOR
INFORMAL
FEEDBACK.—Pursuant to section 
24
587H, prior to filing an application under subsection 
25
02:14 Jul 08, 2021
H4128
52 
•HR 4128 IH
(c) or (d), any person may request a meeting or 
1
written correspondence with the Secretary to discuss 
2
the eligibility of an in vitro clinical test for pre-
3
market review or other information related to the fil-
4
ing of an application. The Secretary shall respond to 
5
such request within 45 calendar days. 
6
‘‘(2) STREAMLINING OF APPLICATIONS.— 
7
‘‘(A) 
PREMARKET
APPLICATION
AND 
8
TECHNOLOGY
CERTIFICATION.—If a person 
9
files a premarket application under this section 
10
and provides any additional documentation re-
11
quired under section 587D, the in vitro clinical 
12
test that is the subject of the application may 
13
be utilized as the representative test reviewed 
14
by the Secretary to provide an approval for 
15
both a premarket application under this section 
16
and a technology certification order under sec-
17
tion 587D. 
18
‘‘(B) REPRESENTATIVE ASSAYS FOR PRE-
19
MARKET APPROVAL.—With respect to a tech-
20
nology certification application filed under sec-
21
tion 587D, the representative test, as described 
22
in subparagraph (A), used to issue a technology 
23
certification order under section 587D shall be 
24
02:14 Jul 08, 2021
H4128
53 
•HR 4128 IH
deemed a test with premarket approval under 
1
this section. 
2
‘‘(c) APPLICATION.— 
3
‘‘(1) FILING.—Any person may file with the 
4
Secretary an application for premarket approval of 
5
an in vitro clinical test. 
6
‘‘(2) APPLICATION
CONTENT.—An application 
7
submitted under paragraph (1) with respect to an in 
8
vitro clinical test shall include the following, in such 
9
format as the Secretary specifies: 
10
‘‘(A) General information regarding the in 
11
vitro clinical test, including— 
12
‘‘(i) the name and address of the ap-
13
plicant; 
14
‘‘(ii) the table of contents for the ap-
15
plication and the identification of the infor-
16
mation the applicant claims as trade secret 
17
or confidential commercial or financial in-
18
formation; 
19
‘‘(iii) a description of the test’s in-
20
tended use; 
21
‘‘(iv) an explanation regarding test 
22
function and any significant performance 
23
characteristics; and 
24
02:14 Jul 08, 2021
H4128
54 
•HR 4128 IH
‘‘(v) an explanation of how the devel-
1
opment and validation activities support 
2
the test meeting the applicable standard. 
3
‘‘(B) A summary of the data and informa-
4
tion in the application for the in vitro clinical 
5
test, including— 
6
‘‘(i) a brief description of any existing 
7
alternative practices or procedures for di-
8
agnosing the disease or condition for which 
9
the in vitro clinical test is intended, as ap-
10
plicable; 
11
‘‘(ii) a brief description of the foreign 
12
and domestic marketing history of the test, 
13
if any, including a list of all countries in 
14
which the test has been marketed and a 
15
list of all countries in which the test has 
16
been withdrawn from marketing for any 
17
reason related to the applicable standard 
18
of the in vitro clinical test, if known by the 
19
applicant; 
20
‘‘(iii) a summary of the any studies 
21
submitted for such test, including a de-
22
scription of the objective of the study, a 
23
description of the experimental design of 
24
the study, a brief description of how the 
25
02:14 Jul 08, 2021
H4128
55 
•HR 4128 IH
data were collected and analyzed, a brief 
1
description of the results of the technical 
2
data submitted, and a brief description of 
3
any nonclinical or clinical studies; 
4
‘‘(iv) a risk assessment of the test; 
5
and 
6
‘‘(v) conclusions drawn from any stud-
7
ies described in clause (iii), including a dis-
8
cussion demonstrating that the data and 
9
information in the application constitute 
10
valid scientific evidence and meet the appli-
11
cable standard under section 587(2), an 
12
explanation of how the development and 
13
validation activities, as applicable, support 
14
that the test meets the applicable standard 
15
under section 587(2), and a discussion of 
16
any adverse effects of the test on health 
17
and proposals to mitigate those risks, if 
18
any. 
19
‘‘(C) The signature of the person filing the 
20
premarket application or an authorized rep-
21
resentative. 
22
‘‘(D) A bibliography of all published re-
23
ports reasonably known to the applicant related 
24
to such test and a discussion of data and infor-
25
02:14 Jul 08, 2021
H4128
56 
•HR 4128 IH
mation relevant to the evaluation of the applica-
1
ble standard that may be met by such test. 
2
‘‘(E) A statement that the applicant be-
3
lieves to the best of the applicant’s knowledge 
4
that all data and information submitted to the 
5
Secretary are truthful and accurate and that no 
6
material fact has been omitted in the applica-
7
tion. 
8
‘‘(F) Except as provided under subsection 
9
(d), applicable information regarding the meth-
10
ods used in, or the facilities or controls used 
11
for, the development of the test to demonstrate 
12
compliance with the applicable quality require-
13
ments under section 587J. 
14
‘‘(G) Information demonstrating compli-
15
ance with any relevant— 
16
‘‘(i) mitigating measures under sec-
17
tion 587E; and 
18
‘‘(ii) standards established or recog-
19
nized under section 514 prior to the date 
20
of enactment of the Verifying Accurate 
21
Leading-edge IVCT Development Act of 
22
2021, or, after applicable standards are es-
23
tablished or recognized under section 
24
587Q, with such standards. 
25
02:14 Jul 08, 2021
H4128
57 
•HR 4128 IH
‘‘(H) Valid scientific evidence to support 
1
analytical and clinical validity of the test, which 
2
shall include— 
3
‘‘(i) summary information for all sup-
4
porting validation studies performed; 
5
‘‘(ii) raw data, such as tabulations of 
6
data and results as required under section 
7
814.20(b)(6)(ii) of title 21, Code of Fed-
8
eral Regulations (or any successor regula-
9
tions); 
10
‘‘(iii) for nonclinical laboratory studies 
11
involving the test, a statement that studies 
12
were conducted in compliance with applica-
13
ble good laboratory practices; and 
14
‘‘(iv) 
for 
investigations 
involving 
15
human subjects, statements that any clin-
16
ical investigation involving human subjects 
17
was conducted in compliance with applica-
18
ble— 
19
‘‘(I) institutional review board 
20
regulations; 
21
‘‘(II) informed consent regula-
22
tions; and 
23
‘‘(III) investigational use require-
24
ments in section 587R. 
25
02:14 Jul 08, 2021
H4128
58 
•HR 4128 IH
‘‘(I) To the extent the application seeks 
1
authorization to make modifications to the test 
2
within the scope of the approval, a change pro-
3
tocol that includes validation procedures and 
4
acceptance criteria for anticipated modifications 
5
that could be made to the test within the scope 
6
of the approval. 
7
‘‘(J) Proposed labeling, in accordance with 
8
the requirements of section 587K. 
9
‘‘(K) Such other data or information as 
10
the Secretary may require in accordance with 
11
the least burdensome requirements of sub-
12
section (j). 
13
‘‘(3) GUIDANCE FOR PREMARKET AND SPECIAL 
14
PREMARKET
APPLICATIONS.—In accordance with 
15
section 5 of the Verifying Accurate Leading-edge 
16
IVCT Development Act of 2021, the Secretary shall 
17
issue draft guidance detailing the information to be 
18
provided in a premarket application and special pre-
19
market application under this section. The Secretary 
20
shall issue final guidance not later than 90 calendar 
21
days after the close of the comment period for such 
22
guidance. 
23
‘‘(4) REFUSE TO FILE A PREMARKET OR SPE-
24
CIAL PREMARKET APPLICATION.—If, after receipt of 
25
02:14 Jul 08, 2021
H4128
59 
•HR 4128 IH
an application under this section, the Secretary re-
1
fuses to file such application, the Secretary shall 
2
provide to the developer, within 60 calendar days of 
3
receipt of such application, a description of the rea-
4
son for such refusal, and identify the information re-
5
quired, if any, to allow for the filing of the applica-
6
tion. 
7
‘‘(5) SUBSTANTIVE REVIEW FOR DEFICIENT AP-
8
PLICATION.—If, after receipt of an application under 
9
this section, the Secretary determines that any por-
10
tion of such application is deficient, the Secretary 
11
shall provide to the applicant, within 75 calendar 
12
days of receipt of such application, a description of 
13
such deficiencies and identify the information re-
14
quired to correct such deficiencies. 
15
‘‘(d) SPECIAL PREMARKET REVIEW.— 
16
‘‘(1) IN GENERAL.—Any person may file with 
17
the Secretary an application for special premarket 
18
approval for— 
19
‘‘(A) an instrument; 
20
‘‘(B) a specimen receptacle; 
21
‘‘(C) an in vitro clinical test eligible for a 
22
technology certification order under section 
23
587D; or 
24
02:14 Jul 08, 2021
H4128
60 
•HR 4128 IH
‘‘(D) a first-of-a-kind test (unless it is a 
1
high-risk test), a direct-to-consumer test, or 
2
cross-referenced test that does not have miti-
3
gating measures. 
4
‘‘(2) APPLICATION
CONTENT.—An application 
5
under paragraph (1) shall include— 
6
‘‘(A) the information required for applica-
7
tions submitted under subsection (c)(2), except 
8
that applications under paragraph (1) need not 
9
include— 
10
‘‘(i) quality requirement information; 
11
or 
12
‘‘(ii) raw data unless explicitly re-
13
quested by the Secretary; 
14
‘‘(B) in the case of a specimen receptacle, 
15
safety information; and 
16
‘‘(C) data, as applicable, to support soft-
17
ware validation, electromagnetic compatibility, 
18
and electrical safety, and information dem-
19
onstrating compliance with maintaining quality 
20
systems documentation. 
21
‘‘(3) INSPECTIONS.—With respect to an appli-
22
cation under paragraph (1), preapproval inspections 
23
authorized by an employee of the Food and Drug 
24
Administration or a person accredited under section 
25
02:14 Jul 08, 2021
H4128
61 
•HR 4128 IH
587P need not occur unless requested by the Sec-
1
retary. 
2
‘‘(e) INSTRUMENT FAMILY.—When an in vitro clin-
3
ical test has been approved, or is otherwise legally mar-
4
keted, for use on a specific approved or legally marketed 
5
instrument within an instrument family, a submission 
6
under this section shall not be required for that in vitro 
7
clinical test in order for it to be used on a new instrument 
8
within that instrument’s family. 
9
‘‘(f) AMENDMENTS TO AN APPLICATION.— 
10
‘‘(1) IN GENERAL.—An applicant may amend 
11
an original or supplemental application under sub-
12
section (c) or (d). 
13
‘‘(2) REQUIRED
AMENDMENT
OR
SUPPLE-
14
MENT.—An applicant shall amend or supplement an 
15
application submitted under subsection (c) or (d) if 
16
the applicant becomes aware of information that— 
17
‘‘(A) could reasonably affect an evaluation 
18
of whether the applicable standard has been 
19
met; or 
20
‘‘(B) could reasonably affect the statement 
21
of contraindications, warnings, precautions, and 
22
adverse reactions in the proposed labeling. 
23
‘‘(3) REQUEST FOR AMENDMENT OR SUPPLE-
24
MENT.—The Secretary may request that an appli-
25
02:14 Jul 08, 2021
H4128
62 
•HR 4128 IH
cant amend or supplement an application under sub-
1
section (c) or (d) with any information necessary for 
2
review under this section. 
3
‘‘(g) ACTION ON AN APPLICATION FOR PREMARKET 
4
APPROVAL.— 
5
‘‘(1) REVIEW.— 
6
‘‘(A) DISPOSITION.—As promptly as pos-
7
sible, but not later than 90 calendar days after 
8
an application under subsection (c) is accepted 
9
for submission (unless the Secretary determines 
10
that an extension is necessary to review one or 
11
more major amendments to the application), or 
12
not later than 60 calendar days after an appli-
13
cation under subsection (d) is accepted for sub-
14
mission, the Secretary, after considering any 
15
applicable report and recommendations pursu-
16
ant to advisory committees under section 587G, 
17
or prior to the establishment of such advisory 
18
committees, any recommendations by a classi-
19
fication panel under section 513, shall issue an 
20
order approving the application, unless the Sec-
21
retary finds that the grounds for approval in 
22
paragraph (2) are not met. 
23
‘‘(B) RELIANCE
ON
PROPOSED
LABEL-
24
ING.—In determining whether to approve or 
25
02:14 Jul 08, 2021
H4128
63 
•HR 4128 IH
deny an application under paragraph (1), the 
1
Secretary shall rely on the intended use in-
2
cluded in the proposed labeling, provided that 
3
such labeling is not false or misleading based on 
4
a fair evaluation of all material facts. 
5
‘‘(2) APPROVAL OF AN APPLICATION.— 
6
‘‘(A) IN
GENERAL.—The Secretary shall 
7
approve an application submitted under sub-
8
section (c) with respect to an in vitro clinical 
9
test if the Secretary finds that there is a rea-
10
sonable assurance that the applicable standard 
11
is met, and— 
12
‘‘(i) except as provided under sub-
13
section (d), the applicant is in compliance 
14
with applicable quality requirements in sec-
15
tion 587J or as otherwise specified in a 
16
condition of approval, or maintains the 
17
documentation required to be in compli-
18
ance with such requirements if the appli-
19
cant is not required to submit such docu-
20
mentation as a part of the application 
21
under this section; 
22
‘‘(ii) the application does not contain 
23
a false statement of material fact; 
24
02:14 Jul 08, 2021
H4128
64 
•HR 4128 IH
‘‘(iii) based on a fair evaluation of all 
1
material facts, the proposed labeling is 
2
truthful and non-misleading and complies 
3
with the requirements of section 587K; 
4
‘‘(iv) except as provided under sub-
5
section (d), the applicant permits, if re-
6
quested, authorized employees of the Food 
7
and Drug Administration and persons ac-
8
credited under section 587P an oppor-
9
tunity— 
10
‘‘(I) to inspect at a reasonable 
11
time and in a reasonable manner the 
12
facilities and all pertinent equipment, 
13
finished and unfinished materials, 
14
containers, and labeling therein, in-
15
cluding all things (including records, 
16
files, papers, and controls) bearing on 
17
whether an in vitro clinical test is 
18
adulterated, misbranded, or otherwise 
19
in violation of this Act; and 
20
‘‘(II) to view and to copy and 
21
verify all records pertinent to the ap-
22
plication and the in vitro clinical test; 
23
‘‘(v) the test conforms with any appli-
24
cable performance standards under section 
25
02:14 Jul 08, 2021
H4128
65 
•HR 4128 IH
587Q and any applicable mitigating meas-
1
ures under section 587E; and 
2
‘‘(vi) all nonclinical laboratory studies 
3
and clinical investigations involving human 
4
subjects that are described in the applica-
5
tion were conducted in a manner that 
6
meets the requirements of this section. 
7
‘‘(B) CONDITIONS
OF
APPROVAL.—An 
8
order approving an application pursuant to this 
9
paragraph may require conditions of approval 
10
for the in vitro clinical test, including conform-
11
ance with performance standards under section 
12
587Q and restrictions under section 587N. 
13
‘‘(C) FIRST-OF-A-KIND TEST.—For a first- 
14
of-a-kind in vitro clinical test, an order approv-
15
ing an application pursuant to this paragraph— 
16
‘‘(i) may impose requirements for 
17
tests with the same indications for use, in-
18
cluding conformance with performance 
19
standards under section 587Q and miti-
20
gating measures under section 587E, and 
21
comply with restrictions under section 
22
587N; and 
23
‘‘(ii) shall indicate whether subsequent 
24
in vitro clinical tests with the same in-
25
02:14 Jul 08, 2021
H4128
66 
•HR 4128 IH
tended use may meet an exemption set 
1
forth in section 587A. 
2
‘‘(D) PUBLICATION.—The Secretary shall 
3
publish each order approving an application 
4
pursuant to this paragraph on the public 
5
website of the Food and Drug Administration 
6
and make publicly available a summary of the 
7
data used to grant the approval, except to the 
8
extent the Secretary determines that such 
9
order— 
10
‘‘(i) contains commercially confidential 
11
or trade secret information; or 
12
‘‘(ii) relates to national security or 
13
countermeasures is restricted from disclo-
14
sure pursuant to statutory provisions other 
15
than this section. 
16
‘‘(3) REVIEW
OF
DENIALS.—An applicant 
17
whose application submitted under subsection (c) or 
18
(d) has been denied approval may, by petition filed 
19
not more than 60 calendar days after the date on 
20
which the applicant receives notice of such denial, 
21
obtain review of the denial in accordance with sec-
22
tion 587O. 
23
‘‘(h) SUPPLEMENTS TO AN APPLICATION.— 
24
02:14 Jul 08, 2021
H4128
67 
•HR 4128 IH
‘‘(1) RISK
ANALYSIS.—Prior to implementing 
1
any modification to an in vitro clinical test, the hold-
2
er of the application approved under subsection (c) 
3
or (d) for such test shall perform risk analyses in 
4
accordance with section 587J, unless such modifica-
5
tion is included in the change protocol submitted by 
6
the applicant and approved under this section or ex-
7
empt under section 587A(l). 
8
‘‘(2) SUPPLEMENT REQUIREMENT.— 
9
‘‘(A) IN GENERAL.—Except as provided in 
10
subparagraph (B), or otherwise specified by the 
11
Secretary, the holder of the application ap-
12
proved under subsection (g) for an in vitro clin-
13
ical test shall submit to the Secretary and re-
14
ceive approval of a supplement before imple-
15
menting a modification to the test, unless such 
16
modification is exempt under section 587A(l). 
17
‘‘(B) ADJUSTMENTS
TO
CHANGE
PRO-
18
TOCOL.—A person may submit under this para-
19
graph a supplemental application adjusting the 
20
change protocol of the test at any time after the 
21
initial filing of an application under subsection 
22
(c) or (d). 
23
‘‘(C) EXCEPTIONS.—Subject to subpara-
24
graphs (D) and (E), and so long as the holder 
25
02:14 Jul 08, 2021
H4128
68 
•HR 4128 IH
of an approved application submitted under 
1
subsection (c) or (d) for an in vitro clinical test 
2
does not add a manufacturing site, or change 
3
activities at an existing manufacturing site, 
4
with respect to the test, the holder may, with-
5
out prior approval of a supplement, implement 
6
the following modifications to the test: 
7
‘‘(i) Modifications included in and im-
8
plemented in accordance with an approved 
9
change protocol under subsection (c)(2)(I). 
10
‘‘(ii) 
Modifications 
that 
do 
not 
11
change— 
12
‘‘(I) the analytical or clinical va-
13
lidity of the test; 
14
‘‘(II) the intended use of the test 
15
unless provided under an approved 
16
change 
protocol 
under 
subsection 
17
(c)(2)(I); or 
18
‘‘(III) the safety of the specimen 
19
receptacles. 
20
‘‘(iii) Labeling changes to appro-
21
priately address a safety concern. 
22
‘‘(iv) Modifications that are exempt 
23
under section 587A(l). 
24
02:14 Jul 08, 2021
H4128
69 
•HR 4128 IH
‘‘(D) REPORTING FOR CHANGE PROTOCOL 
1
MODIFICATIONS.—As a component of the report 
2
required under subsection (k), the holder of an 
3
application approved under subsection (g) for 
4
an in vitro clinical test shall— 
5
‘‘(i) report any modification to the 
6
test described in clause (i) or (ii) of sub-
7
paragraph (C) in the next annual report 
8
for the test under subsection (k) following 
9
the date on which the test, with such modi-
10
fication, is introduced into interstate com-
11
merce; and 
12
‘‘(ii) include in such report— 
13
‘‘(I) a description of the modi-
14
fication; and 
15
‘‘(II) as applicable, a summary of 
16
the analytical validity and clinical va-
17
lidity of the test, as modified, and any 
18
changes to acceptance criteria. 
19
‘‘(E) REPORTING FOR OTHER CATEGORY 
20
OF EXCEPTIONS.—The holder of the application 
21
approved under subsection (c) or (d) for an in 
22
vitro clinical test shall— 
23
‘‘(i) report to the Secretary any modi-
24
fication to the test described in clause (iii) 
25
02:14 Jul 08, 2021
H4128
70 
•HR 4128 IH
of subparagraph (C) not more than 60 
1
days after the date on which the test, with 
2
the modification, is introduced into inter-
3
state commerce; and 
4
‘‘(ii) include in the report— 
5
‘‘(I) a summary of the relevant 
6
change or changes; 
7
‘‘(II) the rationale for imple-
8
menting such change or changes; and 
9
‘‘(III) a description of how the 
10
change or changes were evaluated. 
11
‘‘(F) REQUEST FOR SUPPLEMENT.—Upon 
12
review of the information received under sub-
13
paragraph (D) and a finding that the relevant 
14
modification is inconsistent with the standard 
15
specified under subparagraph (C), the Secretary 
16
may require a supplement under subparagraph 
17
(A). If the Secretary determines that a supple-
18
ment under subparagraph (A) is required, the 
19
Secretary shall notify the applicant of such de-
20
termination. Such notification shall include a 
21
justification for the submission of a supplement. 
22
Prior to the submission of a supplement under 
23
this subparagraph, the applicant may request a 
24
meeting or written correspondence to gain agen-
25
02:14 Jul 08, 2021
H4128
71 
•HR 4128 IH
cy feedback as to the necessity of such supple-
1
mental filing. The Secretary shall respond to 
2
such meeting request within 30 calendar days 
3
of receipt. 
4
‘‘(3) CONTENTS OF SUPPLEMENT.—Unless oth-
5
erwise specified by the Secretary, a supplement 
6
under this subsection shall include— 
7
‘‘(A) for modifications other than manufac-
8
turing site changes— 
9
‘‘(i) a description of the modification; 
10
‘‘(ii) data to demonstrate that the ap-
11
plicable standard is met; 
12
‘‘(iii) acceptance criteria; and 
13
‘‘(iv) any revised labeling; and 
14
‘‘(B) for manufacturing site changes— 
15
‘‘(i) the information listed in subpara-
16
graph (A); and 
17
‘‘(ii) information regarding the meth-
18
ods used in, or the facilities or controls 
19
used for, the development of the test to 
20
demonstrate compliance with the applicable 
21
quality requirements under section 587J. 
22
‘‘(4) ADDITIONAL DATA.—The Secretary may 
23
require, when necessary, data to evaluate a modifica-
24
tion to an in vitro clinical test that is in addition to 
25
02:14 Jul 08, 2021
H4128
72 
•HR 4128 IH
the data otherwise required under the preceding 
1
paragraphs if the data request is in accordance with 
2
the least burdensome requirements under subsection 
3
(j). 
4
‘‘(5) CONDITIONS OF APPROVAL.—In an order 
5
approving a supplement under this subsection, the 
6
Secretary may require conditions of approval for the 
7
in vitro clinical test, including compliance with re-
8
strictions under section 587N and conformance to 
9
performance standards under section 587Q. 
10
‘‘(6) APPROVAL.—The Secretary shall approve 
11
a supplement under this subsection if— 
12
‘‘(A) the data demonstrate that the modi-
13
fied in vitro clinical test meets the applicable 
14
standard; and 
15
‘‘(B) the holder of the application approved 
16
under subsection (g) for the test has dem-
17
onstrated compliance with applicable quality 
18
and inspection requirements, as applicable and 
19
appropriate. 
20
‘‘(7) PUBLICATION.—The Secretary shall pub-
21
lish on the public website of the Food and Drug Ad-
22
ministration notice of any order approving a supple-
23
ment under this subsection, except that such publi-
24
cation shall exclude— 
25
02:14 Jul 08, 2021
H4128
73 
•HR 4128 IH
‘‘(A) commercial confidential or trade se-
1
cret information; and 
2
‘‘(B) any other information that the Sec-
3
retary determines to relate to national security 
4
or countermeasures or to be restricted from dis-
5
closure pursuant to another provision of law. 
6
‘‘(8) REVIEW OF DENIAL.—An applicant whose 
7
supplement under this subsection has been denied 
8
approval may, by petition filed on or before the 60th 
9
calendar day after the date upon which the applicant 
10
receives notice of such denial, obtain review of the 
11
denial in accordance with section 587O. 
12
‘‘(i) WITHDRAWAL AND TEMPORARY SUSPENSION OF 
13
APPROVAL.— 
14
‘‘(1) ORDER WITHDRAWING APPROVAL.— 
15
‘‘(A) IN
GENERAL.—The Secretary may, 
16
within 10 calendar days of providing due notice 
17
and an opportunity for an informal hearing to 
18
the holder of an approved application for an in 
19
vitro clinical test under this section, issue an 
20
order withdrawing approval of the application if 
21
the Secretary finds that— 
22
‘‘(i) the grounds for approval under 
23
subsection (g) are no longer met; or 
24
02:14 Jul 08, 2021
H4128
74 
•HR 4128 IH
‘‘(ii) there is a reasonable likelihood 
1
that the test would cause death or serious 
2
adverse health consequences, including by 
3
causing the absence, delay, or discontinu-
4
ation of life-saving or life sustaining med-
5
ical treatment. 
6
‘‘(B) CONTENT.—An order under subpara-
7
graph (A) withdrawing approval of an applica-
8
tion shall state each ground for withdrawal and 
9
shall notify the holder of such application 60 
10
calendar days prior to issuing such order. 
11
‘‘(C) PUBLICATION.—The Secretary shall 
12
publish any order under subparagraph (A) on 
13
the public website of the Food and Drug Ad-
14
ministration, except that such publication shall 
15
exclude— 
16
‘‘(i) commercial confidential or trade 
17
secret information; and 
18
‘‘(ii) any other information that the 
19
Secretary determines to relate to national 
20
security or countermeasures or to be re-
21
stricted from disclosure pursuant to an-
22
other provision of law. 
23
‘‘(2) ORDER OF TEMPORARY SUSPENSION.—If, 
24
after providing due notice and an opportunity for an 
25
02:14 Jul 08, 2021
H4128
75 
•HR 4128 IH
informal hearing to the holder of an approved appli-
1
cation for an in vitro clinical test under this section, 
2
the Secretary determines there is a reasonable likeli-
3
hood that the in vitro clinical test would cause death 
4
or serious adverse health consequences, including by 
5
causing the absence, delay, or discontinuation of life- 
6
saving or life-sustaining medical treatment, the Sec-
7
retary shall by order temporarily suspend the ap-
8
proval of the application. If the Secretary issues 
9
such an order, the Secretary shall proceed expedi-
10
tiously under paragraph (1) to withdraw approval of 
11
such application. 
12
‘‘(j) LEAST BURDENSOME REQUIREMENTS.— 
13
‘‘(1) IN GENERAL.—In carrying out this sub-
14
chapter, the Secretary shall consider the least bur-
15
densome means necessary to provide a reasonable 
16
assurance of analytical and clinical validity, or appli-
17
cable standard, and other regulatory requirements, 
18
as determined by the Secretary. 
19
‘‘(2) NECESSARY DEFINED.—For purposes of 
20
paragraph (1) and paragraph (3), the term ‘nec-
21
essary’ means the minimum required information 
22
that would support a determination by the Secretary 
23
that the application provides a reasonable assurance 
24
of analytical and clinical validity, or other applicable 
25
02:14 Jul 08, 2021
H4128
76 
•HR 4128 IH
standard or regulatory requirement, as determined 
1
by the Secretary. 
2
‘‘(3) 
CONSIDERATION
OF
ROLE
OF 
3
4
subsection, the Secretary shall consider the role of 
5
postmarket information in determining the least bur-
6
densome appropriate means necessary to dem-
7
onstrate that the applicable standard and other reg-
8
ulatory requirements have been met. 
9
‘‘(k) ANNUAL REPORT.— 
10
‘‘(1) IN GENERAL.—Unless the Secretary speci-
11
fies otherwise, the holder of an approved application 
12
under this section shall submit an annual report 
13
each year at a time designated by the Secretary in 
14
the approval order. Such report shall— 
15
‘‘(A) identify all modifications required to 
16
be reported that an approved application holder 
17
has made to any test that is covered by the ap-
18
proval order, including any modification that 
19
requires a supplement under subsection (h)(2); 
20
and 
21
‘‘(B) include any other information re-
22
quired by the Secretary. 
23
‘‘(2) EXCEPTION.—The annual reporting re-
24
quirement in paragraph (1) shall not apply to in 
25
02:14 Jul 08, 2021
H4128
77 
•HR 4128 IH
vitro clinical tests that are deemed to have a pre-
1
market approval based on a prior approval under 
2
section 515(c), clearance under section 510(k), or 
3
authorization under section 513(f) of this Act, or 
4
that are grandfathered under 587A(c). 
5
‘‘(l) SERVICE OF ORDERS.—Orders of the Secretary 
6
under this section with respect to applications under sub-
7
section (c) or (d) or supplements under subsection (h) 
8
shall be served— 
9
‘‘(1) in person by any officer or employee of the 
10
Department of Health and Human Services des-
11
ignated by the Secretary; or 
12
‘‘(2) by mailing the order by registered mail or 
13
certified mail or electronic equivalent addressed to 
14
the applicant at the last known address in the 
15
records of the Secretary. 
16
‘‘SEC. 587C. BREAKTHROUGH IN VITRO CLINICAL TESTS. 
17
‘‘(a) IN GENERAL.—The purpose of this section is 
18
to encourage the Secretary to apply efficient and flexible 
19
approaches to expedite the development of, and prioritize 
20
the review of, in vitro clinical tests that represent break-
21
through technologies, and to provide the Secretary with 
22
sufficient authority to do so. 
23
‘‘(b) ESTABLISHMENT OF PROGRAM.—The Secretary 
24
shall establish a program to expedite the development of, 
25
02:14 Jul 08, 2021
H4128
78 
•HR 4128 IH
and provide for the priority review of, in vitro clinical 
1
tests. 
2
‘‘(c) ELIGIBILITY.—The program developed under 
3
subsection (b) shall be available for any in vitro clinical 
4
test that— 
5
‘‘(1) provides or enables more effective treat-
6
ment or diagnosis of life-threatening or irreversibly 
7
debilitating human disease or conditions compared 
8
to existing approved or precertified alternatives; and 
9
‘‘(2) is a test— 
10
‘‘(A) that represents a breakthrough tech-
11
nology; 
12
‘‘(B) for which no approved or precertified 
13
alternative exists; 
14
‘‘(C) that offers a clinically meaningful ad-
15
vantage over existing approved or precertified 
16
alternatives, including the potential, compared 
17
to existing approved or precertified alternatives, 
18
to reduce or eliminate the need for hospitaliza-
19
tion, improve patient quality of life, facilitate 
20
patients’ ability to manage their own care (such 
21
as through self-directed personal assistance), or 
22
establish long-term clinical efficiencies; or 
23
‘‘(D) the availability of which is in the best 
24
interest of patients or public health. 
25
02:14 Jul 08, 2021
H4128
79 
•HR 4128 IH
‘‘(d) DESIGNATION.— 
1
‘‘(1) REQUEST.—To receive breakthrough ap-
2
proval under this section, an applicant may request 
3
that the Secretary designate the in vitro clinical test 
4
for expedited development and priority review. Any 
5
such request for designation may be made at any 
6
time prior to the submission of an application under 
7
section 587B, and shall include information dem-
8
onstrating that the test is eligible for designation 
9
under subsection (c). 
10
‘‘(2) DETERMINATION.—Not later than 60 cal-
11
endar days after the receipt of a request under para-
12
graph (1), the Secretary shall determine whether the 
13
in vitro clinical test that is the subject of the request 
14
meets the criteria described in subsection (c). If the 
15
Secretary determines that the test meets the criteria, 
16
the Secretary shall designate the test for expedited 
17
development and priority review. 
18
‘‘(3) REVIEW.—Review of a request under para-
19
graph (1) shall be undertaken by a team that is 
20
composed of experienced staff and senior managers 
21
of the Food and Drug Administration. 
22
‘‘(4) WITHDRAWAL.— 
23
‘‘(A) IN GENERAL.—The designation of an 
24
in vitro clinical test under this subsection is 
25
02:14 Jul 08, 2021
H4128
80 
•HR 4128 IH
deemed to be withdrawn, and such in vitro clin-
1
ical test shall no longer be eligible for designa-
2
tion under this section, if an application for ap-
3
proval under section 587B is denied. Such test 
4
shall be eligible for designation upon a new re-
5
quest for such designation. 
6
‘‘(B) EXCEPTION.—The Secretary may not 
7
withdraw a designation granted under this sub-
8
section based on the subsequent approval or 
9
technology certification of another test that— 
10
‘‘(i) is designated under this section; 
11
or 
12
‘‘(ii) was given priority review under 
13
section 515B. 
14
‘‘(e) ACTIONS.—For purposes of expediting the devel-
15
opment and review of in vitro clinical tests under this sec-
16
tion, the Secretary may take the actions and additional 
17
actions set forth in paragraphs (1) and (2), respectively, 
18
of section 515B(e) when reviewing such tests. Any ref-
19
erence or authorization in section 515B(e) with respect 
20
to a device shall be deemed a reference or authorization 
21
with respect to an in vitro clinical test for purposes of this 
22
section. 
23
‘‘(f) GUIDANCE.— 
24
02:14 Jul 08, 2021
H4128
81 
•HR 4128 IH
‘‘(1) IN GENERAL.—Not later than one year 
1
after the date of enactment of the Verifying Accu-
2
rate Leading-edge IVCT Development Act of 2021, 
3
the Secretary shall issue draft guidance on the im-
4
plementation of this section. Such guidance shall— 
5
‘‘(A) set forth the process by which a per-
6
son may seek a designation under subsection 
7
(d); 
8
‘‘(B) provide a template for request under 
9
subsection (d); 
10
‘‘(C) identify the criteria the Secretary will 
11
use in evaluating a request for designation; and 
12
‘‘(D) identify the criteria and processes the 
13
Secretary will use to assign a team of staff, in-
14
cluding team leaders, to review in vitro clinical 
15
tests designated for expedited development and 
16
priority review, including any training required 
17
for such personnel to ensure effective and effi-
18
cient review. 
19
‘‘(2) PROCESS.—Prior to finalizing the guid-
20
ance under paragraph (1), the Secretary shall seek 
21
public comment on the draft guidance. The Sec-
22
retary shall issue final guidance one year after the 
23
close of the comment period for the draft guidance. 
24
02:14 Jul 08, 2021
H4128
82 
•HR 4128 IH
‘‘(g) ANNUAL REPORT.—Unless otherwise specified 
1
by the Secretary, the requirements under section 587B(k) 
2
apply to in vitro clinical tests designated under this sec-
3
tion. 
4
‘‘(h) SERVICE OF ORDERS.—Orders of the Secretary 
5
under this section shall be served— 
6
‘‘(1) in person by any officer or employee of the 
7
Department of Health and Human Services des-
8
ignated by the Secretary; or 
9
‘‘(2) by mailing the order by registered mail or 
10
certified mail or electronic equivalent addressed to 
11
the applicant at his last known address in the 
12
records of the Secretary. 
13
‘‘SEC. 587D. TECHNOLOGY CERTIFICATION. 
14
‘‘(a) IN GENERAL.— 
15
‘‘(1) ELIGIBILITY.—Any eligible person may 
16
seek a technology certification order in accordance 
17
with this section. 
18
‘‘(2) EXCEPTION.—An in vitro clinical test is 
19
exempt from premarket review under section 587B 
20
and may be introduced into interstate commerce if 
21
the developer is eligible under this section and the 
22
in vitro clinical test— 
23
‘‘(A) is an eligible in vitro clinical test 
24
under subsection (b)(2); and 
25
02:14 Jul 08, 2021
H4128
83 
•HR 4128 IH
‘‘(B) falls within the scope of a technology 
1
certification order issued under this section that 
2
is in effect. 
3
‘‘(b) ELIGIBILITY.— 
4
‘‘(1) ELIGIBLE PERSON.—In this section, the 
5
term ‘eligible person’ means an in vitro clinical test 
6
developer unless, at the time such person seeks or 
7
would seek technology certification order, the per-
8
son— 
9
‘‘(A) has been found to have committed a 
10
significant violation of section 353 of the Public 
11
Health Service Act, unless— 
12
‘‘(i) such violation occurred more than 
13
5 years prior to the date on which such 
14
technology certification order is or would 
15
be sought; or 
16
‘‘(ii) such violation has been resolved; 
17
‘‘(B) fails to maintain required certifi-
18
cations under section 353 of the Public Health 
19
Service Act, as applicable; or 
20
‘‘(C) has been found to have submitted in-
21
formation to the Secretary that— 
22
‘‘(i) makes false or misleading state-
23
ments about a technology certification 
24
02:14 Jul 08, 2021
H4128
84 
•HR 4128 IH
order previously issued or an application 
1
approved under section 587B; or 
2
‘‘(ii) violates any requirement of this 
3
subchapter, where such violation exposes 
4
individuals to serious risk of illness, injury, 
5
or death. 
6
‘‘(2) TECHNOLOGY CERTIFICATION ELIGIBILITY 
7
LIMITATIONS.—An in vitro clinical test is not eligible 
8
under subsection (a)(2) for exemption from pre-
9
market review under section 587B, if— 
10
‘‘(A) such test is— 
11
‘‘(i) a component or part of an in 
12
vitro clinical test as described in section 
13
201(ss)(1)(B)(v); 
14
‘‘(ii) an instrument under section 
15
201(ss)(1)(B)(ii); 
16
‘‘(iii) a specimen receptacle under sec-
17
tion 201(ss)(1)(B)(iii); 
18
‘‘(iv) an in vitro clinical test, including 
19
reagents used in such tests, intended for 
20
use for testing donors, donations, and re-
21
cipients 
of 
blood, 
blood 
components, 
22
human cells, tissues, cellular-based prod-
23
ucts, or tissue-based products; or 
24
02:14 Jul 08, 2021
H4128
85 
•HR 4128 IH
‘‘(v) a high-risk in vitro clinical test 
1
without mitigating measures under section 
2
587E, which may include first-of-a-kind in 
3
vitro clinical tests, home use in vitro clin-
4
ical tests, cross-referenced in vitro clinical 
5
tests, and direct-to-consumer in vitro clin-
6
ical tests. 
7
‘‘(c) PUBLIC MEETING AND INPUT.— 
8
‘‘(1) PUBLIC DOCKET.—Not later than 30 days 
9
after the date of enactment of the Verifying Accu-
10
rate Leading-edge IVCT Development Act of 2021, 
11
the Secretary shall establish a public docket to re-
12
ceive comments concerning recommendations for im-
13
plementation of this section, including criteria and 
14
procedures for subsections (e) through (j). The pub-
15
lic docket shall remain open for the duration of time 
16
that this section remains in effect. 
17
‘‘(2) PUBLIC
MEETING.—Not later than 180 
18
days after the date of enactment of the Verifying 
19
Accurate Leading-edge IVCT Development Act of 
20
2021, the Secretary shall convene a public meeting 
21
to which stakeholders from organizations rep-
22
resenting patients and consumers, academia, and the 
23
in vitro clinical test industry are invited in order to 
24
discuss the technology certification process including 
25
02:14 Jul 08, 2021
H4128
86 
•HR 4128 IH
application requirements, inspections, alignment 
1
with third-party accreditors, and the definition of 
2
‘technology’ under section 587(17). 
3
‘‘(d) REGULATIONS.—The Secretary shall issue regu-
4
lations on technology certification including describing cri-
5
teria or procedures relating to technology certification 
6
under this section, which shall be subject to public com-
7
ment for a minimum of 60 days from issuance prior to 
8
finalizing such regulations after considering the comments 
9
received. The regulation shall include an outline of the ap-
10
plication and recertification process, opportunities to meet 
11
with officials of the Food and Drug Administration and 
12
plans to streamline inspections. 
13
‘‘(e) APPLICATION
FOR
TECHNOLOGY
CERTIFI-
14
CATION.— 
15
‘‘(1) IN GENERAL.—A person seeking a tech-
16
nology certification order shall submit an application 
17
under this subsection, which shall contain the infor-
18
mation specified under paragraph (2). 
19
‘‘(2) CONTENT OF APPLICATION.—An applica-
20
tion for technology certification shall contain— 
21
‘‘(A) a statement identifying the scope of 
22
the proposed technology certification, which 
23
shall be no broader than a single technology in-
24
tended to be offered under the application; 
25
02:14 Jul 08, 2021
H4128
87 
•HR 4128 IH
‘‘(B) information describing that the per-
1
son seeking a technology certification order is 
2
an eligible person under subsection (b)(1); 
3
‘‘(C) information describing that the meth-
4
ods used in, and the facilities and controls used 
5
for, the development of eligible in vitro clinical 
6
tests covered by the scope of the technology cer-
7
tification conform to the applicable quality re-
8
quirements of section 587J; 
9
‘‘(D) procedures for analytical validation, 
10
including 
all 
procedures 
for 
validation, 
11
verification, and acceptance criteria, and an ex-
12
planation as to how such procedures, when 
13
used, provide a reasonable assurance of analyt-
14
ical validity of eligible in vitro clinical tests 
15
within the proposed scope of the technology cer-
16
tification order; 
17
‘‘(E) procedures for clinical validation, in-
18
cluding 
all 
procedures 
for 
validation, 
19
verification, and acceptance criteria, and an ex-
20
planation as to how such procedures, when 
21
used, provide a reasonable assurance of clinical 
22
validity of eligible in vitro clinical tests within 
23
the proposed scope of the technology certifi-
24
cation order; 
25
02:14 Jul 08, 2021
H4128
88 
•HR 4128 IH
‘‘(F) a submission under section 587I(b) 
1
for each in vitro clinical test that the developer 
2
intends to introduce into interstate commerce 
3
upon receiving a technology certification order; 
4
‘‘(G) information concerning one or more 
5
representative in vitro clinical tests, including— 
6
‘‘(i) a test within the scope of the 
7
technology certification application with 
8
the appropriate analytical complexity at 
9
the time of the filing of the application 
10
under this section to serve as the rep-
11
resentative test and validate and run with-
12
in the developer’s stated scope; 
13
‘‘(ii) the information specified in sub-
14
section (c) or (d) of section 587B, as appli-
15
cable, for the representative in vitro clin-
16
ical test or tests, including information and 
17
data required pursuant to subsection 
18
(c)(2)(H) of section 587B, unless the Sec-
19
retary determines that such information is 
20
not necessary; 
21
‘‘(iii) an explanation of the choice of 
22
the representative in vitro clinical test or 
23
tests for the technology certification appli-
24
cation and how such test adequately dem-
25
02:14 Jul 08, 2021
H4128
89 
•HR 4128 IH
onstrates the range of procedures that the 
1
developer includes in the application under 
2
subparagraphs (C), (D), (E), and (F); and 
3
‘‘(iv) a brief explanation of the ways 
4
in which the procedures included in the ap-
5
plication under subparagraphs (C), (D), 
6
(E), and (F) have been applied to the rep-
7
resentative in vitro clinical test or tests; 
8
‘‘(H) such other information as the Sec-
9
retary may determine necessary; and 
10
‘‘(I) a statement that the applicant believes 
11
to the best of the applicant’s knowledge that all 
12
data and information submitted to the Sec-
13
retary are truthful and accurate and that no 
14
material fact has been omitted. 
15
‘‘(3) REFERENCE
TO
APPROVED
PREMARKET 
16
APPLICATION UNDER SECTION 587B.—With respect 
17
to the content requirements in the technology certifi-
18
cation application described in paragraph (2), a de-
19
veloper may incorporate by reference any content of 
20
an application previously submitted by the developer 
21
and approved under section 587B. 
22
‘‘(f) ACTION ON AN APPLICATION FOR TECHNOLOGY 
23
CERTIFICATION.— 
24
‘‘(1) SECRETARY RESPONSE.— 
25
02:14 Jul 08, 2021
H4128
90 
•HR 4128 IH
‘‘(A) IN GENERAL.—As promptly as prac-
1
ticable, and no later than 90 days after receipt 
2
of an application under subsection (c), the Sec-
3
retary shall— 
4
‘‘(i) issue a technology certification 
5
order granting the application, which shall 
6
specify the scope of the technology certifi-
7
cation, if the Secretary finds that all of the 
8
grounds in paragraph (3) are met; or 
9
‘‘(ii) deny the application if the Sec-
10
retary finds (and sets forth the basis of 
11
such finding as part of or accompanying 
12
such denial) that one or more grounds for 
13
granting the application specified in para-
14
graph (3) are not met. 
15
‘‘(B) EXTENSION.—The timeline described 
16
in subparagraph (A) may be extended by mu-
17
tual agreement between the Secretary and the 
18
applicant. 
19
‘‘(2) DEFICIENT APPLICATIONS.— 
20
‘‘(A) If, after receipt of an application 
21
under this section, the Secretary determines 
22
that any portion of such application is deficient, 
23
the Secretary, not later than 60 days after re-
24
ceipt of such application, shall provide to the 
25
02:14 Jul 08, 2021
H4128
91 
•HR 4128 IH
applicant a description of such deficiencies and 
1
identify the information required to correct 
2
such deficiencies. 
3
‘‘(B) When responding to the deficiency 
4
letter, the applicant may convert the application 
5
for technology certification under subsection (c) 
6
into a premarket application under section 
7
587B. 
8
‘‘(3) TECHNOLOGY
CERTIFICATION
ORDER.— 
9
The Secretary shall grant a technology certification 
10
order under this section if, on the basis of the infor-
11
mation submitted to the Secretary as part of the ap-
12
plication and any other information with respect to 
13
such applicant, the Secretary finds that— 
14
‘‘(A) 
in 
accordance 
with 
subsection 
15
(e)(2)(D), there is a showing of reasonable as-
16
surance of analytical validity for all eligible in 
17
vitro clinical tests within the proposed scope of 
18
the technology certification, as evidenced by the 
19
procedures for analytical validation; 
20
‘‘(B) 
in 
accordance 
with 
subsection 
21
(e)(2)(E), there is a showing of reasonable as-
22
surance of clinical validity for eligible in vitro 
23
clinical tests within the proposed scope of the 
24
technology certification, as evidenced by the 
25
02:14 Jul 08, 2021
H4128
92 
•HR 4128 IH
clinical program, including procedures for clin-
1
ical validation; 
2
‘‘(C) the methods used in, or the facilities 
3
or controls used for, the development of eligible 
4
in vitro clinical tests covered by the proposed 
5
scope of the technology certification conform to 
6
the applicable requirements of section 587J; 
7
‘‘(D) based on a fair evaluation of all ma-
8
terial facts, the applicant’s proposed labeling 
9
and advertising is not false or misleading in any 
10
particular; 
11
‘‘(E) the application does not contain a 
12
false statement of material fact; 
13
‘‘(F) there is a showing that the represent-
14
ative in vitro clinical test or tests— 
15
‘‘(i) meet the applicable standard for 
16
such order; and 
17
‘‘(ii) reasonably represent the range of 
18
procedures for analytical validation and 
19
clinical validation included in the applica-
20
tion, as applicable; and 
21
‘‘(G) the applicant permits authorized em-
22
ployees of the Food and Drug Administration 
23
or persons accredited under this Act an oppor-
24
tunity to inspect at a reasonable time and in a 
25
02:14 Jul 08, 2021
H4128
93 
•HR 4128 IH
reasonable manner the facilities and all perti-
1
nent equipment, finished and unfinished mate-
2
rials, containers, and labeling therein, including 
3
all things (including records, files, papers, and 
4
controls) bearing on whether an in vitro clinical 
5
test is adulterated, misbranded, or otherwise in 
6
violation of this Act, and permits such author-
7
ized employees or persons accredited under this 
8
Act to view and to copy and verify all records 
9
pertinent to the application and the in vitro 
10
clinical test. 
11
‘‘(4) EFFECT OF TECHNOLOGY CERTIFICATION 
12
ORDER.—An in vitro clinical test or tests within the 
13
scope of a granted technology certification order are 
14
cleared to be introduced into interstate commerce. 
15
‘‘(5) REVIEW OF DENIALS.—If the Secretary 
16
denies an application for technology certification, in-
17
cluding an application for renewal under subsection 
18
(g), the Secretary will provide a summary of defi-
19
ciencies on which the Secretary based its denial. An 
20
applicant whose application has been denied may, by 
21
petition filed on or before the date that is 30 cal-
22
endar days after the date upon which such applicant 
23
receives notice of such denial, obtain review thereof 
24
in accordance with section 587O. 
25
02:14 Jul 08, 2021
H4128
94 
•HR 4128 IH
‘‘(g) DURATION; SUBSEQUENT SUBMISSIONS.— 
1
‘‘(1) ORDER DURATION.—A technology certifi-
2
cation order shall remain in effect until the earlier 
3
of— 
4
‘‘(A) the expiration of such technology cer-
5
tification order under paragraph (2); or 
6
‘‘(B) the withdrawal of such technology 
7
certification order under subsection (j). 
8
‘‘(2) EXPIRATION.— 
9
‘‘(A) An initial technology certification 
10
order issued under subsection (f)(3) shall expire 
11
4 years after the date that such order is issued, 
12
except that if an application for renewal under 
13
paragraph (3) has been received not later than 
14
30 days prior to the expiration of such order 
15
under this paragraph, such order shall expire 
16
on the date on which the Secretary has granted 
17
or denied the application for renewal. Any such 
18
subsequent renewal of a technology certification 
19
shall expire on such date specified by the Sec-
20
retary that is not later than 4 years after the 
21
date that such technology certification order is 
22
issued. 
23
‘‘(B) In the event of expiration of tech-
24
nology certification order, the clearance of tests 
25
02:14 Jul 08, 2021
H4128
95 
•HR 4128 IH
introduced into interstate commerce under such 
1
order prior to its expiration pursuant to sub-
2
section (f)(3) remain in effect. 
3
‘‘(3) RENEWAL.— 
4
‘‘(A) IN GENERAL.—Any person previously 
5
granted a technology certification order in ef-
6
fect may seek renewal of such order provided 
7
that— 
8
‘‘(i) such person is an eligible person 
9
under subsection (b)(1); 
10
‘‘(ii) the previously granted technology 
11
certification order— 
12
‘‘(I) is not on temporary hold 
13
under subsection (i); and 
14
‘‘(II) was not withdrawn under 
15
subsection (j); and 
16
‘‘(iii) none of the information specified 
17
in subsection (e)(2) has substantially 
18
changed, except as described in supple-
19
ments to orders granted under paragraph 
20
(4). 
21
‘‘(B) CONTENT.—An application for re-
22
newal under this paragraph shall include infor-
23
mation concerning one or more representative 
24
in vitro clinical tests in accordance with sub-
25
02:14 Jul 08, 2021
H4128
96 
•HR 4128 IH
section (e)(2)(G), except that such representa-
1
tive test or tests shall be different from the rep-
2
resentative test or tests relied upon as the rep-
3
resentative assay in any prior technology certifi-
4
cation, if applicable. 
5
‘‘(C) PROCESS.—The Secretary’s action on 
6
an application for renewal of technology certifi-
7
cation under this paragraph shall be conducted, 
8
to the extent practicable, in coordination with 
9
inspections conducted under section 353 of the 
10
Public Health Service Act, if applicable, and 
11
any order resulting from such renewal applica-
12
tion shall be treated as a technology certifi-
13
cation order for purposes of this subchapter. 
14
‘‘(4) SUPPLEMENTS AND REPORTS.— 
15
‘‘(A) SUPPLEMENTS.—Except as provided 
16
in subparagraph (B), any person with a tech-
17
nology certification order in effect may seek a 
18
supplement to such order upon a change or 
19
changes to the information provided in the ap-
20
plication for technology certification under sub-
21
paragraphs (C), (D), and (E) of subsection 
22
(e)(2), provided that— 
23
‘‘(i) such person is an eligible person 
24
under subsection (b)(1); and 
25
02:14 Jul 08, 2021
H4128
97 
•HR 4128 IH
‘‘(ii) such change does not expand the 
1
scope of the technology certification, unless 
2
the Secretary determines that such expan-
3
sion is appropriate. 
4
A supplement to an order may contain only in-
5
formation relevant to the change or changes. 
6
The Secretary’s action on a supplement shall be 
7
in accordance with subsection (f), and any 
8
order resulting from such supplement shall be 
9
treated as an amendment to a technology cer-
10
tification order that is in effect. 
11
‘‘(B) REPORTS.— 
12
‘‘(i) IN
GENERAL.—If a change is 
13
made to an in vitro clinical test or tests 
14
that is beyond the scope of a technology 
15
certification order but is made in order to 
16
address a potential risk to public health by 
17
adding a new specification or test method, 
18
the person may immediately implement 
19
such change or changes and shall report 
20
such changes or changes to the Secretary 
21
within 30 days. 
22
‘‘(ii) CONTENT.—Any report to the 
23
Secretary under this subparagraph shall 
24
include— 
25
02:14 Jul 08, 2021
H4128
98 
•HR 4128 IH
‘‘(I) a summary of the relevant 
1
change or changes; 
2
‘‘(II) the rationale for imple-
3
menting such change or changes; 
4
‘‘(III) a description of how the 
5
change or changes were evaluated; 
6
and 
7
‘‘(IV) data indicating analytical 
8
and clinical validity. 
9
‘‘(iii) 
SUPPLEMENTAL
REPORTS.— 
10
Upon review of such report and a finding 
11
that the relevant change or changes are in-
12
consistent with the standard specified 
13
under this subparagraph, the Secretary 
14
may require a supplement under subpara-
15
graph (A). 
16
‘‘(h) MAINTENANCE REQUIREMENTS.—For the dura-
17
tion of a technology certification order, a holder of a tech-
18
nology certification order shall— 
19
‘‘(1) use the procedures included in the relevant 
20
application, supplement, or report under subsections 
21
(b) and (e); 
22
‘‘(2) ensure compliance with any applicable 
23
mitigating measures; 
24
02:14 Jul 08, 2021
H4128
99 
•HR 4128 IH
‘‘(3) maintain, and provide to the Secretary 
1
upon request, records related to any in vitro clinical 
2
test offered under the technology certification order, 
3
where those records are necessary to demonstrate 
4
compliance with applicable provisions of this sub-
5
chapter; and 
6
‘‘(4) comply with the listing requirements under 
7
section 587I for each in vitro clinical test offered 
8
under the technology certification order. 
9
‘‘(i) TEMPORARY HOLD.— 
10
‘‘(1) IN GENERAL.—Upon one or more findings 
11
under paragraph (4) and after promptly notifying 
12
the developer of such findings, the Secretary may 
13
issue a temporary hold prohibiting any holder of a 
14
technology certification order from introducing into 
15
interstate commerce an in vitro clinical test that was 
16
not previously the subject of a notification under 
17
section 587I. The temporary hold must identify the 
18
grounds for the temporary hold under paragraph (4) 
19
and the rationale for such finding, and may only re-
20
main in place until the Secretary responds to a writ-
21
ten request under paragraph (3). 
22
‘‘(2) NOTIFICATION TO THE DEVELOPER.—The 
23
Secretary shall not place a temporary hold under 
24
this subsection unless the Secretary has promptly 
25
02:14 Jul 08, 2021
H4128
100 
•HR 4128 IH
notified the developer of such hold and provided 30 
1
calendar days for the developer to come into compli-
2
ance with or resolve the findings under paragraph 
3
(4). 
4
‘‘(3) WRITTEN
REQUESTS.—Any written re-
5
quest to the Secretary from the holder of a tech-
6
nology certification order that a temporary hold 
7
under paragraph (1) be removed shall receive a deci-
8
sion, in writing and specifying the reasons therefore, 
9
within 90 days after receipt of such request. Any 
10
such request shall include information to support the 
11
removal of the temporary hold. 
12
‘‘(4) GROUNDS
FOR
TEMPORARY
HOLD.—A 
13
temporary hold under this subsection may be 
14
instated upon a finding or findings that the holder 
15
of a technology certification order— 
16
‘‘(A) is not in compliance with any mainte-
17
nance requirements under subsection (h); 
18
‘‘(B) labels or advertises one or more in 
19
vitro clinical tests with false or misleading 
20
claims; or 
21
‘‘(C) is no longer an eligible person under 
22
subsection (b)(1). 
23
‘‘(j) WITHDRAWAL.—The Secretary may, after due 
24
notice and opportunity for informal hearing, issue an 
25
02:14 Jul 08, 2021
H4128
101 
•HR 4128 IH
order withdrawing a technology certification order if the 
1
Secretary finds that— 
2
‘‘(1) the application, supplement, or report 
3
under subsection (e) or (g) contains materially false 
4
or misleading information or fails to reveal a mate-
5
rial fact; 
6
‘‘(2) such holder fails to correct materially false 
7
or misleading labeling or advertising upon the re-
8
quest of the Secretary; 
9
‘‘(3) in connection with a technology certifi-
10
cation, the holder provides materially false or mis-
11
leading information to the Secretary; or 
12
‘‘(4) the holder of such technology certification 
13
order fails to correct the grounds for temporary hold 
14
within a timeframe specified in the temporary hold 
15
order. 
16
‘‘(k) REPORTS TO CONGRESS.— 
17
‘‘(1) IN GENERAL.—Not later than one year 
18
after date of enactment of the Verifying Accurate 
19
Leading-edge IVCT Development Act of 2021, and 
20
annually thereafter for the next 4 years, the Sec-
21
retary shall submit to the Committee on Energy and 
22
Commerce of the House of Representatives and the 
23
Committee on Health, Education, Labor, and Pen-
24
sions of the Senate, and make publicly available, in-
25
02:14 Jul 08, 2021
H4128
102 
•HR 4128 IH
cluding through posting on the website of the Food 
1
and Drug Administration, a report containing the 
2
information described in paragraph (2). 
3
‘‘(2) CONTENT.— 
4
‘‘(A) IN
GENERAL.—Each report under 
5
paragraph (1) shall address, at a minimum— 
6
‘‘(i) the total number of applications 
7
for technology certifications filed, granted, 
8
withdrawn and denied; 
9
‘‘(ii) the total number of technology 
10
certification orders put on temporary hold 
11
under subsection (i) and the number of 
12
technology certification orders withdrawn 
13
under subsection (j); 
14
‘‘(iii) the types of technologies for 
15
which technology certification orders were 
16
granted; 
17
‘‘(iv) the total number of developers, 
18
including laboratories, with technology cer-
19
tification orders in effect; and 
20
‘‘(v) the total number of approved 
21
tests under section 587B that were reclas-
22
sified and granted a technology certifi-
23
cation order under this section. 
24
02:14 Jul 08, 2021
H4128
103 
•HR 4128 IH
‘‘(B) FINAL
REPORT.—The fifth report 
1
submitted under paragraph (1) shall include a 
2
summary of, and responses to, comments raised 
3
in the meeting and docket. 
4
‘‘(C) PERFORMANCE
REPORTS.—The re-
5
ports required under this section may be issued 
6
with performance reports as required under sec-
7
tion 9 of the Verifying Accurate Leading-edge 
8
IVCT Development Act of 2021. 
9
‘‘SEC. 587E. MITIGATING MEASURES. 
10
‘‘(a) ESTABLISHMENT OF MITIGATING MEASURES.— 
11
‘‘(1) ESTABLISHING, 
CHANGING, 
OR
WITH-
12
DRAWING.— 
13
‘‘(A) ESTABLISHMENT.—If the Secretary 
14
requires the establishment of mitigating meas-
15
ures pursuant to clause (i) or (ii) of section 
16
587(15)(A) for any in vitro clinical test, the 
17
Secretary may require such mitigating meas-
18
ures for any other in vitro clinical test with the 
19
same indications for use. 
20
‘‘(B) 
PROCESS.—Notwithstanding 
sub-
21
chapter II of chapter 5 of title 5, United States 
22
Code, the Secretary may— 
23
‘‘(i) establish, change, or withdraw 
24
mitigating measures by— 
25
02:14 Jul 08, 2021
H4128
104 
•HR 4128 IH
‘‘(I) publishing a proposed ad-
1
ministrative order in the Federal Reg-
2
ister; 
3
‘‘(II) providing an opportunity 
4
for public comment for a period of not 
5
less than 30 calendar days; and 
6
‘‘(III) after consideration of any 
7
comments submitted, publishing a 
8
final administrative order in the Fed-
9
eral Register; and 
10
‘‘(ii) may establish mitigating meas-
11
ures with respect to a category in a pre-
12
market approval order or technology cer-
13
tification order. 
14
‘‘(2) IN
VITRO
CLINICAL
TESTS
PREVIOUSLY 
15
APPROVED, CLEARED, OR EXEMPTED AS DEVICES.— 
16
‘‘(A) IN GENERAL.—Any special controls 
17
or restrictions applicable to an in vitro clinical 
18
test with the same indications for use pursuant 
19
to section 587(10) based on prior regulation as 
20
a device approved under section 515, cleared or 
21
exempt under section 510(k), or classified 
22
under section 513(f)(2), including any such spe-
23
cial controls or restrictions established during 
24
the period beginning on the date of enactment 
25
02:14 Jul 08, 2021
H4128
105 
•HR 4128 IH
of the Verifying Accurate Leading-edge IVCT 
1
Development Act of 2021 and ending on the ef-
2
fective date of such Act (as described in section 
3
5(b) of such Act)— 
4
‘‘(i) shall continue to apply to such 
5
approved, cleared, or exempted in vitro 
6
clinical test after such effective date; and 
7
‘‘(ii) are deemed to be mitigating 
8
measures as of the effective date of such 
9
approval, clearance, or exemption. 
10
‘‘(B) CHANGES.—The Secretary may es-
11
tablish, change, or withdraw mitigating meas-
12
ures for such a test or indications for use the 
13
procedures under paragraph (1). 
14
‘‘(b) DOCUMENTATION.— 
15
‘‘(1) TESTS
SUBJECT
TO
PREMARKET
RE-
16
VIEW.—The developer of an in vitro clinical test sub-
17
ject to premarket review under section 587B and to 
18
which mitigating measures apply shall— 
19
‘‘(A) 
in 
accordance 
with 
section 
20
587B(c)(2)(G)(i), submit documentation to the 
21
Secretary as part of the application for the test 
22
under subsection (c) or (d) of section 587B 
23
demonstrating that such mitigating measures 
24
have been met; 
25
02:14 Jul 08, 2021
H4128
106 
•HR 4128 IH
‘‘(B) if such application is approved, main-
1
tain documentation demonstrating that such 
2
mitigating measures continue to be met fol-
3
lowing a test modification by the developer; and 
4
‘‘(C) after responding to any informal com-
5
munications from the Secretary, make such 
6
documentation available to the Secretary upon 
7
request or inspection. 
8
‘‘(2) OTHER TESTS.—The developer of an in 
9
vitro clinical test that is marketed within the scope 
10
of a technology certification order or other exemp-
11
tion from premarket review under section 587B and 
12
to which mitigating measures apply shall— 
13
‘‘(A) maintain documentation in accord-
14
ance with the applicable quality requirements 
15
under section 587J demonstrating that such 
16
mitigating measures continue to be met fol-
17
lowing a test modification by the developer; 
18
‘‘(B) after responding to any informal 
19
communications from the Secretary, make such 
20
documentation available to the Secretary upon 
21
request or inspection; and 
22
‘‘(C) include in the performance summary 
23
for such test a brief description of how such 
24
mitigating measures are met, if applicable. 
25
02:14 Jul 08, 2021
H4128
107 
•HR 4128 IH
‘‘(c) MITIGATING
MEASURES
FOR
CROSS-REF-
1
ERENCED TESTS.—Not later than 1 year after the imple-
2
mentation of the Verifying Accurate Leading-edge IVCT 
3
Development Act of 2021, the Secretary shall issue miti-
4
gating measures for cross-referenced tests. 
5
‘‘SEC. 587F. REGULATORY PATHWAY REDESIGNATION. 
6
‘‘(a) TECHNOLOGY CERTIFICATION AND EXEMPTION 
7
DETERMINATIONS.— 
8
‘‘(1) IN GENERAL.—Based on new information, 
9
including the establishment of mitigating measures 
10
under section 587E, and after considering available 
11
evidence respecting tests with the same indications 
12
for use pursuant to section 587(10), the Secretary 
13
may, upon the initiative of the Secretary or upon pe-
14
tition of an interested person— 
15
‘‘(A) revoke any exemption or requirement 
16
in effect under this subchapter with respect to 
17
such indications for use; or 
18
‘‘(B) determine that such indications for 
19
use are eligible for technology certification in 
20
accordance with section 587D(b)(2). 
21
‘‘(2) PROCESS.—Any action under paragraph 
22
(1) shall be made by publication of a notice of such 
23
proposed action on the website of the Food and 
24
Drug Administration, the consideration of comments 
25
02:14 Jul 08, 2021
H4128
108 
•HR 4128 IH
to a public docket on such proposal, and publication 
1
of a final action on such website within 60 calendar 
2
days of the close of the comment period posted to 
3
such public docket, notwithstanding subchapter II of 
4
chapter 5 of title 5, United States Code. 
5
‘‘(b) REVOCATION.—The Secretary may revoke any 
6
exemption with respect to such test or indications for use 
7
pursuant to section 587(10), if— 
8
‘‘(1) new clinical information indicates that the 
9
exemption of an in vitro clinical test or tests from 
10
premarket review under section 587B or exemption 
11
under section 587A has a reasonable probability of 
12
severe adverse health consequences, including the 
13
absence, delay, or discontinuation of appropriate 
14
medical treatment. 
15
‘‘(2) PROCESS.—Any action under this sub-
16
section shall be made by publication of a notice of 
17
such proposed action in the Federal Register, con-
18
sideration of comments to a public docket on such 
19
proposal, and publication of a final notice in the 
20
Federal Register, notwithstanding subchapter II of 
21
chapter 5 of title 5, United States Code. 
22
‘‘SEC. 587G. ADVISORY COMMITTEES. 
23
‘‘(a) IN GENERAL.—The Secretary may establish ad-
24
visory committees or use advisory committee panels of ex-
25
02:14 Jul 08, 2021
H4128
109 
•HR 4128 IH
perts established before the date of enactment of this sec-
1
tion for the purposes of providing expert scientific advice 
2
and making recommendations related to— 
3
‘‘(1) the approval of an application for an in 
4
vitro clinical test submitted under this subchapter, 
5
including for evaluating, as applicable, the analytical 
6
validity, clinical validity, and safety of in vitro clin-
7
ical tests; 
8
‘‘(2) the potential effectiveness of mitigating 
9
measures for a determination on the applicable regu-
10
latory pathway under section 587F or risk evalua-
11
tion for an in vitro clinical test or tests; 
12
‘‘(3) quality requirements under section 587J 
13
or applying such requirements to in vitro clinical 
14
tests developed or imported by developers; or 
15
‘‘(4) such other purposes as the Secretary de-
16
termines appropriate. 
17
‘‘(b) APPOINTMENTS.— 
18
‘‘(1) VOTING MEMBERS.—The Secretary shall 
19
appoint to each committee established under sub-
20
section (a), as voting members, individuals who are 
21
qualified by training and experience to evaluate in 
22
vitro clinical tests referred to the committee for the 
23
purposes specified in subsection (a), including indi-
24
viduals with, to the extent feasible, scientific exper-
25
02:14 Jul 08, 2021
H4128
110 
•HR 4128 IH
tise in the development, manufacture, or utilization 
1
of such in vitro clinical tests, laboratory operations, 
2
and the use of in vitro clinical tests. The Secretary 
3
shall designate one member of each committee to 
4
serve as chair. 
5
‘‘(2) NONVOTING MEMBERS.—In addition to the 
6
individuals appointed pursuant to paragraph (1), the 
7
Secretary shall appoint to each committee estab-
8
lished under subsection (a), as nonvoting members— 
9
‘‘(A) a representative of consumer inter-
10
ests; and 
11
‘‘(B) a representative of interests of in 
12
vitro clinical test developers not directly af-
13
fected by the matter to be brought before the 
14
committee. 
15
‘‘(3) LIMITATION.—No individual who is in the 
16
regular full-time employee of the United States and 
17
engaged in the administration of this Act may be a 
18
member of any advisory committee established under 
19
subsection (a). 
20
‘‘(4) EDUCATION
AND
TRAINING.—The Sec-
21
retary shall, as appropriate, provide education and 
22
training to each new committee member before such 
23
member participates in a committee’s activities, in-
24
cluding education regarding requirements under this 
25
02:14 Jul 08, 2021
H4128
111 
•HR 4128 IH
Act and related regulations of the Secretary, and the 
1
administrative processes and procedures related to 
2
committee meetings. 
3
‘‘(5) MEETINGS.—The Secretary shall ensure 
4
that scientific advisory committees meet regularly 
5
and at appropriate intervals so that any matter to 
6
be reviewed by such a committee can be presented 
7
to the committee not more than 60 calendar days 
8
after the matter is ready for such review. Meetings 
9
of the committee may be held using electronic com-
10
munication to convene the meetings. 
11
‘‘(6) COMPENSATION.—Members of an advisory 
12
committee established under subsection (a), while at-
13
tending meetings or conferences or otherwise en-
14
gaged in the business of the advisory committee— 
15
‘‘(A) shall be entitled to receive compensa-
16
tion at rates to be fixed by the Secretary, but 
17
not to exceed the daily equivalent of the rate in 
18
effect for positions classified above level GS–15 
19
of the General Schedule; and 
20
‘‘(B) may be allowed travel expenses as au-
21
thorized by section 5703 of title 5, United 
22
States Code, for employees serving intermit-
23
tently in the Government service. 
24
02:14 Jul 08, 2021
H4128
112 
•HR 4128 IH
‘‘(c) GUIDANCE.—The Secretary may issue guidance 
1
on the policies and procedures governing advisory commit-
2
tees established under subsection (a). 
3
‘‘SEC. 587H. REQUEST FOR INFORMAL FEEDBACK. 
4
‘‘Before submitting a premarket application or tech-
5
nology certification application for an in vitro clinical 
6
test— 
7
‘‘(1) the developer of the test may submit to the 
8
Secretary a written request for a meeting, con-
9
ference, or written feedback to discuss and provide 
10
information relating to the regulation of such in 
11
vitro clinical test which may include— 
12
‘‘(A) the submission process and the type 
13
and amount of evidence expected to dem-
14
onstrate the applicable standard; 
15
‘‘(B) which regulatory pathway is appro-
16
priate for an in vitro clinical test; and 
17
‘‘(C) an investigation plan for an in vitro 
18
clinical test, including a clinical protocol; and 
19
‘‘(2) upon receipt of such a request, the Sec-
20
retary shall— 
21
‘‘(A) within 60 calendar days after such 
22
receipt, or within such time period as may be 
23
agreed to by the developer, meet or confer with 
24
the developer submitting the request; and 
25
02:14 Jul 08, 2021
H4128
113 
•HR 4128 IH
‘‘(B) within 15 calendar days after such 
1
meeting or conference, provide to the developer 
2
a written record or response describing the 
3
issues discussed and conclusions reached in the 
4
meeting or conference. 
5
‘‘SEC. 587I. REGISTRATION AND LISTING. 
6
‘‘(a) REGISTRATION OF ESTABLISHMENTS FOR IN 
7
VITRO CLINICAL TESTS.— 
8
‘‘(1) IN GENERAL.—Each person described in 
9
subsection (b)(1), or an accredited person under sec-
10
tion 587P, acting on behalf of such a person, shall— 
11
‘‘(A) during the period beginning on Octo-
12
ber 1 and ending on December 31 of each year, 
13
register with the Secretary the name of such 
14
person, places of business of such person, all es-
15
tablishments engaged in the activities specified 
16
under this paragraph, the establishment reg-
17
istration number of each such establishment, 
18
and a point of contact for each such establish-
19
ment, including an electronic point of contact; 
20
and 
21
‘‘(B) submit an initial registration con-
22
taining the information required under subpara-
23
graph (A) not later than— 
24
02:14 Jul 08, 2021
H4128
114 
•HR 4128 IH
‘‘(i) the date of implementation of this 
1
section if such establishment is engaged in 
2
any activity described in subsection (b)(1) 
3
on the date of enactment of this section, 
4
unless the Secretary establishes by guid-
5
ance a date later than such implementation 
6
date for all or a category of such establish-
7
ments; or 
8
‘‘(ii) 30 days prior to engaging in any 
9
activity described in subsection (b)(1) after 
10
enactment of this section, if such establish-
11
ment is not engaged in any activity de-
12
scribed in this paragraph on the date of 
13
enactment of this section. 
14
‘‘(2) REGISTRATION NUMBERS.—The Secretary 
15
may assign a registration number to any person or 
16
an establishment registration number to any estab-
17
lishment registered in accordance with this section. 
18
Registration information shall be made publicly 
19
available by publication on the website maintained 
20
by the Food and Drug Administration, in accord-
21
ance with subsection (d). 
22
‘‘(3) INSPECTION.—Each person or establish-
23
ment that is required to be registered with the Sec-
24
02:14 Jul 08, 2021
H4128
115 
•HR 4128 IH
retary under this section shall be subject to inspec-
1
tion pursuant to section 704. 
2
‘‘(b) LISTING INFORMATION FOR IN VITRO CLINICAL 
3
TESTS.— 
4
‘‘(1) IN GENERAL.—Each person who— 
5
‘‘(A) is a developer, a contract manufac-
6
turer (including contract packaging), contract 
7
sterilizer, repackager, relabeler, or distributor of 
8
an in vitro clinical test; and 
9
‘‘(B) introduces or proposes to begin the 
10
introduction or delivery for introduction into 
11
interstate commerce through an exemption 
12
under section 587A(f)(2)(b) or 587A(g) or 
13
through the filing of an application under sec-
14
tion 587B or 587D, 
15
shall submit a listing to the Secretary containing the 
16
information described in paragraph (2) in accord-
17
ance with the applicable schedule described under 
18
subsection (c). Such listing shall be prepared in such 
19
form and manner as the Secretary may specify in 
20
guidance. Listing information shall be submitted 
21
through the comprehensive test information system 
22
in accordance with section 587T, as appropriate. 
23
‘‘(2) SUBMISSIONS.—Each developer submitting 
24
a listing under paragraph (1) shall electronically 
25
02:14 Jul 08, 2021
H4128
116 
•HR 4128 IH
submit to the comprehensive test information system 
1
under section 587T the following information for 
2
each in vitro clinical test for which such person is 
3
a developer in the form and manner prescribed by 
4
the Secretary: 
5
‘‘(A) Name of the establishment and its es-
6
tablishment registration number. 
7
‘‘(B) Contact information for the official 
8
correspondent for the listing. 
9
‘‘(C) Name (common name and trade 
10
name, if applicable) of the in vitro clinical test 
11
and its test listing number (when available). 
12
‘‘(D) CLIA certificate number for any lab-
13
oratory certified by the Secretary under section 
14
353 of the Public Health Service Act that 
15
meets the requirements for performing high- 
16
complexity testing that is the developer of the 
17
in vitro clinical test, and CLIA certificate num-
18
ber for any laboratory under common ownership 
19
that is performing the test developed by such 
20
test developer. 
21
‘‘(E) Whether the in vitro clinical test is, 
22
as applicable, offered as a test approved under 
23
section 587B, offered under a technology cer-
24
tification o, or offered as an in vitro clinical test 
25
02:14 Jul 08, 2021
H4128
117 
•HR 4128 IH
under section 587Arder issued under section 
1
587D. 
2
‘‘(F) Indications for use information under 
3
section 587(10). 
4
‘‘(G) Brief narrative description of the in 
5
vitro clinical test. 
6
‘‘(H) A brief summary of the analytical 
7
and clinical performance of the in vitro clinical 
8
test, and as applicable, the lot release criteria. 
9
‘‘(I) A brief description of conformance 
10
with any applicable mitigating measures, re-
11
strictions, and standards. 
12
‘‘(J) Representative labeling for the in 
13
vitro clinical test, as appropriate. 
14
‘‘(K) A statement that the information 
15
submitted is truthful and accurate. 
16
‘‘(3) TEST LISTING NUMBER.—The Secretary 
17
may assign a test listing number to each in vitro 
18
clinical test that is the subject of a listing under this 
19
section. The process for assigning test listing num-
20
bers may be established through guidance, and may 
21
include the recognition of standards, formats, or 
22
conventions developed by a third-party organization. 
23
‘‘(4) ABBREVIATED LISTING.—A person who is 
24
not a developer but is otherwise required to register 
25
02:14 Jul 08, 2021
H4128
118 
•HR 4128 IH
pursuant to subsection (a) shall submit an abbre-
1
viated listing to the Secretary containing the infor-
2
mation described in subparagraphs (A) through (C) 
3
of paragraph (2), and the name of the developer. 
4
The information shall be submitted in accordance 
5
with the applicable schedule described under sub-
6
section (c). Such abbreviated listing shall be pre-
7
pared in such form and manner as the Secretary 
8
may specify in guidance. Listing information shall be 
9
submitted to the comprehensive test information sys-
10
tem in accordance with section 587T, as appro-
11
priate. 
12
‘‘(5) GRANDFATHERED TESTS.—A developer of 
13
an in vitro clinical test developer offering a test that 
14
is grandfathered under section 587A(c) shall submit 
15
listing information required under subparagraphs 
16
(A) through (K) of paragraph (2). 
17
‘‘(6) LOW-RISK TESTS.—A developer of a low 
18
risk in vitro clinical test shall notify and submit list-
19
ing information to the Secretary within one year of 
20
offering such test for clinical use. 
21
‘‘(7) EXEMPT
TESTS.—A developer of an in 
22
vitro clinical test who introduces or proposes to 
23
begin the introduction or delivery for introduction 
24
into interstate commerce pursuant to an exemption 
25
02:14 Jul 08, 2021
H4128
119 
•HR 4128 IH
under section 587A may submit listing information 
1
under this subsection. 
2
‘‘(c) TIMELINES FOR SUBMISSION.— 
3
‘‘(1) IN GENERAL.—The timelines for submis-
4
sion of registration and listing under subsections (a) 
5
and (b) are as follows: 
6
‘‘(A) For an in vitro clinical test that was 
7
listed as a device under section 510(j) prior to 
8
the date of enactment of this section, a person 
9
shall maintain a device listing under section 
10
510 until such time as the system for submit-
11
ting the notification information required under 
12
subsection (b) becomes available and thereafter 
13
shall submit the notification information no 
14
later than 1 year after the system for submit-
15
ting the notification under this section becomes 
16
available. 
17
‘‘(B) For an in vitro clinical test that is 
18
subject to the grandfathering provisions of sec-
19
tion 587A(c), a person shall submit the listing 
20
information required under subsection (b)(5) no 
21
later than 1 year after the system for submit-
22
ting the notification under this section becomes 
23
available. 
24
02:14 Jul 08, 2021
H4128
120 
•HR 4128 IH
‘‘(C) For an in vitro clinical test that is 
1
not described in subparagraph (A) or (B), a 
2
person shall submit the required notification in-
3
formation prior to offering, introducing, or mar-
4
keting the in vitro clinical test as follows: 
5
‘‘(i) For an in vitro clinical test that 
6
is not exempt from premarket approval 
7
under section 587B, a person shall submit 
8
the required listing information no later 
9
than 30 business days after the date of ap-
10
proval of the premarket approval applica-
11
tion. 
12
‘‘(ii) For a developer who has received 
13
a technology certification order under sec-
14
tion 587D, a person shall submit the re-
15
quired listing information at least 30 busi-
16
ness days after receiving such technology 
17
certification order. 
18
‘‘(2) UPDATES.— 
19
‘‘(A) UPDATES
AFTER
CHANGES.—Each 
20
developer required to submit listing information 
21
under this section shall update such informa-
22
tion within 10 business days of any change that 
23
causes any previously notified information to be 
24
inaccurate or incomplete. 
25
02:14 Jul 08, 2021
H4128
121 
•HR 4128 IH
‘‘(B) ANNUAL UPDATES.—Each developer 
1
required to submit listing information under 
2
this section shall update its information annu-
3
ally during the period beginning on October 1 
4
and ending on December 31 of each year as a 
5
component of the annual report submitted 
6
under sections 587B and 587D. 
7
‘‘(d) PUBLIC AVAILABILITY OF NOTIFICATION IN-
8
FORMATION.— 
9
‘‘(1) IN
GENERAL.—Notification information 
10
submitted pursuant to this section shall be made 
11
publicly available on the website of the Food and 
12
Drug Administration in accordance with paragraph 
13
(3). 
14
‘‘(2) CONFIDENTIALITY.—Notification informa-
15
tion for an in vitro clinical test that is subject to 
16
premarket approval or technical certification shall 
17
remain confidential until such date as the in vitro 
18
clinical test receives the applicable premarket ap-
19
proval or the developer receives a technology certifi-
20
cation order. 
21
‘‘(3) EXCEPTIONS FROM PUBLIC AVAILABILITY 
22
REQUIREMENTS.—The registration and listing infor-
23
mation requirements described in subsections (a) 
24
02:14 Jul 08, 2021
H4128
122 
•HR 4128 IH
and (b) shall not apply to the extent the Secretary 
1
determines that such information relates to— 
2
‘‘(A) trade secret or commercial confiden-
3
tial information; or 
4
‘‘(B) national security or countermeasures 
5
or is restricted from disclosure pursuant to an-
6
other provision of law. 
7
‘‘(e) SUBMISSION OF INFORMATION BY ACCREDITED 
8
PERSONS.—If agreed upon by the developer, the informa-
9
tion required under this section may be submitted by an 
10
accredited person under section 587P. 
11
‘‘SEC. 587J. TEST DESIGN AND QUALITY REQUIREMENTS. 
12
‘‘(a) APPLICABILITY.— 
13
‘‘(1) IN GENERAL.—Each developer and each 
14
other person required to register under section 
15
587I(b)(1) shall establish and maintain quality re-
16
quirements in accordance with the applicable re-
17
quirements set forth in subsection (b), except as pro-
18
vided in section 587A. 
19
‘‘(2) 
CERTIFIED
LABORATORY
REQUIRE-
20
MENTS.—A developer that operates a clinical labora-
21
tory certified by the Secretary under section 353 of 
22
the Public Health Service Act that— 
23
‘‘(A) meets the requirements for per-
24
forming high-complexity testing; 
25
02:14 Jul 08, 2021
H4128
123 
•HR 4128 IH
‘‘(B)(i) develops an vitro clinical test or in-
1
dications for use; or 
2
‘‘(ii) modifies another developer’s in vitro 
3
clinical test in that certified laboratory in a 
4
manner described in section 587(6)(C); and 
5
‘‘(C) develops an in vitro clinical test or in-
6
dications for use that are for use only within 
7
that certified laboratory or within another cer-
8
tified laboratory with common ownership, 
9
shall establish and maintain quality requirements 
10
that comply with the requirements set forth in sub-
11
section (b)(2). 
12
‘‘(3) APPLICABILITY
FOR
CERTAIN
IN
VITRO 
13
CLINICAL TESTS.—The applicable requirements set 
14
forth in subsection (b)(1) shall apply to any instru-
15
ment, specimen receptacle, or component or part 
16
that is developed for use by a clinical laboratory to 
17
which paragraph (2) applies. 
18
‘‘(4) REGULATIONS.—In promulgating regula-
19
tions under this section, the Secretary shall consider 
20
whether and to what extent international harmoni-
21
zation is appropriate. 
22
‘‘(b) QUALITY REQUIREMENTS.— 
23
‘‘(1) QUALITY
REQUIREMENTS
FOR
LABORA-
24
TORIES WITHOUT CLIA CERTIFICATION TO CONDUCT 
25
02:14 Jul 08, 2021
H4128
124 
•HR 4128 IH
HIGH-COMPLEXITY
TESTS.—The quality require-
1
ments applicable under this section shall— 
2
‘‘(A) avoid duplication of regulations under 
3
section 353 of the Public Health Service Act; 
4
‘‘(B) apply only to the development, valida-
5
tion, production, preparation, propagation, or 
6
assembly related to the design and associated 
7
manufacture and distribution of an in vitro clin-
8
ical test offered under this subchapter; 
9
‘‘(C) not apply with respect to laboratory 
10
operations; and 
11
‘‘(D) shall include the following, subject to 
12
paragraphs (2) and (3)— 
13
‘‘(i) management responsibility; 
14
‘‘(ii) quality audits; 
15
‘‘(iii) personnel; 
16
‘‘(iv) design controls; 
17
‘‘(v) document controls; 
18
‘‘(vi) purchasing controls; 
19
‘‘(vii) identification and traceability; 
20
‘‘(viii) production and process con-
21
trols; 
22
‘‘(ix) acceptance activities; 
23
‘‘(x) nonconforming product; 
24
‘‘(xi) corrective and preventive action; 
25
02:14 Jul 08, 2021
H4128
125 
•HR 4128 IH
‘‘(xii) labeling and packaging controls; 
1
‘‘(xiii) handling, storage, distribution, 
2
and installation; 
3
‘‘(xiv) records; 
4
‘‘(xv) servicing; and 
5
‘‘(xvi) statistical techniques. 
6
‘‘(2) QUALITY
REQUIREMENTS
FOR
LABORA-
7
TORIES CERTIFIED TO CONDUCT HIGH-COMPLEXITY 
8
TESTS.—Quality requirements applicable to the in 
9
vitro clinical tests and developers described in sub-
10
section (a)(2) shall— 
11
‘‘(A) avoid duplication of regulations under 
12
section 353 of the Public Health Service Act; 
13
and 
14
‘‘(B) consist of, as directed related to the 
15
design and development— 
16
‘‘(i) design controls; 
17
‘‘(ii) purchasing controls; 
18
‘‘(iii) acceptance activities; 
19
‘‘(iv) corrective and preventative ac-
20
tion; and 
21
‘‘(v) records. 
22
‘‘(3) QUALITY
REQUIREMENTS
FOR
CERTAIN 
23
LABORATORIES
DISTRIBUTING
IN
VITRO
CLINICAL 
24
02:14 Jul 08, 2021
H4128
126 
•HR 4128 IH
TESTS OR TEST PROTOCOLS WITHIN ORGANIZATIONS 
1
OR PUBLIC HEALTH NETWORKS.— 
2
‘‘(A) IN GENERAL.—Quality requirements 
3
applicable to the developer who is distributing 
4
in vitro clinical test distributed as described in 
5
subparagraph (B) shall consist of the following: 
6
‘‘(i) The requirements in paragraph 
7
(2). 
8
‘‘(ii) The labeling requirements in 
9
paragraph (1)(C)(xii). 
10
‘‘(iii) The requirement to maintain 
11
records of the laboratories to which the in 
12
vitro clinical test or test protocol is distrib-
13
uted. 
14
‘‘(B) DISTRIBUTING
LABORATORY.—Sub-
15
paragraph (A) shall apply to developers that 
16
meet the following conditions: 
17
‘‘(i) The laboratory distributing the 
18
test protocol is certified by the Secretary 
19
under section 353 of the Public Health 
20
Service Act and meets the requirements for 
21
performing high-complexity testing. 
22
‘‘(ii) The laboratory develops its own 
23
in vitro clinical test or modifies another de-
24
02:14 Jul 08, 2021
H4128
127 
•HR 4128 IH
veloper’s in vitro clinical test in a manner 
1
described in section 587(6)(C). 
2
‘‘(iii) The laboratory distributes the in 
3
vitro clinical test or test protocol for such 
4
test only to another laboratory that— 
5
‘‘(I) is certified by the Secretary 
6
under section 353 of the Public 
7
Health Service Act and meets the re-
8
quirements for performing high-com-
9
plexity testing; 
10
‘‘(II) is within the same cor-
11
porate organization and having com-
12
mon ownership by the same parent 
13
corporation; or as applicable, is a lab-
14
oratory within a public health labora-
15
tory network coordinated or managed 
16
by the Centers for Disease Control 
17
and Prevention; and 
18
‘‘(III) implements the test pro-
19
tocol without further modification. 
20
‘‘(c) REGULATIONS.—In implementing quality re-
21
quirements for test developers under this section, the Sec-
22
retary shall— 
23
‘‘(1) for purposes of facilitating international 
24
harmonization, consider whether the developer par-
25
02:14 Jul 08, 2021
H4128
128 
•HR 4128 IH
ticipates in an audit program in which the United 
1
States participates or the United States recognizes 
2
or conforms with standards recognized by the Sec-
3
retary; and 
4
‘‘(2) ensure a least burdensome approach de-
5
scribed in section 587B(j) by leveraging, to the ex-
6
tent applicable, the quality assurance requirements 
7
applicable to developers certified by the Secretary 
8
under section 353 of the Public Health Service Act. 
9
‘‘SEC. 587K. LABELING REQUIREMENTS. 
10
‘‘(a) IN GENERAL.—An in vitro clinical test shall 
11
bear or be accompanied by labeling, and a label as applica-
12
ble, that meet the requirements set forth in subsections 
13
(b) and (c), unless such test is exempt as specified in sub-
14
section (d) or (e). 
15
‘‘(b) LABELS.— 
16
‘‘(1) IN GENERAL.—The label of an in vitro 
17
clinical test shall meet the requirements set forth in 
18
paragraph (2), except this requirement shall not 
19
apply to an in vitro clinical test that— 
20
‘‘(A) consists solely of a test protocol; or 
21
‘‘(B) is developed, manufactured, and used 
22
solely within a single laboratory certified by the 
23
Secretary under section 353 of the Public 
24
02:14 Jul 08, 2021
H4128
129 
•HR 4128 IH
Health Service Act that meets the requirements 
1
for performing high-complexity testing. 
2
‘‘(2) REGULATIONS.—The label of an in vitro 
3
clinical test shall state the name and place of busi-
4
ness of its developer and meet the requirements set 
5
forth in regulations promulgated under this section. 
6
‘‘(c) LABELING.— 
7
‘‘(1) IN GENERAL.—Labeling accompanying an 
8
in vitro clinical test, including labeling in the form 
9
of a package insert, standalone laboratory reference 
10
document, or other similar document except the la-
11
beling specified in paragraph (2), shall include ade-
12
quate directions for use and shall meet the require-
13
ments set forth in regulations promulgated under 
14
this section, except as provided in subsection (d) or 
15
(e). 
16
‘‘(2) CONTENT.— 
17
‘‘(A) 
IN
GENERAL.—Labeling 
accom-
18
panying an in vitro clinical test that is in the 
19
form of a test report template or ordering infor-
20
mation shall include— 
21
‘‘(i) the test listing number that was 
22
provided to the developer at the time of 
23
listing; 
24
02:14 Jul 08, 2021
H4128
130 
•HR 4128 IH
‘‘(ii) instructions for how and where 
1
to report an adverse event under section 
2
587L; 
3
‘‘(iii) instructions for how and where 
4
to access the performance summary data 
5
displayed in the listing database for the 
6
test; 
7
‘‘(iv) the intended use of the in vitro 
8
clinical test; and 
9
‘‘(v) any warnings, contraindications, 
10
or limitations. 
11
‘‘(B) PUBLIC AVAILABILITY OF INFORMA-
12
TION.—The Secretary shall make all of the in-
13
formation described in subparagraph (A) with 
14
respect to each in vitro clinical test available to 
15
the public, as applicable, in accordance with 
16
section 587T, except to the extent that the Sec-
17
retary determines that such information is— 
18
‘‘(i) trade secret or commercial con-
19
fidential information; or 
20
‘‘(ii) national security or counter-
21
measures or is restricted from disclosure 
22
pursuant to another provision of law. 
23
‘‘(3) ADDITIONAL
REQUIREMENTS.—Labeling 
24
for 
an 
in 
vitro 
clinical 
test 
used 
for 
25
02:14 Jul 08, 2021
H4128
131 
•HR 4128 IH
immunohematology testing shall meet the applicable 
1
requirements set forth in part 660 of title 21, Code 
2
of Federal Regulations (or any successor regula-
3
tions), related to the labeling of blood grouping re-
4
agents, reagent red blood cells, and anti-human 
5
globulin. 
6
‘‘(d) EXEMPTIONS
AND ALTERNATIVE REQUIRE-
7
MENTS.— 
8
‘‘(1) IN GENERAL.— 
9
‘‘(A) IN GENERAL.—With respect to an in 
10
vitro clinical test that meets the criteria of sub-
11
paragraph (B), the ‘state in one place’ regula-
12
tions under section 809.10(b) of title 21 of the 
13
Code of Federal Regulations (or any successor 
14
regulations) may be satisfied by the laboratory 
15
posting such information on its website or in 
16
multiple documents, if such documents are 
17
maintained and accessible in one place. 
18
‘‘(B) APPLICABLE
TESTS.—An in vitro 
19
clinical test meets the criteria of this subpara-
20
graph if such test is— 
21
‘‘(i) designed and manufactured by a 
22
laboratory certified by the Secretary under 
23
section 353 of the Public Health Service 
24
02:14 Jul 08, 2021
H4128
132 
•HR 4128 IH
Act that meets the requirements for per-
1
forming high-complexity testing; and 
2
‘‘(ii) performed in the same laboratory 
3
in which it was developed or by another 
4
such laboratory certified by the Secretary 
5
under section 353 of the Public Health 
6
Service Act that meets the requirements 
7
for performing high complexity testing and 
8
is under common ownership with the lab-
9
oratory that designed and manufactured 
10
the test. 
11
‘‘(2) TEST INSTRUMENT LABELING.—The label-
12
ing for an instrument is not required to bear the in-
13
formation indicated in paragraphs (3), (4), (5), (7), 
14
(8), (9), (10), (11), (12), and (13) of section 
15
809.10(b) of title 21 of the Code of Federal Regula-
16
tions (or any successor regulations). 
17
‘‘(3) REAGENT
LABELING.—For purposes of 
18
compliance with subsection (c)(1), the labeling for a 
19
reagent intended for use as a replacement in an in 
20
vitro clinical test may be limited to that information 
21
necessary to identify the reagent adequately and to 
22
describe its proper use in the system. 
23
‘‘(4) LAB
RESEARCH
OR
INVESTIGATIONAL 
24
USE.—A shipment or other delivery of an in vitro 
25
02:14 Jul 08, 2021
H4128
133 
•HR 4128 IH
clinical test for research or investigational use pur-
1
suant to section 587A(m) shall be exempt from the 
2
labeling requirements of subsections (b) and (c)(1) 
3
and from any standard promulgated through regula-
4
tions, except as required under section 353 of the 
5
Public Health Service Act or section 587R of this 
6
Act. 
7
‘‘(5) GENERAL
PURPOSE
LABORATORY
RE-
8
AGENTS.—The labeling of general purpose labora-
9
tory reagents (such as hydrochloric acid) whose uses 
10
are generally known by persons trained in their use 
11
need not bear the directions for use required by sub-
12
sections (b) and (c)(1). 
13
‘‘(6) ANALYTE SPECIFIC REAGENTS.—The la-
14
beling for analyte specific reagents shall bear the fol-
15
lowing statement: ‘This product is intended solely 
16
for further development of an in vitro clinical test 
17
and is exempt from most FDA regulation. This 
18
product must be evaluated by the in vitro clinical 
19
test developer in accordance with applicable require-
20
ments.’. If the labeling of an analyte specific reagent 
21
bears the statement set forth in this paragraph, it 
22
need not bear the information required by subsection 
23
(c)(1). 
24
02:14 Jul 08, 2021
H4128
134 
•HR 4128 IH
‘‘(7) OVER-THE-COUNTER TEST SAMPLE COL-
1
LECTION
SYSTEMS
LABELING.—The labeling for 
2
over-the-counter test sample collection systems for 
3
drugs of abuse testing shall bear the name and place 
4
of business of the developer included in the registra-
5
tion listing under section 587I, in language appro-
6
priate for the intended users. 
7
‘‘(e) TESTS IN THE STRATEGIC NATIONAL STOCK-
8
PILE.— 
9
‘‘(1) IN GENERAL.—The Secretary may grant 
10
an exception or alternative to any provision listed in 
11
this section, unless explicitly required by a statutory 
12
provision outside this subchapter, for specified lots, 
13
batches, or other units of an in vitro clinical test, if 
14
the Secretary determines that compliance with such 
15
labeling requirement could adversely affect the safe-
16
ty, effectiveness, or availability of such products that 
17
are or will be included in the Strategic National 
18
Stockpile under section 319F–2 of the Public Health 
19
Service Act. 
20
‘‘(2) REGULATIONS.—The Secretary may issue 
21
regulations amending section 809.11 of title 21 of 
22
the Code of Federal Regulations or any successor 
23
regulation to apply in full or in part to in vitro clin-
24
ical tests and in vitro clinical test developers. 
25
02:14 Jul 08, 2021
H4128
135 
•HR 4128 IH
‘‘(f) GUIDANCE.—The Secretary may, in collabora-
1
tion with developers, issue guidance on standardized, gen-
2
eral content and format for in vitro clinical test labeling 
3
to help ensure compliance with applicable requirements in 
4
this subsection. 
5
‘‘SEC. 587L. ADVERSE EVENT REPORTING. 
6
‘‘(a) APPLICABILITY.— 
7
‘‘(1) IN GENERAL.—Each in vitro clinical test 
8
developer shall establish and maintain a system for 
9
reporting adverse events in accordance with sub-
10
section (b), except as provided in section 587A. 
11
‘‘(2) REGULATIONS.—The Secretary shall pro-
12
mulgate regulations to implement this section, in-
13
cluding information necessary to be reported to en-
14
sure the analytical and clinical validity of in vitro 
15
clinical tests, and the safety of articles for taking or 
16
deriving specimens from the human body. 
17
‘‘(b) 
ADVERSE
EVENT
REPORTING
REQUIRE-
18
MENTS.—Each developer shall report to the Secretary 
19
whenever information that reasonably suggests that one 
20
of the developer’s in vitro clinical tests is associated with 
21
an adverse event becomes known to the developer. 
22
‘‘(c) REPORTS.—Reports required under this section 
23
shall be submitted as follows: 
24
02:14 Jul 08, 2021
H4128
136 
•HR 4128 IH
‘‘(1) An individual adverse event report shall be 
1
submitted for the following events not later than— 
2
‘‘(A) 5 calendar days after an in vitro clin-
3
ical test developer receives or otherwise becomes 
4
aware of information that reasonably suggests 
5
the adverse event involves a patient death; or 
6
‘‘(B) 5 calendar days after an in vitro clin-
7
ical test developer receives or otherwise becomes 
8
aware of information that reasonably suggests 
9
the event presents an imminent threat to public 
10
health. 
11
‘‘(2) Quarterly reports shall be submitted for all 
12
other adverse events, if any, and no later than the 
13
end of the quarter following the quarter in which the 
14
adverse event information was received by the in 
15
vitro clinical test developer. 
16
‘‘(d) DEFINITIONS.—In this section— 
17
‘‘(1) the term ‘adverse event’— 
18
‘‘(A) means— 
19
‘‘(i) death of, or serious injury to, a 
20
specific patient or user for which it is rea-
21
sonably believed that an in vitro clinical 
22
test error contributed to such death or se-
23
rious injury; or 
24
02:14 Jul 08, 2021
H4128
137 
•HR 4128 IH
‘‘(ii) an in vitro clinical test error that 
1
may have reasonable likelihood to cause se-
2
rious injury or death; and 
3
‘‘(B) excludes laboratory errors that are 
4
subject to the requirements of section 353 of 
5
the Public Health Service Act and corrective or 
6
preventive actions to prevent such errors; 
7
‘‘(2) the term ‘in vitro clinical test error’— 
8
‘‘(A) means a failure in an in vitro clinical 
9
test to meet the analytical or clinical validity 
10
standard or otherwise perform as intended by 
11
the developer; and 
12
‘‘(B) includes an inaccurate false result 
13
that reaches a health care provider, patient, or 
14
consumer, except that such term excludes any 
15
such event or error related to laboratory oper-
16
ations pursuant to section 353 of the Public 
17
Health Service Act; and 
18
‘‘(3) the term ‘serious injury’ means— 
19
‘‘(A) a significant delay in a critical diag-
20
nosis or causing the absence, delay, or dis-
21
continuation of critical medical treatment or 
22
that irreversibly or seriously and negatively al-
23
ters the course of the disease or condition; or 
24
‘‘(B) an injury that— 
25
02:14 Jul 08, 2021
H4128
138 
•HR 4128 IH
‘‘(i) is life threatening; 
1
‘‘(ii) results in permanent impairment 
2
of a body function or permanent damage 
3
to a body structure; or 
4
‘‘(iii) necessitates medical or surgical 
5
intervention to preclude permanent impair-
6
ment of a body function or permanent 
7
damage to a body structure. 
8
‘‘SEC. 587M. CORRECTIONS AND REMOVALS. 
9
‘‘(a) IN GENERAL.—The Secretary shall promulgate 
10
regulations to implement this section, including informa-
11
tion necessary to be reported to ensure the analytical and 
12
clinical validity of in vitro clinical tests, and the safety of 
13
specimen receptacles. 
14
‘‘(b) REPORTS OF REMOVALS AND CORRECTIONS.— 
15
‘‘(1) IN GENERAL.—Each in vitro clinical test 
16
developer or importer shall report to the Secretary 
17
any correction or removal of an in vitro clinical test 
18
undertaken by such developer or importer if the re-
19
moval or correction was undertaken— 
20
‘‘(A) to reduce the risk to health posed by 
21
the in vitro clinical test; or 
22
‘‘(B) to remedy a violation of this Act 
23
caused by the in vitro clinical test which may 
24
present a risk to health. 
25
02:14 Jul 08, 2021
H4128
139 
•HR 4128 IH
‘‘(2) EXCEPTION.—No report of the correction 
1
or removal of an in vitro clinical test is required 
2
under paragraph (1) if a report of the correction or 
3
removal is required under, and has been submitted 
4
under, section 587L. 
5
‘‘(c) TIMING.—A developer or importer shall submit 
6
any report required under this subsection to the Secretary 
7
within 15 business days of initiating such correction or 
8
removal. 
9
‘‘(d) RECORDKEEPING.—A developer or importer of 
10
an in vitro clinical test who undertakes a correction or re-
11
moval of an in vitro clinical test which is not required to 
12
be reported under this subsection shall keep a record of 
13
such correction or removal. 
14
‘‘(e) RECALL
COMMUNICATIONS.—Upon the vol-
15
untary reporting of a correction or removal by the devel-
16
oper— 
17
‘‘(1) the Secretary shall classify such correction 
18
or removal under this section within 15 calendar 
19
days; and 
20
‘‘(2) not later than 45 calendar days after the 
21
developer or other responsible party notifies the Sec-
22
retary that it has completed a recall action, the Sec-
23
retary shall provide the developer or other respon-
24
sible party with a written statement closing the re-
25
02:14 Jul 08, 2021
H4128
140 
•HR 4128 IH
call action or stating the reasons the Secretary can-
1
not close the recall at that time. 
2
‘‘(f) LIMITATION.—The developer is not required to 
3
report a correction or removal of an in vitro clinical test 
4
based solely on an adverse event report under section 
5
587L that captures an error within the approved perform-
6
ance standards for such test. 
7
‘‘(g) DEFINITIONS.—For purposes of this section— 
8
‘‘(1) the term ‘correction’ means the repair, 
9
modification, adjustment, relabeling, destruction, or 
10
inspection (including patient monitoring) of an in 
11
vitro clinical test without its physical removal from 
12
its point of use to another location, and does not in-
13
clude routine servicing; and 
14
‘‘(2) the term ‘removal’ means the physical re-
15
moval of an in vitro clinical test from its point of use 
16
to another location for repair, modification, adjust-
17
ment, relabeling, destruction, or inspection, and does 
18
not include routine servicing. 
19
‘‘SEC. 587N. RESTRICTED IN VITRO CLINICAL TESTS. 
20
‘‘(a) APPLICABILITY.— 
21
‘‘(1) IN GENERAL.—The Secretary, in issuing 
22
an approval of an in vitro clinical test under section 
23
587B of a category described in paragraph (3) may 
24
require that such test be restricted to sale, distribu-
25
02:14 Jul 08, 2021
H4128
141 
•HR 4128 IH
tion, or use upon such conditions as the Secretary 
1
may prescribe under paragraph (2). 
2
‘‘(2) CONDITIONS
PRESCRIBED
BY
THE
SEC-
3
RETARY.—The conditions prescribed by the Sec-
4
retary under this paragraph, with respect to an in 
5
vitro clinical test described in paragraph (3), are 
6
those conditions which the Secretary determines due 
7
to the potentiality for harmful effect of such test (in-
8
cluding any resulting absence, delay, or discontinu-
9
ation of appropriate medical treatment), are nec-
10
essary to assure the analytical or clinical validity of 
11
the test, or the safety of a specimen receptacle. 
12
‘‘(3) IN VITRO CLINICAL TESTS SUBJECT TO 
13
RESTRICTIONS.—The restrictions authorized under 
14
this section may be applied by the Secretary to any 
15
high-risk in vitro clinical test, prescription home-use 
16
in vitro clinical test, direct-to-consumer in vitro clin-
17
ical test, or over-the-counter in vitro clinical test. 
18
‘‘(b) LABELING AND ADVERTISING OF A RESTRICTED 
19
IN VITRO CLINICAL TEST.—The label, labeling, and ad-
20
vertising of an in vitro clinical test to which restrictions 
21
apply under subsection (a) shall bear such appropriate 
22
statements of the restrictions as the Secretary may pre-
23
scribe in the approval, provisional approval, technology 
24
certification, or regulation, as applicable. 
25
02:14 Jul 08, 2021
H4128
142 
•HR 4128 IH
‘‘(c) REQUIREMENTS PRIOR TO ENACTMENT.—An in 
1
vitro clinical test that was offered, sold, or distributed as 
2
a restricted device prior to the enactment date of this sub-
3
chapter shall continue to comply with the applicable re-
4
strictions under section 515 or section 520(e) until the 
5
effective date of restrictions issued under subsection (a). 
6
‘‘SEC. 587O. APPEALS. 
7
‘‘(a) SIGNIFICANT DECISION.— 
8
‘‘(1) IN GENERAL.—The Secretary shall provide 
9
a substantive summary of the scientific and regu-
10
latory rationale for any significant decision of the 
11
Center for Devices and Radiological Health regard-
12
ing submission of an application for, or a review of, 
13
an in vitro clinical test under section 587B or sec-
14
tion 587D or regarding an exemption under section 
15
587A, including documentation of significant con-
16
troversies or differences of opinion and the resolu-
17
tion of such controversies or differences of opinion. 
18
‘‘(2) PROVISION
OF
DOCUMENTATION.—Upon 
19
request, the Secretary shall furnish a substantive 
20
summary described in paragraph (1) to the person 
21
who has made, or is seeking to make, a submission 
22
described in such paragraph. 
23
‘‘(3) APPLICATION OF LEAST BURDENSOME RE-
24
QUIREMENTS.—The substantive summary required 
25
02:14 Jul 08, 2021
H4128
143 
•HR 4128 IH
under this subsection shall include a brief statement 
1
regarding how the least burdensome requirements 
2
were considered and applied consistent with section 
3
587B(j), as applicable. 
4
‘‘(b) REVIEW OF SIGNIFICANT DECISIONS.— 
5
‘‘(1) REQUEST FOR SUPERVISORY REVIEW OF 
6
SIGNIFICANT DECISION.—Any person may request a 
7
supervisory review of the significant decision de-
8
scribed in subsection (a)(1). Such review may be 
9
conducted at the next supervisory level or higher 
10
above the agency official who made the significant 
11
decision. 
12
‘‘(2) SUBMISSION OF REQUEST.—A person re-
13
questing a supervisory review under paragraph (1) 
14
shall submit such request to the Secretary not later 
15
than 30 days after the decision for which the review 
16
is requested and shall indicate in the request wheth-
17
er such person seeks an in-person meeting or a tele-
18
conference review. 
19
‘‘(3) TIMEFRAME.—The Secretary shall sched-
20
ule an in-person or teleconference review, if so re-
21
quested, not later than 30 days after such request 
22
is made. The Secretary shall issue a decision to the 
23
person requesting a review under this subsection not 
24
later than 45 days after the request is made under 
25
02:14 Jul 08, 2021
H4128
144 
•HR 4128 IH
paragraph (1), or, in the case of a person who re-
1
quests an in-person meeting or teleconference, 30 
2
days after such meeting or teleconference. 
3
‘‘(c) ADVISORY PANELS.—The process established 
4
under subsection (a) shall permit the appellant to request 
5
review by an advisory committee established under section 
6
513 or 587G. The Secretary shall provide a response to 
7
an appellant under this subsection not later than 45 days 
8
after the requested advisory committee is convened. 
9
‘‘SEC. 587P. ACCREDITED PERSONS. 
10
‘‘(a) IN GENERAL.— 
11
‘‘(1) REVIEW OF APPLICATIONS.— 
12
‘‘(A) ACCREDITATION
FOR
APPLICATION 
13
REVIEW.—Subject to subparagraph (C), during 
14
the period beginning on the date of enactment 
15
of the Verifying Accurate Leading-edge IVCT 
16
Development Act of 2021 and ending 2 years 
17
after the date of enactment of such Act, the 
18
Secretary shall accredit persons for any of the 
19
following purposes: 
20
‘‘(i) Reviewing applications for pre-
21
market approval under section 587B and 
22
applications for technology certification 
23
under section 587D. 
24
02:14 Jul 08, 2021
H4128
145 
•HR 4128 IH
‘‘(ii) Making recommendations to the 
1
Secretary with respect to an approval of an 
2
application under section 587B or issuance 
3
of a technology certification order under 
4
section 587D. 
5
‘‘(B) REQUIREMENT
REGARDING
REVIEW 
6
RECOMMENDATIONS.— 
7
‘‘(i) IN GENERAL.—In making a rec-
8
ommendation to the Secretary under this 
9
section, an accredited person shall notify 
10
the Secretary in writing of the reasons for 
11
the recommendation concerning the appli-
12
cation. 
13
‘‘(ii) TIME
PERIOD
FOR
REVIEW.— 
14
Not later than 30 calendar days after the 
15
date on which the Secretary is notified of 
16
a recommendation under this section with 
17
respect to an application for premarket ap-
18
proval or technology certification, the Sec-
19
retary shall make a determination with re-
20
spect to the application. 
21
‘‘(C) LACK OF APPLICATIONS WITHIN 2- 
22
YEAR TIMEFRAME.—If the Secretary does not 
23
receive applications from persons that meet the 
24
02:14 Jul 08, 2021
H4128
146 
•HR 4128 IH
criteria under subsection (c) within such period, 
1
the Secretary— 
2
‘‘(i) may accredit persons under this 
3
paragraph after the 2-year period de-
4
scribed in subparagraph (A); and 
5
‘‘(ii) shall issue a public notice on the 
6
website of the Food and Drug Administra-
7
tion calling for applications for such ac-
8
creditation. 
9
‘‘(2) INSPECTIONS.— 
10
‘‘(A) ACCREDITATION FOR INSPECTIONS.— 
11
Subject to subparagraph (B), during the period 
12
beginning on the date of enactment of the 
13
Verifying Accurate Leading-edge IVCT Devel-
14
opment Act of 2021 and ending 2 years after 
15
the date of enactment of such Act, the Sec-
16
retary shall accredit persons for the purpose of 
17
conducting inspections of in vitro clinical test 
18
developers and other persons required to reg-
19
ister pursuant to section 587I. 
20
‘‘(B) LACK OF APPLICATIONS WITHIN 2- 
21
YEAR TIMEFRAME.—If no persons who meet the 
22
criteria for such accreditation apply during the 
23
2-year period described in subparagraph (A), 
24
the Secretary— 
25
02:14 Jul 08, 2021
H4128
147 
•HR 4128 IH
‘‘(i) may accredit persons under this 
1
subparagraph after such period; and 
2
‘‘(ii) shall issue a public notice on the 
3
website of the Food and Drug Administra-
4
tion calling for applications for such ac-
5
creditation. 
6
‘‘(C) EFFECT OF ACCREDITATION.— 
7
‘‘(i) IN GENERAL.—Persons accredited 
8
under subparagraph (A) to conduct inspec-
9
tions, when conducting such inspections, 
10
shall record in writing their specific obser-
11
vations and shall present their observations 
12
to the designated representative of the in-
13
spected establishment. 
14
‘‘(ii) INSPECTION
REPORT
REQUIRE-
15
MENTS.—Each person accredited under 
16
this paragraph shall prepare and submit to 
17
the Secretary an inspection report in a 
18
form and manner designated by the Sec-
19
retary for conducting inspections, taking 
20
into consideration the goals of inter-
21
national harmonization of quality systems 
22
standards. Any official classification of the 
23
inspection shall be determined by the Sec-
24
retary. Any statement or representation 
25
02:14 Jul 08, 2021
H4128
148 
•HR 4128 IH
made by an employee or agent of an estab-
1
lishment to a person accredited to conduct 
2
inspections shall be subject to section 1001 
3
of title 18, United States Code. 
4
‘‘(D) SAVINGS CLAUSE.—Nothing in this 
5
section affects the authority of the Secretary to 
6
inspect any in vitro clinical test developer or 
7
other person registered under section 587I. 
8
‘‘(E) INSPECTION LIMITATIONS.—The Sec-
9
retary shall ensure that inspections carried out 
10
under this section are not duplicative of inspec-
11
tions carried out under section 353 of the Pub-
12
lic Health Service Act. Inspections under this 
13
section shall be limited to the data and informa-
14
tion necessary— 
15
‘‘(i) for routine surveillance activities 
16
associated with applications under sections 
17
587B and 587D; or 
18
‘‘(ii) to meet the requirements to re-
19
ceive premarket approval under section 
20
587B or a technology certification order 
21
under section 587D, as applicable. 
22
‘‘(b) ACCREDITATION.— 
23
‘‘(1) ACCREDITATION PROGRAM.— 
24
02:14 Jul 08, 2021
H4128
149 
•HR 4128 IH
‘‘(A) IN
GENERAL.—The Secretary may 
1
provide for accreditation under this section 
2
through programs administered by the Food 
3
and Drug Administration, by other non-Federal 
4
government agencies, or by qualified nongovern-
5
mental organizations. A person may be accred-
6
ited for the review of both applications sub-
7
mitted under sections 587B and 587D as de-
8
scribed in subsection (a)(1)(A) and to conduct 
9
inspection activities under subsection (a)(2)(A), 
10
or for a subset of such review or activities. 
11
‘‘(B) ELIGIBLE PERSONS.—Not later than 
12
180 days after the date of enactment of the 
13
Verifying Accurate Leading-edge IVCT Devel-
14
opment Act of 2021, the Secretary shall issue 
15
draft guidance on the criteria that the Sec-
16
retary will use to accredit or deny accreditation 
17
to a person who requests such accreditation 
18
under subsection (a), and not later than one 
19
year after the close of the comment period for 
20
the draft guidance issued in this section, issue 
21
final guidance. 
22
‘‘(C) REQUIREMENTS.— 
23
‘‘(i) IN
GENERAL.—The Secretary 
24
shall not accredit or maintain accreditation 
25
02:14 Jul 08, 2021
H4128
150 
•HR 4128 IH
for a person unless such person meets the 
1
minimum qualifications required under 
2
subsection (c). 
3
‘‘(ii) SCOPE
OF
ACCREDITATION.— 
4
The accreditation of a person under this 
5
section shall specify the particular activi-
6
ties under subsection (a) for which such 
7
person is accredited. 
8
‘‘(D) PUBLIC LIST.—The Secretary shall 
9
publish on the website of the Food and Drug 
10
Administration a list of persons who are accred-
11
ited under this section. Such list shall be up-
12
dated on at least a monthly basis. The list shall 
13
specify the particular activity or activities under 
14
this section for which the person is accredited. 
15
‘‘(2) ACCREDITATION PROCESS.— 
16
‘‘(A) 
ACCREDITATION
PROCESS
GUID-
17
ANCE.—The Secretary shall— 
18
‘‘(i) not later than 180 days after the 
19
date of enactment of the Verifying Accu-
20
rate Leading-edge IVCT Development Act 
21
of 2021, issue draft guidance specifying 
22
the process for submitting a request for 
23
each type of accreditation and reaccredita-
24
tion under this section, including the form 
25
02:14 Jul 08, 2021
H4128
151 
•HR 4128 IH
and content of information to be submitted 
1
in such a request; and 
2
‘‘(ii) not later than 1 year after the 
3
close of the comment period for the draft 
4
guidance, issue final guidance. 
5
‘‘(B) RESPONSE TO REQUEST.—The Sec-
6
retary shall respond to a request for accredita-
7
tion or reaccreditation within 60 calendar days 
8
of the receipt of the request. The Secretary’s 
9
response may be to accredit or reaccredit the 
10
person, to deny accreditation, or to request ad-
11
ditional information in support of the request. 
12
If the Secretary requests additional informa-
13
tion, the Secretary shall respond within 60 cal-
14
endar days of receipt of such additional infor-
15
mation to accredit or deny the accreditation. 
16
‘‘(C) TYPE OF ACCREDITATION.—The ac-
17
creditation or reaccreditation of a person shall 
18
specify the particular activity or activities under 
19
subsection (a) for which such person is accred-
20
ited, and shall include any limitation to certain 
21
eligible in vitro clinical tests. 
22
‘‘(D) AUDIT.—The Secretary may audit 
23
the performance of persons accredited under 
24
this section for purposes of ensuring that such 
25
02:14 Jul 08, 2021
H4128
152 
•HR 4128 IH
persons continue to meet the published criteria 
1
for accreditation, and may modify the scope or 
2
particular activities for which a person is ac-
3
credited if the Secretary determines that such 
4
person fails to meet one or more criteria for ac-
5
creditation. 
6
‘‘(E) SUSPENSION OR WITHDRAWAL.—The 
7
Secretary may suspend or withdraw accredita-
8
tion of any person accredited under this section, 
9
after providing notice and an opportunity for an 
10
informal hearing, when such person is substan-
11
tially not in compliance with the requirements 
12
of this section or the published criteria for ac-
13
creditation, or poses a threat to public health, 
14
or fails to act in a manner that is consistent 
15
with the purposes of this section. 
16
‘‘(F) REACCREDITATION.—Accredited per-
17
sons may be initially accredited for up to 4 
18
years. After expiration of such initial period, 
19
persons may be reaccredited for unlimited addi-
20
tional 4-year periods, as determined by the Sec-
21
retary. 
22
‘‘(c) QUALIFICATIONS OF ACCREDITED PERSONS.— 
23
‘‘(1) ELIGIBILITY.—An accredited person, at a 
24
minimum, shall— 
25
02:14 Jul 08, 2021
H4128
153 
•HR 4128 IH
‘‘(A) not be an employee of the Federal 
1
Government; 
2
‘‘(B) not engage in the activities of a de-
3
veloper, as defined in section 587(7); 
4
‘‘(C) not be a person required to register 
5
under section 587I, unless such person has es-
6
tablished sufficient processes and protocols to 
7
separate activities to develop in vitro clinical 
8
tests and the activities for which such person 
9
would be accredited under subsection (a) and 
10
discloses applicable information under this sec-
11
tion; 
12
‘‘(D) not be owned or controlled by, and 
13
shall have no organizational, material or finan-
14
cial affiliation with, an in vitro clinical test de-
15
veloper or other person required to register 
16
under section 587I; 
17
‘‘(E) be a legally constituted entity per-
18
mitted to conduct the activities for which it 
19
seeks accreditation; 
20
‘‘(F) ensure that the operations of such 
21
person are in accordance with generally accept-
22
ed professional and ethical business practices; 
23
and 
24
02:14 Jul 08, 2021
H4128
154 
•HR 4128 IH
‘‘(G) include in its request for accredita-
1
tion a commitment to, at the time of accredita-
2
tion and at any time it is performing activities 
3
pursuant to this section— 
4
‘‘(i) certify that the information re-
5
ported to the Secretary accurately reflects 
6
the data or protocol reviewed, and the doc-
7
umented inspection findings, as applicable; 
8
‘‘(ii) limit work to that for which com-
9
petence and capacity are available; 
10
‘‘(iii) treat information received or 
11
learned, records, reports, and recommenda-
12
tions as proprietary information of the per-
13
son submitting such information; and 
14
‘‘(iv) in conducting the activities for 
15
which the person is accredited in respect to 
16
a particular in vitro clinical test, protect 
17
against the use of any employee or consult-
18
ant who has a financial conflict of interest 
19
regarding that in vitro clinical test. 
20
‘‘(2) WAIVER.—The Secretary may waive any 
21
requirements in subparagraph (A), (B), (C), or (D) 
22
of paragraph (1) upon making a determination that 
23
such person has implemented other appropriate con-
24
02:14 Jul 08, 2021
H4128
155 
•HR 4128 IH
trols sufficient to ensure a competent and impartial 
1
review. 
2
‘‘(d) COMPENSATION OF ACCREDITED PERSONS.— 
3
‘‘(1) IN
GENERAL.—Compensation of an ac-
4
credited person who reviews an application for pre-
5
market approval submitted under section 587B or 
6
an application for technical certification submitted 
7
under section 587D shall be determined by agree-
8
ment between the accredited person and the person 
9
who engages the services of the accredited person, 
10
and shall be paid by the person who engages such 
11
services. 
12
‘‘(2) INSPECTION ACCREDITATION.—Compensa-
13
tion of an accredited person who is conducting an 
14
inspection under section 704 shall be determined by 
15
agreement between the accredited person and the 
16
person who engages the services of the accredited 
17
person, and shall be paid by the person who engages 
18
such services. 
19
‘‘(e) COOPERATIVE AGREEMENTS.—The Secretary is 
20
authorized to enter into cooperative arrangements with of-
21
ficials of foreign countries to ensure that adequate and 
22
effective means are available for purposes of determining, 
23
from time to time, whether in vitro clinical tests intended 
24
for use in the United States by a person whose facility 
25
02:14 Jul 08, 2021
H4128
156 
•HR 4128 IH
is located outside the United States shall be refused ad-
1
mission on any of the grounds set forth in section 801(a). 
2
‘‘(f) INFORMATION SHARING AGREEMENTS.—An ac-
3
credited person may enter into an agreement with a test 
4
developer to provide information to the comprehensive test 
5
information system under section 587T, including any re-
6
quirements under section 587I. 
7
‘‘SEC. 587Q. RECOGNIZED STANDARDS. 
8
‘‘(a) IN GENERAL.—The Secretary may by order es-
9
tablish performance standards for an in vitro clinical test 
10
or tests with the same indication for use to provide reason-
11
able assurance of the analytical validity, clinical validity, 
12
or as applicable safety, of that in vitro clinical test or tests 
13
with the same indications for use. 
14
‘‘(b) OTHER STANDARDS.—The Secretary may recog-
15
nize all or part of appropriate standards established by 
16
nationally or internationally recognized standard develop-
17
ment organizations for which a person may submit a dec-
18
laration of conformity in order to meet a requirement 
19
under this subchapter to which that standard is applicable. 
20
In recognizing a standard, any person requesting recogni-
21
tion of a standard or seeking to use a recognized standard, 
22
the Secretary shall follow the processes and requirements, 
23
in accordance with section 514(c). Standards for in vitro 
24
diagnostic devices previously recognized under section 
25
02:14 Jul 08, 2021
H4128
157 
•HR 4128 IH
514(c) shall be considered recognized standards under this 
1
section. The application of any such consensus standard 
2
shall only apply prospectively. The Secretary shall issue 
3
guidance establishing the criteria and process for such rec-
4
ognition and adoption. 
5
‘‘(c) ORDER PROCESS.—In establishing a standard 
6
under subsection (a), the Secretary shall issue a draft 
7
order proposing to establish a standard and shall provide 
8
for a comment period of not less than 60 calendar days. 
9
The Secretary may seek the recommendation of an advi-
10
sory committee under section 587G concerning a proposed 
11
standard either prior to or after issuance of a proposed 
12
order. After considering the comments and within 90 days 
13
of the close of the comment period, the Secretary shall 
14
issue a final order adopting the proposed standard, adopt-
15
ing a modification of the proposed standard or terminating 
16
the proceeding. 
17
‘‘(d) AMENDMENT PROCESS.—The procedures estab-
18
lished in this section or in guidance issued under this sec-
19
tion shall apply to amendment of an existing standard. 
20
‘‘SEC. 587R. INVESTIGATIONAL USE. 
21
‘‘(a) IN GENERAL.—Except as provided in subsection 
22
(c), an in vitro clinical test for investigational use shall 
23
be exempt from the requirements of this subchapter other 
24
than sections 587A, 587O, and 587U. 
25
02:14 Jul 08, 2021
H4128
158 
•HR 4128 IH
‘‘(b) REGULATIONS.—Not later than 2 years after 
1
the date of enactment of the Verifying Accurate Leading- 
2
edge IVCT Development Act of 2021, the Secretary shall 
3
promulgate regulations to implement this section. 
4
‘‘(c) APPLICATION FOR INVESTIGATIONAL USE.— 
5
‘‘(1) IN GENERAL.—The following shall apply 
6
with respect to in vitro clinical tests for investiga-
7
tional use: 
8
‘‘(A) STREAMLINING
APPLICATIONS
SUB-
9
MITTED UNDER THIS SECTION.—Requirements 
10
with respect to such tests shall be completed in 
11
accordance with current, at the time of submit-
12
ting the application, investigational use require-
13
ments for institutional review boards and cur-
14
rent processes for any analytical or clinical vali-
15
dation. 
16
‘‘(B) VARIATION.—The requirements in 
17
the regulations promulgated under this section 
18
shall take into account variations based on— 
19
‘‘(i) the scope and duration of clinical 
20
testing to be conducted under investigation 
21
that is the subject of such application; 
22
‘‘(ii) the number of human subjects 
23
that are to be involved in such testing; 
24
02:14 Jul 08, 2021
H4128
159 
•HR 4128 IH
‘‘(iii) the need to permit changes to be 
1
made in the in vitro clinical test involved 
2
during testing conducted in accordance 
3
with a plan required under paragraph 
4
(3)(B); or 
5
‘‘(iv) whether the clinical testing of 
6
such in vitro clinical test is for the purpose 
7
of developing data to obtain approval to 
8
offer such test. 
9
‘‘(C) SIGNIFICANT RISK STUDIES.—In the 
10
case of an in vitro clinical test the investiga-
11
tional use of which poses a significant risk, a 
12
sponsor of an investigation of such a test seek-
13
ing an investigational use exemption shall sub-
14
mit to the Secretary an investigational use ap-
15
plication with respect to the test in accordance 
16
with paragraphs (2) and (3). For purposes of 
17
this subparagraph, the term ‘significant risk’ 
18
means, with respect to an in vitro clinical test 
19
that is a high-risk test, and that the use of the 
20
test— 
21
‘‘(i) is a use of substantial importance 
22
in performing an activity or activities de-
23
scribed in subsection (ss)(1)(A) for, a seri-
24
ous or life-threatening disease or condition 
25
02:14 Jul 08, 2021
H4128
160 
•HR 4128 IH
without confirmation of the diagnosis by a 
1
medically established means; 
2
‘‘(ii) requires an invasive sampling 
3
procedure that presents a significant risk 
4
to the human subject; or 
5
‘‘(iii) otherwise presents a reasonably 
6
foreseeable serious risk to the health of a 
7
human subject. 
8
‘‘(D) NON-SIGNIFICANT
RISK
TESTS.—In 
9
the case of an in vitro clinical test, the inves-
10
tigational use of which does not pose a signifi-
11
cant risk— 
12
‘‘(i) the sponsor of such investigation 
13
shall— 
14
‘‘(I) conduct such investigation in 
15
compliance with an investigational 
16
plan specified in paragraph (5) and 
17
labeling 
specified 
in 
paragraph 
18
(3)(A)(ii); 
19
‘‘(II) ensure each investigator ob-
20
tains informed consent under part 50 
21
of title 21, Code of Federal Regula-
22
tions (or any successor regulations), 
23
subject to the exceptions set forth in 
24
paragraphs (5)(A)(iii) and (5)(B); 
25
02:14 Jul 08, 2021
H4128
161 
•HR 4128 IH
‘‘(III) submit a listing to the Sec-
1
retary of such investigation; and 
2
‘‘(IV) maintain records with re-
3
spect to all requirements in this sub-
4
paragraph; and 
5
‘‘(ii) the sponsor may rely on any ex-
6
ception or exemption identified in para-
7
graph (5)(B) or as established by the Sec-
8
retary in regulations issued under sub-
9
section (b). 
10
‘‘(2) APPLICATION
CONTENT.—An investiga-
11
tional use application shall be submitted in such 
12
time and manner and contain such information as 
13
the Secretary may require in regulation, and shall 
14
include an investigational plan for proposed clinical 
15
testing and assurances that the sponsor submitting 
16
the application will— 
17
‘‘(A) establish and maintain records rel-
18
evant to the investigation of such in vitro clin-
19
ical test; and 
20
‘‘(B) submit to the Secretary annual re-
21
ports of data obtained as a result of the inves-
22
tigational use of the in vitro clinical test during 
23
the period covered by the exemption that the 
24
02:14 Jul 08, 2021
H4128
162 
•HR 4128 IH
Secretary reasonably determines will enable the 
1
Secretary— 
2
‘‘(i) to ensure compliance with the 
3
conditions for the exemption specified in 
4
paragraph (3); 
5
‘‘(ii) to review the progress of the in-
6
vestigation involved; and 
7
‘‘(iii) to evaluate the analytical valid-
8
ity and clinical validity of such test. 
9
‘‘(3) CONDITIONS FOR EXEMPTION.— 
10
‘‘(A) IN GENERAL.—A request for an in-
11
vestigational use exemption with respect to sig-
12
nificant risk tests shall be granted only if each 
13
of the following conditions is met: 
14
‘‘(i) The risks to the subjects of the in 
15
vitro clinical test are outweighed by the an-
16
ticipated benefits to the subjects and the 
17
importance of the knowledge to be gained, 
18
and adequate assurance of informed con-
19
sent is provided in accordance with para-
20
graph (5)(A)(iii). 
21
‘‘(ii) The proposed labeling for the in 
22
vitro clinical test involved clearly and con-
23
spicuously states ‘For investigational use’. 
24
02:14 Jul 08, 2021
H4128
163 
•HR 4128 IH
‘‘(iii) Such other requirements the 
1
Secretary determines to be necessary for 
2
the protection of the public health and 
3
safety as long as the requirements do not 
4
unduly delay investigation after finding 
5
that the results of such investigation estab-
6
lish sufficient data to support clinical or 
7
analytical validity. 
8
‘‘(B) CERTAIN SIGNIFICANT RISK IN VITRO 
9
CLINICAL TESTS FOR AN UNMET NEED.—As a 
10
condition for granting an exemption under this 
11
paragraph, the Secretary shall not impose a 
12
limit on the sample size for a significant risk in 
13
vitro clinical test that meets the requirements 
14
of section 587C, as long as such test is devel-
15
oped within a laboratory that is certified to con-
16
duct high-complexity testing under section 353 
17
of the Public Health Service Act. 
18
‘‘(4) COORDINATION
WITH
INVESTIGATIONAL 
19
NEW
DRUG
APPLICATIONS.—Any requirement for 
20
the submission of a report to the Secretary pursuant 
21
to a request for an investigational new drug exemp-
22
tion involving an in vitro clinical test shall supersede 
23
the reporting requirement in paragraph (2)(B), but 
24
only to the extent the requirement with respect to 
25
02:14 Jul 08, 2021
H4128
164 
•HR 4128 IH
the request for exemption with respect to the drug 
1
is duplicative of the reporting requirement under 
2
such paragraph. 
3
‘‘(5) INVESTIGATION PLAN REQUIREMENTS.— 
4
‘‘(A) IN GENERAL.—With respect to an in-
5
vestigational plan submitted under paragraph 
6
(2)(A), the sponsor submitting such plan 
7
shall— 
8
‘‘(i) in the case of such a plan sub-
9
mitted to an institutional review com-
10
mittee, promptly notify the Secretary of 
11
the approval or the suspension or termi-
12
nation of the approval of such plan by an 
13
institutional review committee; 
14
‘‘(ii) in the case of an in vitro clinical 
15
test made available to investigators for 
16
clinical testing, assurance that all inves-
17
tigators will comply with this section, regu-
18
lations promulgated or revised under this 
19
section, and applicable human subjects reg-
20
ulations; and 
21
‘‘(iii) submit an assurance to the Sec-
22
retary that informed consent will be ob-
23
tained from each human subject (or the 
24
representative of such subject) of proposed 
25
02:14 Jul 08, 2021
H4128
165 
•HR 4128 IH
clinical testing involving such in vitro clin-
1
ical test, except in the case that— 
2
‘‘(I) there is a life-threatening 
3
situation involving the human subject 
4
of such testing which necessitates the 
5
use of such in vitro clinical test; 
6
‘‘(II) it is not feasible to obtain 
7
informed consent from the subject; 
8
and 
9
‘‘(III) there is not sufficient time 
10
to obtain such consent from a rep-
11
resentative of such subject. 
12
‘‘(B) EXCEPTION.—The informed consent 
13
of human subjects shall not be required with re-
14
spect to clinical testing conducted as part of an 
15
investigation, if— 
16
‘‘(i) the clinical testing uses remnants 
17
of specimens collected for routine clinical 
18
care or analysis that would have been dis-
19
carded, leftover specimens that were pre-
20
viously collected for other research pur-
21
poses, or specimens obtained from speci-
22
men repositories; 
23
‘‘(ii) the identity of the subject of the 
24
specimen is not known to, and may not 
25
02:14 Jul 08, 2021
H4128
166 
•HR 4128 IH
readily be ascertained by, the investigator 
1
or any other individual associated with the 
2
investigation, including the sponsor; 
3
‘‘(iii) any clinical information that ac-
4
companies the specimens does not make 
5
the specimen source identifiable to the in-
6
vestigator or any other individual associ-
7
ated with the investigation, including the 
8
sponsor; 
9
‘‘(iv) the individuals caring for the 
10
human subjects as patients are different 
11
from, and do not share information about 
12
the patient with, the individuals conducting 
13
the investigation; and 
14
‘‘(v) the specimens are provided to the 
15
investigators without personally identifiable 
16
information and the supplier of the speci-
17
mens has established policies and proce-
18
dures to prevent the release of personally 
19
identifiable information. 
20
‘‘(d) REVIEW OF APPLICATIONS.— 
21
‘‘(1) IN GENERAL.—The Secretary may issue 
22
an order approving an investigation as proposed, ap-
23
proving it with conditions or modifications, or dis-
24
approving it. 
25
02:14 Jul 08, 2021
H4128
167 
•HR 4128 IH
‘‘(2) FAILURE TO ACT.—Unless the Secretary, 
1
not later than the date that is 30 calendar days 
2
after the date of the submission of an investigational 
3
use exemption request that meets the requirements 
4
of subsection (c)(2), issues an order under sub-
5
section (d)(1) and notifies the sponsor submitting 
6
the application, the request shall be treated as 
7
granted as of such date without further action by 
8
the Secretary. 
9
‘‘(3) DISAPPROVAL.—The Secretary may deny 
10
an investigational use request submitted under this 
11
subsection if the Secretary determines that the in-
12
vestigation with respect to which the request is sub-
13
mitted does not conform to the requirements of sub-
14
section (c)(3). A listing of such denial submitted to 
15
the sponsor with respect to such a request shall con-
16
tain the order of disapproval and a complete state-
17
ment of the reasons for the Secretary’s denial of the 
18
request. 
19
‘‘(e) WITHDRAWAL OF APPROVAL.— 
20
‘‘(1) IN GENERAL.—The Secretary may, by ad-
21
ministrative order, withdraw an exemption granted 
22
under this section with respect to an in vitro clinical 
23
test, including an exemption granted based on the 
24
Secretary’s failure to act pursuant to subsection 
25
02:14 Jul 08, 2021
H4128
168 
•HR 4128 IH
(d)(2), if the Secretary determines that the test does 
1
not meet the applicable conditions under subsection 
2
(c)(3) for such exemption. 
3
‘‘(2) OPPORTUNITY TO BE HEARD.— 
4
‘‘(A) IN
GENERAL.—Subject to subpara-
5
graph (B), an order withdrawing the exemption 
6
granted under this section may be issued only 
7
after the Secretary provides the applicant or 
8
sponsor of the test with an opportunity for an 
9
informal hearing. 
10
‘‘(B) EXCEPTION.—An order referred to in 
11
subparagraph (A) with respect to an exemption 
12
granted under this subsection may be issued on 
13
a preliminary basis before the provision of an 
14
opportunity for an informal hearing if the Sec-
15
retary determines that the continuation of test-
16
ing under the exemption will result in an unrea-
17
sonable risk to the public health. The Secretary 
18
will provide an opportunity for an informal 
19
hearing promptly following any preliminary ac-
20
tion under this subparagraph. 
21
‘‘(f) CHANGES.— 
22
‘‘(1) IN
GENERAL.—The regulations promul-
23
gated under subsection (b) shall provide, with re-
24
spect to an in vitro clinical test for which an exemp-
25
02:14 Jul 08, 2021
H4128
169 
•HR 4128 IH
tion under this subsection is in effect, procedures 
1
and conditions under which the changes to the test 
2
are allowed without the additional determination on 
3
a request for an exemption or submission of a sup-
4
plement to such a request. Such regulations shall 
5
provide that such a change may be made if— 
6
‘‘(A) the sponsor or applicant determines, 
7
on the basis of credible information (as defined 
8
by the Secretary) that the change meets the 
9
conditions specified in paragraph (2); and 
10
‘‘(B) the sponsor or applicant submits to 
11
the Secretary, not later than 5 calendar days 
12
after making the change, a notice of the 
13
change. 
14
‘‘(2) CONDITIONS.—The conditions specified in 
15
this paragraph are that— 
16
‘‘(A) in the case of developmental changes 
17
to an in vitro clinical test (including manufac-
18
turing changes), the changes— 
19
‘‘(i) do not constitute a significant 
20
change in design or in basic principles of 
21
operation; 
22
‘‘(ii) do not affect the rights, safety, 
23
or welfare of the human subjects (if any) 
24
involved in the investigation; and 
25
02:14 Jul 08, 2021
H4128
170 
•HR 4128 IH
‘‘(iii) are made in response to infor-
1
mation gathered during the course of an 
2
investigation; and 
3
‘‘(B) in the case of changes to clinical pro-
4
tocols applicable to the test, the changes do not 
5
affect— 
6
‘‘(i) the validity of data or information 
7
resulting from the completion of an ap-
8
proved clinical protocol; 
9
‘‘(ii) the scientific soundness of a plan 
10
submitted under subsection (c)(5); or 
11
‘‘(iii) the rights, safety, or welfare of 
12
the human subjects (if any) involved in the 
13
investigation. 
14
‘‘(g) CLINICAL HOLD.— 
15
‘‘(1) IN GENERAL.—At any time, the Secretary 
16
may impose a clinical hold with respect to an inves-
17
tigation of an in vitro clinical test if the Secretary 
18
makes a determination described in paragraph (2). 
19
The Secretary shall, in imposing such clinical hold, 
20
specify the basis for the clinical hold, including the 
21
specific information available to the Secretary which 
22
served as the basis for such clinical hold, and con-
23
firm such determination in writing. The applicant or 
24
02:14 Jul 08, 2021
H4128
171 
•HR 4128 IH
sponsor may immediately appeal any such deter-
1
mination pursuant to section 587O. 
2
‘‘(2) DETERMINATION.—For purposes of para-
3
graph (1), a determination described in this sub-
4
paragraph with respect to a clinical hold is a deter-
5
mination that— 
6
‘‘(A) the in vitro clinical test involved rep-
7
resents an unreasonable risk to the safety of 
8
the persons who are the subjects of the clinical 
9
investigation, taking into account the qualifica-
10
tions of the clinical investigators, information 
11
about the in vitro clinical test, the design of the 
12
clinical investigation, the condition for which 
13
the in vitro clinical test is to be investigated, 
14
and the health status of the subjects involved; 
15
‘‘(B) the clinical hold should be issued for 
16
such other reasons as the Secretary may by 
17
regulation establish; or 
18
‘‘(C) any written request to the Secretary 
19
from the sponsor of an investigation that a clin-
20
ical hold be removed shall receive a decision, in 
21
writing and specifying the reasons therefor, 
22
within 30 days after receipt of such request. 
23
Any such request shall include sufficient infor-
24
02:14 Jul 08, 2021
H4128
172 
•HR 4128 IH
mation to support the removal of such clinical 
1
hold. 
2
‘‘SEC. 587S. COLLABORATIVE COMMUNITIES FOR IN VITRO 
3
CLINICAL TESTS. 
4
‘‘(a) IN GENERAL.— 
5
‘‘(1) For the purposes of facilitating community 
6
solutions and decision making with respect to in 
7
vitro clinical tests, the Secretary may participate in 
8
collaborative communities comprised of public and 
9
private participants that may provide recommenda-
10
tions and other advice to the Secretary on the devel-
11
opment and regulation of in vitro clinical tests. 
12
‘‘(2) A collaborative community under this sec-
13
tion shall have broad representation of interested 
14
private and public-sector stakeholder communities 
15
and may include patients, care partners, academics, 
16
health care professionals, health care systems, 
17
payors, Federal and State agencies, entities respon-
18
sible for accrediting clinical laboratories, inter-
19
national regulatory bodies, test developers, or other 
20
interested entities or communities. 
21
‘‘(b) GUIDANCE.—The Secretary shall issue a draft 
22
guidance not later than 180 days after the date of enact-
23
ment of the Verifying Accurate Leading-edge IVCT Devel-
24
opment Act of 2021, addressing the participation process 
25
02:14 Jul 08, 2021
H4128
173 
•HR 4128 IH
and framework to build consensus, and how the Secretary 
1
may consider, review, and implement recommendations 
2
under subsection (c). 
3
‘‘(c) RECOMMENDATIONS.—A collaborative commu-
4
nity for in vitro clinical tests may make recommendations 
5
to the Secretary on matters including— 
6
‘‘(1) mitigating measures for in vitro clinical 
7
tests; 
8
‘‘(2) standards development activities and per-
9
formance standards for in vitro clinical tests or 
10
groups of such tests; 
11
‘‘(3) scientific and clinical evidence to support 
12
new claims for in vitro clinical tests; 
13
‘‘(4) new technologies and methodologies re-
14
lated to in vitro clinical tests; 
15
‘‘(5) stakeholder communication and engage-
16
ment; and 
17
‘‘(6) development of effective policies and proc-
18
esses, including to develop tests, and to regulate 
19
such tests in accordance with least burdensome re-
20
quirements described in section 587B(j). 
21
‘‘(d) USE BY SECRETARY.— 
22
‘‘(1) IN GENERAL.—The Secretary may adopt 
23
recommendations made under subsection (b), or oth-
24
erwise incorporate the feedback from collaborative 
25
02:14 Jul 08, 2021
H4128
174 
•HR 4128 IH
communities 
into 
regulatory 
decision 
making, 
1
through rulemaking or guidance, as appropriate. 
2
‘‘(2) CLARIFICATION.—The Secretary is not re-
3
quired to adopt recommendations submitted by col-
4
laborative communities. 
5
‘‘(e) TRANSPARENCY.—The Secretary shall— 
6
‘‘(1) publish on the website of the Food and 
7
Drug Administration matters for which it is seeking 
8
comments or recommendations, in a timely manner; 
9
‘‘(2) maintain a list of all collaborative commu-
10
nities in which the Secretary participates and make 
11
such list available on the website of the Food and 
12
Drug Administration; and 
13
‘‘(3) post on the website of the Food and Drug 
14
Administration at least once every year a report on 
15
the recommendations it has adopted and rec-
16
ommendations it has not adopted from collaborative 
17
communities. 
18
‘‘(f) PARTICIPATION.—The Secretary may participate 
19
in a collaborative community only if such community re-
20
quires members to disclose conflicts of interest and has 
21
established a process to address conflicts of interest. 
22
‘‘(g) EXEMPTION.—The collaborative communities 
23
established and used in accordance with this section shall 
24
02:14 Jul 08, 2021
H4128
175 
•HR 4128 IH
be exempt from the Federal Advisory Committee Act (5 
1
U.S.C. App.). 
2
‘‘SEC. 587T. COMPREHENSIVE TEST INFORMATION SYSTEM. 
3
‘‘(a) PURPOSE.—For the purposes of improving the 
4
transparency of information on in vitro clinical tests and 
5
allowing patients and health care providers better access 
6
to information about in vitro clinical tests, the Secretary 
7
shall establish a comprehensive test information system. 
8
‘‘(b) ESTABLISHMENT.—Not later than 2 years after 
9
the date of enactment of the Verifying Accurate Leading- 
10
edge IVCT Development Act of 2021, the Secretary shall 
11
make available a comprehensive test information system 
12
for in vitro clinical tests that is designed to— 
13
‘‘(1) provide a transparent interface on the 
14
website of the Food and Drug Administration for 
15
stakeholders, to the extent permitted by applicable 
16
law, to access the— 
17
‘‘(A) regulatory pathway designation infor-
18
mation for each in vitro clinical test or tests 
19
with the same indications for use; 
20
‘‘(B) registration and listing information 
21
provided by developers under section 587I, in-
22
cluding the use of a link for labels; 
23
‘‘(C) adverse event reports submitted 
24
under section 587L; 
25
02:14 Jul 08, 2021
H4128
176 
•HR 4128 IH
‘‘(D) reports of corrections and removals 
1
submitted under section 587M; and 
2
‘‘(E) other information pertaining to an in 
3
vitro clinical test or tests with the same indica-
4
tions for use, as the Secretary determines ap-
5
propriate; and 
6
‘‘(2) provide a secure portal for electronic sub-
7
mission, including applications and other in vitro 
8
clinical test submissions, registration and listing in-
9
formation, and adverse event reports. 
10
‘‘(c) SUBMISSION FUNCTION.—The comprehensive 
11
test information system shall serve as the electronic sub-
12
mission service for test developers submitting information 
13
for applications under sections 587B and 587D. 
14
‘‘SEC. 587U. PREEMPTION. 
15
‘‘(a) IN GENERAL.—No State, Tribal, or local gov-
16
ernment (or political subdivision thereof) may establish or 
17
continue in effect any requirement related to the develop-
18
ment, manufacture, labeling, distribution, sale, or use of 
19
an in vitro clinical test that is different from, or in addi-
20
tion to, the requirements of this subchapter. 
21
‘‘(b) EXCEPTIONS.—Subsection (a) shall not be con-
22
strued to affect the authority of a State, Tribal, or local 
23
government— 
24
02:14 Jul 08, 2021
H4128
177 
•HR 4128 IH
‘‘(1) to license laboratory personnel, health care 
1
practitioners, or health care facilities or to regulate 
2
any aspect of a health care practitioner-patient rela-
3
tionship; or 
4
‘‘(2) to enforce laws of general applicability, 
5
such as zoning laws, environmental laws, labor laws, 
6
and general business laws. 
7
‘‘(c) CLARIFICATION.—This section shall not be con-
8
strued to shift liability to health care practitioners or other 
9
users. 
10
‘‘SEC. 587V. ADULTERATION. 
11
‘‘An in vitro clinical test shall be deemed to be adul-
12
terated: 
13
‘‘(1) If it consists in whole or in part of any 
14
filthy, putrid, or decomposed substance. 
15
‘‘(2) If it has been developed, prepared, packed, 
16
or held under insanitary conditions whereby it may 
17
have been contaminated with filth, or whereby it 
18
may have been rendered injurious to health. 
19
‘‘(3) If its container or package is composed, in 
20
whole or in part, of any poisonous or deleterious 
21
substance which may render the contents injurious 
22
to health. 
23
02:14 Jul 08, 2021
H4128
178 
•HR 4128 IH
‘‘(4) If it bears or contains, for purposes of 
1
coloring only, a color additive which is unsafe within 
2
the meaning of section 721(a). 
3
‘‘(5) If its analytical or clinical validity, or with 
4
respect to a specimen receptacle, its safety, or its 
5
strength, purity, or quality, differs from or falls 
6
below that which it purports or is represented to 
7
possess. 
8
‘‘(6) If it is required to be, declared to be, pur-
9
ports to be, or is represented as being, in conformity 
10
with any performance standard established or recog-
11
nized under section 587Q and is not in all respects 
12
in conformity with such standard. 
13
‘‘(7) If it is required to be in conformity with 
14
a mitigating measure established under section 
15
587E and is not in all respects in conformity with 
16
such mitigating measure. 
17
‘‘(8) If it fails to have an approved premarket 
18
application under section 587B unless such in vitro 
19
clinical test can be lawfully offered— 
20
‘‘(A) for clinical use pursuant to an exemp-
21
tion under section 587A; 
22
‘‘(B) for emergency use pursuant to an au-
23
thorization under section 564; or 
24
02:14 Jul 08, 2021
H4128
179 
•HR 4128 IH
‘‘(C) for investigational use pursuant to 
1
section 587R. 
2
‘‘(9) If it is not in conformity with any condi-
3
tion established under section 587B, 587D, or 564. 
4
‘‘(10) If it purports to be an in vitro clinical 
5
test that is offered for clinical use subject to an ex-
6
emption under section 587A and it fails to meet or 
7
maintain any criteria, condition, or requirement of 
8
such exemption. 
9
‘‘(11) If it has been granted an exemption 
10
under section 587R for investigational use, and the 
11
person granted such exemption or any investigator 
12
who uses such in vitro clinical test under such ex-
13
emption fails to comply with a requirement pre-
14
scribed by or under such section. 
15
‘‘(12) If it fails to meet the quality require-
16
ments prescribed in or established under section 
17
587J (as applicable), or the methods used in, or fa-
18
cilities or controls used for, its development, manu-
19
facture, packing, storage, or installation are not in 
20
conformity with applicable requirements established 
21
under such section. 
22
‘‘(13) If it has been developed, manufactured, 
23
processed, packed or held in any establishment, fac-
24
tory, or warehouse and the owner, operator or agent 
25
02:14 Jul 08, 2021
H4128
180 
•HR 4128 IH
of such establishment, factory, or warehouse delays, 
1
denies, or limits an inspection, or refuses to permit 
2
entry or inspection. 
3
‘‘(14) If it is not in compliance with any restric-
4
tion required under section 587N. 
5
‘‘SEC. 587W. MISBRANDING. 
6
‘‘An in vitro clinical test shall be deemed to be mis-
7
branded: 
8
‘‘(1) If its labeling is false or misleading in any 
9
particular. 
10
‘‘(2) If in a package form unless it bears a label 
11
containing— 
12
‘‘(A) the name and place of business of the 
13
test developer, manufacturer, packer, or dis-
14
tributor; and 
15
‘‘(B) an accurate statement of the quantity 
16
of contents in terms of weight, measure, or nu-
17
merical count with respect to small packages, 
18
unless an exemption is granted by the Secretary 
19
by the issuance of guidance. 
20
‘‘(3) If any word, statement, or other informa-
21
tion required by or under authority of this Act to 
22
appear on the label or labeling, including a test re-
23
port, is not prominently placed thereon with such 
24
conspicuousness (as compared with other words, 
25
02:14 Jul 08, 2021
H4128
181 
•HR 4128 IH
statements, designs, or devices, in the labeling) and 
1
in such terms as to render it likely to be read and 
2
understood by the ordinary individual under cus-
3
tomary conditions of purchase and use. 
4
‘‘(4) Unless its labeling bears adequate direc-
5
tions for use and such adequate warnings as are 
6
necessary for the protection of users of the in vitro 
7
clinical test and recipients of the results of such in 
8
vitro clinical test, including patients, consumers, do-
9
nors, and related health care professionals. Required 
10
labeling for in vitro clinical tests intended for use in 
11
health care facilities or by a health care professional 
12
may be made available solely by electronic means, 
13
provided that the labeling complies with all applica-
14
ble requirements of law, and that the test developer, 
15
manufacturer, or distributor affords such users the 
16
opportunity to request the labeling in paper form, 
17
and after such request, promptly provides the re-
18
quested information without additional cost. 
19
‘‘(5) If it causes serious or adverse health con-
20
sequences or death, including through absence, 
21
delay, or discontinuation in diagnosis or treatment, 
22
when used in the manner prescribed, recommended, 
23
or suggested in the labeling thereof. 
24
02:14 Jul 08, 2021
H4128
182 
•HR 4128 IH
‘‘(6) If it was developed or manufactured in an 
1
establishment not duly registered under section 587I 
2
or it was not included in a listing under section 
3
587I, in accordance with timely reporting require-
4
ments under this subchapter. 
5
‘‘(7) In the case of any in vitro clinical test sub-
6
ject to restrictions under section 587N, (1) if its ad-
7
vertising is false or misleading in any particular, (2) 
8
if it is offered for clinical use, sold, distributed, or 
9
used in violation of such restrictions, or (3) unless 
10
the test developer, manufacturer, or distributor in-
11
cludes in all advertisements and other descriptive 
12
printed matter that such person issues or causes to 
13
be issued, a brief statement of the intended uses of 
14
the in vitro clinical test and relevant warnings, pre-
15
cautions, side effects, and contraindications. This 
16
subsection shall not be applicable to any printed 
17
matter that the Secretary determines to be labeling 
18
as defined in section 201(m) or section 587K. 
19
‘‘(8) If it was subject to a mitigating measure 
20
established under section 587E, unless it bears such 
21
labeling as may be prescribed in such mitigating 
22
measure. 
23
02:14 Jul 08, 2021
H4128
183 
•HR 4128 IH
‘‘(9) If it was subject to a standard established 
1
under section 587Q, unless it bears such labeling as 
2
may be prescribed in such standard. 
3
‘‘(10) Unless it bears such labeling as may be 
4
prescribed by or established under an applicable la-
5
beling requirement under this Act. 
6
‘‘(11) If there was a failure or refusal to comply 
7
with any requirement prescribed under section 587I 
8
or 587X, or to comply with a requirement under sec-
9
tion 587Y, or to provide any report, material, or in-
10
formation required under this subchapter. 
11
‘‘SEC. 587X. POSTMARKET SURVEILLANCE. 
12
‘‘(a) IN GENERAL.— 
13
‘‘(1) IN GENERAL.—In addition to other appli-
14
cable requirements under this Act, the Secretary 
15
may issue an order requiring a developer to conduct 
16
postmarket surveillance of a single in vitro clinical 
17
test as a condition of approval under section 587B. 
18
‘‘(2) EXEMPT
TESTS.—The Secretary may 
19
order postmarket surveillance for tests exempt pur-
20
suant to section 587A for which the failure of the 
21
in vitro clinical test to meet the applicable standard 
22
for approval is likely to result in serious or adverse 
23
health consequences or death from use of the single 
24
in vitro clinical test. 
25
02:14 Jul 08, 2021
H4128
184 
•HR 4128 IH
‘‘(3) CONSIDERATION.—In determining whether 
1
to require a developer to conduct postmarket surveil-
2
lance of an in vitro clinical test, the Secretary shall 
3
take into consideration the benefits and risks for the 
4
patient and the least burdensome principles under 
5
section 587B. 
6
‘‘(b) SURVEILLANCE APPROVAL.— 
7
‘‘(1) Each developer required to conduct a sur-
8
veillance of an in vitro clinical test shall submit, 
9
within 30 days of receiving an order from the Sec-
10
retary, a plan for the required surveillance. The Sec-
11
retary, within 60 days of the receipt of such plan, 
12
shall determine if the person designated to conduct 
13
the surveillance has the appropriate qualifications 
14
and experience to undertake such surveillance and if 
15
the plan will result in useful data that can reveal un-
16
foreseen adverse events or other information nec-
17
essary to protect the health of patients or the public. 
18
‘‘(2) The developer shall commence surveillance 
19
under this section not later than 15 months after 
20
the day on which the Secretary orders such postmar-
21
ket surveillance, unless the Secretary determines 
22
more time is needed to commence surveillance. 
23
‘‘(3) The Secretary may order a prospective 
24
surveillance period of up to 3 years. Any determina-
25
02:14 Jul 08, 2021
H4128
185 
•HR 4128 IH
tion by the Secretary that a longer period is nec-
1
essary shall be made by mutual agreement between 
2
the Secretary and the manufacturer or, if no agree-
3
ment can be reached, after the completion of a dis-
4
pute resolution process. 
5
‘‘SEC. 587Y. ELECTRONIC FORMAT FOR SUBMISSIONS. 
6
‘‘(a) IN GENERAL.—All presubmissions and submis-
7
sions to the Food and Drug Administration with respect 
8
to an in vitro clinical test shall include an electronic copy 
9
of such presubmission or submission, and, with respect to 
10
the information required under sections 587B and 587D, 
11
shall utilize the system described in section 587T. 
12
‘‘(b) ELECTRONIC FORMAT.—Beginning on such date 
13
as the Secretary specifies in final guidance issued under 
14
subsection (c), presubmissions and submissions for in vitro 
15
clinical tests (and any appeals of action taken by the Sec-
16
retary with respect to such presubmissions and submis-
17
sions) shall be submitted solely in such electronic format 
18
as specified by the Secretary in such guidance. 
19
‘‘(c) GUIDANCE.—The Secretary shall issue guidance 
20
implementing this section. In such guidance, the Secretary 
21
may— 
22
‘‘(1) provide standards for the electronic copy 
23
required under subsection (a) or the submission in 
24
electronic format required under subsection (b); 
25
02:14 Jul 08, 2021
H4128
186 
•HR 4128 IH
‘‘(2) set forth criteria for waivers of or exemp-
1
tions from the requirements of subsection (a) or (b); 
2
and 
3
‘‘(3) provide any other information for the effi-
4
cient implementation and enforcement of this sec-
5
tion. 
6
‘‘SEC. 587Z. POSTMARKET REMEDIES. 
7
‘‘(a) SAFETY NOTICE.— 
8
‘‘(1) IN GENERAL.—If the Secretary determines 
9
that an in vitro clinical test presents an unreason-
10
able risk of substantial harm to the public health, 
11
and notification under this subsection is necessary to 
12
eliminate the unreasonable risk of such harm and no 
13
more practicable means is available under the provi-
14
sions of this Act (other than this section) to elimi-
15
nate the risk, the Secretary may issue such order as 
16
may be necessary to ensure that adequate safety no-
17
tice is provided in an appropriate form, by the per-
18
sons and means best suited under the circumstances, 
19
to all health care professionals who prescribe, order, 
20
or use the in vitro clinical test and to any other per-
21
son (including developers, manufacturers, importers, 
22
distributors, retailers, and users) who should prop-
23
erly receive such notice. 
24
02:14 Jul 08, 2021
H4128
187 
•HR 4128 IH
‘‘(2) NOTICE
TO
INDIVIDUALS.—An order 
1
under this subsection shall require that the individ-
2
uals subject to the risk with respect to which the 
3
order is to be issued be included in the persons to 
4
be notified of the risk unless the Secretary deter-
5
mines that notice to such individuals would present 
6
a greater danger to the health of such individuals 
7
than no such notice. If the Secretary makes such a 
8
determination with respect to such individuals, the 
9
order shall advise the health care professionals who 
10
prescribed, ordered, or used the in vitro clinical test 
11
provide notification to the individuals for whom the 
12
health professionals prescribed, ordered, or used 
13
such test, of the risk presented by such in vitro clin-
14
ical test and of any action which may be taken by 
15
or on behalf of such individuals to eliminate or re-
16
duce such risk. Before issuing an order under this 
17
subsection, the Secretary shall consult with the per-
18
sons required to give notice under the order. 
19
‘‘(b) REPAIR, REPLACEMENT, OR REFUND.— 
20
‘‘(1) DETERMINATION
AFTER
AN
INFORMAL 
21
HEARING.— 
22
‘‘(A) IN GENERAL.—If, after affording op-
23
portunity for an informal hearing, the Secretary 
24
determines that— 
25
02:14 Jul 08, 2021
H4128
188 
•HR 4128 IH
‘‘(i) an in vitro clinical test presents 
1
an unreasonable risk of substantial harm 
2
to the public health; 
3
‘‘(ii) there are reasonable grounds to 
4
believe that the in vitro clinical test was 
5
not properly developed or manufactured 
6
considering the state of the art as it ex-
7
isted at the time of its development or 
8
manufacture; 
9
‘‘(iii) there are reasonable grounds to 
10
believe that the unreasonable risk was not 
11
caused by failure of a person other than a 
12
developer, manufacturer, importer, dis-
13
tributor, or retailer of the in vitro clinical 
14
test to exercise due care in the installation, 
15
maintenance, repair, or use of the in vitro 
16
clinical test; and 
17
‘‘(iv) the notice authorized by sub-
18
section (a) would not by itself be sufficient 
19
to eliminate the unreasonable risk and ac-
20
tion described in paragraph (2) of this sub-
21
section is necessary to eliminate such risk, 
22
the Secretary may order the developer, manu-
23
facturer, importer, or any distributor of such in 
24
vitro clinical test, or any combination of such 
25
02:14 Jul 08, 2021
H4128
189 
•HR 4128 IH
persons, to submit to him within a reasonable 
1
time a plan for taking one or more of the ac-
2
tions described in paragraph (2). An order 
3
issued under the preceding sentence which is di-
4
rected to more than one person shall specify 
5
which person may decide which action shall be 
6
taken under such plan and the person specified 
7
shall be the person who the Secretary deter-
8
mines bears the principal, ultimate financial re-
9
sponsibility for action taken under the plan un-
10
less the Secretary cannot determine who bears 
11
such responsibility or the Secretary determines 
12
that the protection of the public health requires 
13
that such decision be made by a person (includ-
14
ing a health professional or user of the in vitro 
15
clinical test) other than the person the Sec-
16
retary determines bears such responsibility. 
17
‘‘(B) SECRETARY APPROVAL OF PLAN.— 
18
Within 30 calendar days of issuing an order 
19
under subparagraph (A), the Secretary shall ap-
20
prove a plan submitted pursuant to an order 
21
issued under subparagraph (A) unless the Sec-
22
retary determines (after affording opportunity 
23
for an informal hearing) that the action or ac-
24
tions to be taken under the plan or the manner 
25
02:14 Jul 08, 2021
H4128
190 
•HR 4128 IH
in which such action or actions are to be taken 
1
under the plan will not assure that the unrea-
2
sonable risk with respect to which such order 
3
was issued will be eliminated. If the Secretary 
4
disapproves a plan, the Secretary shall order a 
5
revised plan to be submitted within a reason-
6
able time. If the Secretary determines (after af-
7
fording opportunity for an informal hearing) 
8
that the revised plan is unsatisfactory or if no 
9
revised plan or no initial plan has been sub-
10
mitted to the Secretary within the prescribed 
11
time, the Secretary shall (i) prescribe a plan to 
12
be carried out by the person or persons to 
13
whom the order issued under subparagraph (A) 
14
was directed, or (ii) after affording an oppor-
15
tunity for an informal hearing, by order pre-
16
scribe a plan to be carried out by a person who 
17
is a manufacturer, importer, distributor, or re-
18
tailer of the in vitro clinical test with respect to 
19
which the order was issued but to whom the 
20
order under subparagraph (A) was not directed. 
21
‘‘(2) ACTIONS ON A PLAN.—The actions which 
22
may be taken under a plan submitted under an 
23
order issued under paragraph (1) are as follows: 
24
02:14 Jul 08, 2021
H4128
191 
•HR 4128 IH
‘‘(A) To repair the in vitro clinical test so 
1
that it does not present the unreasonable risk 
2
of substantial harm with respect to which the 
3
order under paragraph (1)(A) was issued. 
4
‘‘(B) To replace the in vitro clinical test 
5
with a like or equivalent test which is in con-
6
formity with all applicable requirements of this 
7
Act. 
8
‘‘(C) To refund the purchase price of the 
9
in vitro clinical test (less a reasonable allowance 
10
for use if such in vitro clinical test has been in 
11
the possession of the user for one year or more 
12
at the time of notice ordered under subsection 
13
(a), or at the time the user receives actual no-
14
tice of the unreasonable risk with respect to 
15
which the order was issued under paragraph 
16
(1)(A), whichever occurs first). 
17
‘‘(3) NO CHARGE.—No charge shall be made to 
18
any person (other than a developer, manufacturer, 
19
importer, distributor or retailer) for using a remedy 
20
described in paragraph (2) and provided under an 
21
order issued under paragraph (1), and the person 
22
subject to the order shall reimburse each person 
23
(other than a developer, manufacturer, importer, 
24
distributor, or retailer) who is entitled to such a 
25
02:14 Jul 08, 2021
H4128
192 
•HR 4128 IH
remedy for any reasonable and foreseeable expenses 
1
actually incurred by such person in availing himself 
2
of such remedy. 
3
‘‘(c) REIMBURSEMENT.—An order issued under sub-
4
section (b)(1)(A) with respect to an in vitro clinical test 
5
may require any person who is a developer, manufacturer, 
6
importer, distributor, or retailer of the in vitro clinical test 
7
to reimburse any other person who is a developer, manu-
8
facturer, importer, distributor, or retailer of such in vitro 
9
clinical test for such other person’s expenses actually in-
10
curred in connection with carrying out the order if the 
11
Secretary determines such reimbursement is required for 
12
the protection of the public health. Any such requirement 
13
shall not affect any rights or obligations under any con-
14
tract to which the person receiving reimbursement or the 
15
person making such reimbursement is a party. 
16
‘‘(d) RECALL AUTHORITY.— 
17
‘‘(1) IN GENERAL.—If the Secretary finds that 
18
there is a reasonable probability that an in vitro 
19
clinical test approved under section 587B would 
20
cause serious, adverse health consequences or death, 
21
including by the absence, delay, or discontinuation of 
22
appropriate medical treatment, the Secretary shall 
23
issue an order requiring the appropriate person (in-
24
cluding the developers, manufacturers, importers, 
25
02:14 Jul 08, 2021
H4128
193 
•HR 4128 IH
distributors, or retailers of the in vitro clinical 
1
test)— 
2
‘‘(A) to immediately cease distribution of 
3
such in vitro clinical test; and 
4
‘‘(B) to immediately notify health profes-
5
sionals and user facilities of the order and to 
6
instruct such professionals and facilities to 
7
cease use of such in vitro clinical test. 
8
‘‘(2) INFORMAL
HEARING.—The order issued 
9
under paragraph (1)(A), shall provide the person 
10
subject to the order with an opportunity for an in-
11
formal hearing, to be held not later than 10 calendar 
12
days after the date of the issuance of the order, on 
13
the actions required by the order and on whether the 
14
order should be amended to require a recall of such 
15
in vitro clinical test. If, after providing an oppor-
16
tunity for such a hearing, the Secretary determines 
17
that inadequate grounds exist to support the actions 
18
required by the order, the Secretary shall vacate the 
19
order. 
20
‘‘(3) AMENDED ORDER.— 
21
‘‘(A) IN GENERAL.—If, after providing an 
22
opportunity for an informal hearing under 
23
paragraph (2), the Secretary determines that 
24
the order should be amended to include a recall 
25
02:14 Jul 08, 2021
H4128
194 
•HR 4128 IH
of the in vitro clinical test with respect to which 
1
the order was issued, the Secretary shall, except 
2
as provided in subparagraph (B), amend the 
3
order to require a recall. The Secretary shall 
4
specify a timetable in which the recall will occur 
5
and shall require periodic reports describing the 
6
progress of the recall. 
7
‘‘(B) REQUIREMENTS.—An amended order 
8
under subparagraph (A)— 
9
‘‘(i) shall not include recall of the in 
10
vitro clinical test from individuals; 
11
‘‘(ii) shall not include recall of an in 
12
vitro clinical test from test user facilities if 
13
the Secretary determines that the risk of 
14
recalling such in vitro clinical test from the 
15
facilities presents a greater health risk 
16
than the health risk of not recalling the in 
17
vitro clinical test from use; and 
18
‘‘(iii) shall provide for notice to indi-
19
viduals subject to the risks associated with 
20
the use of such in vitro clinical test. In 
21
providing the notice required by this 
22
clause, the Secretary may use the assist-
23
ance of health professionals who pre-
24
02:14 Jul 08, 2021
H4128
195 
•HR 4128 IH
scribed, ordered, or used such an in vitro 
1
clinical test for individuals. 
2
‘‘(4) CLARIFICATION.—The remedy provided by 
3
this subsection shall be in addition to remedies pro-
4
vided by subsections (b) and (c).’’. 
5
SEC. 4. ENFORCEMENT AND OTHER PROVISIONS. 
6
(a) PROHIBITED ACTS.—Section 301 of the Federal 
7
Food, Drug, and Cosmetic Act (21 U.S.C. 331) is amend-
8
ed— 
9
(1) in paragraphs (a), (b), (c), (g), (k), (q), (r), 
10
and (y), by inserting ‘‘in vitro clinical test,’’ after 
11
‘‘device,’’ each place it appears; 
12
(2) in paragraph (y) by inserting ‘‘or 587P’’ 
13
after ‘‘section 523’’ each place it appears; and 
14
(3) by adding at the end, the following: 
15
‘‘(fff)(1) The introduction or delivery for introduction 
16
into interstate commerce of an in vitro clinical test in vio-
17
lation of section 587B(a). 
18
‘‘(2) The false, fraudulent, or deceptive claiming for 
19
an in vitro clinical test of an exemption from the pre-
20
market review required under section 587B. 
21
‘‘(3) When claiming an exemption under section 
22
587A from the premarket review required under section 
23
587B, the failure to maintain complete and accurate docu-
24
mentation for the exemption as required under section 
25
02:14 Jul 08, 2021
H4128
196 
•HR 4128 IH
587A or the failure to provide labeling required under sec-
1
tion 587A. 
2
‘‘(4) With respect to an in vitro clinical test, the sub-
3
mission of any report that is required by or under this 
4
Act that is false or misleading in any material respect. 
5
‘‘(5) The making of a false, fraudulent, or materially 
6
deceptive analytical or clinical claim for an in vitro clinical 
7
test— 
8
‘‘(A) in any application, report, or notification 
9
submitted to the Secretary under this Act; or 
10
‘‘(B) in the labeling or advertising of an in vitro 
11
clinical test. 
12
‘‘(6) The failure to comply with a condition of ap-
13
proval, performance standard, mitigating measure, or re-
14
striction established in an order approving an application 
15
or supplement under section 587B; the failure to perform 
16
a risk analysis required by section 587B; the failure to 
17
submit an annual report required under section 587B(k); 
18
or the failure to complete postmarket studies required 
19
under section 587V. 
20
‘‘(7) The marketing of an in vitro clinical test in vio-
21
lation of— 
22
‘‘(A) an order issued by the Secretary under 
23
section 587A; or 
24
‘‘(B) any requirement under section 587A. 
25
02:14 Jul 08, 2021
H4128
197 
•HR 4128 IH
‘‘(8) With respect to technology certification under 
1
section 587D, the refusal to permit, or unreasonable delay 
2
in permitting, an inspection authorized under section 
3
587D(f)(3)(G); the failure to comply with applicable re-
4
quirements to submit an application or report under sec-
5
tion 587D(e); or the failure to comply with applicable 
6
maintenance requirements under section 587D(h). 
7
‘‘(9) The failure to comply with an applicable miti-
8
gating measure established under section 587E or to 
9
maintain the documentation required under section 
10
587E(b); or the failure to comply with a performance 
11
standard established under section 587Q. 
12
‘‘(10) The failure to register in accordance with sec-
13
tion 587I, the failure to provide information required 
14
under section 587I(b), or the failure to maintain or submit 
15
information required under section 587I(c). 
16
‘‘(11) The failure to submit a report required under 
17
section 587L or 587M; the failure to comply with a re-
18
striction imposed under section 587N; or the failure to 
19
comply with labeling and advertising requirements under 
20
section 587N(b). 
21
‘‘(12) The failure to comply with the requirements 
22
of section 587P (relating to accredited persons). 
23
‘‘(13) The failure to comply with any requirement 
24
prescribed or established under section 587R; the failure 
25
02:14 Jul 08, 2021
H4128
198 
•HR 4128 IH
to furnish any notification, information, material, or re-
1
port required under section 587R; or the failure to comply 
2
with an order issued under section 587R.’’. 
3
(b) PENALTIES.—Section 303(f)(1) of the Federal 
4
Food, Drug, and Cosmetic Act (21 U.S.C. 333(f)(1)) is 
5
amended— 
6
(1) in subparagraph (A), by inserting ‘‘or in 
7
vitro clinical tests’’ after ‘‘devices’’; and 
8
(2) in subparagraph (B)(i)— 
9
(A) by inserting ‘‘, or 587J or 587L,’’ 
10
after ‘‘520(f)’’; and 
11
(B) by inserting ‘‘, or who violates section 
12
587M(b) with respect to a correction report’’ 
13
after ‘‘risk to public health’’. 
14
(c) SEIZURE.—Section 304 of the Federal Food, 
15
Drug, and Cosmetic Act (21 U.S.C. 334) is amended— 
16
(1) in subsection (a)(2)— 
17
(A) by striking ‘‘and’’ before ‘‘(E) Any’’; 
18
and 
19
(B) by inserting ‘‘, and (F) Any adulter-
20
ated or misbranded in vitro clinical test’’ after 
21
‘‘tobacco product’’; 
22
(2) in subsection (d)(1), by inserting ‘‘in vitro 
23
clinical test,’’ after ‘‘device,’’; and 
24
(3) in subsection (g)— 
25
02:14 Jul 08, 2021
H4128
199 
•HR 4128 IH
(A) in paragraph (1), by inserting ‘‘, in 
1
vitro clinical test,’’ after ‘‘device’’ each place it 
2
appears; and 
3
(B) in paragraph (2)— 
4
(i) in subparagraph (A), by inserting 
5
‘‘, in vitro clinical test,’’ after ‘‘device’’; 
6
and 
7
(ii) in subparagraph (B), by inserting 
8
‘‘or in vitro clinical test’’ after ‘‘device’’ 
9
each place it appears. 
10
(d) DEBARMENT, TEMPORARY
DENIAL
OF
AP-
11
PROVAL, AND SUSPENSION.—Section 306 of the Federal 
12
Food, Drug, and Cosmetic Act (21 U.S.C. 335a) is 
13
amended by adding at the end the following: 
14
‘‘(n) IN VITRO CLINICAL TESTS; MANDATORY DE-
15
BARMENT REGARDING THIRD-PARTY INSPECTIONS AND 
16
REVIEWS.— 
17
‘‘(1) IN GENERAL.—If the Secretary finds that 
18
a person has been convicted of a felony under sec-
19
tion 301(gg), 301(fff)(2), 301(fff)(5), or 301(fff)(8), 
20
the Secretary shall debar such person from being ac-
21
credited under section 587P and from carrying out 
22
activities under an agreement described in section 
23
803(b). 
24
02:14 Jul 08, 2021
H4128
200 
•HR 4128 IH
‘‘(2) DEBARMENT
PERIOD.—The Secretary 
1
shall debar a person under paragraph (1) for the fol-
2
lowing periods: 
3
‘‘(A) The period of debarment of a person 
4
(other than an individual) shall not be less than 
5
1 year or more than 10 years, but if an act 
6
leading to a subsequent debarment under such 
7
paragraph occurs within 10 years after such 
8
person has been debarred under such para-
9
graph, the period of debarment shall be perma-
10
nent. 
11
‘‘(B) The debarment of an individual shall 
12
be permanent. 
13
‘‘(3) TERMINATION OF DEBARMENT; JUDICIAL 
14
REVIEW; OTHER MATTERS.—Subsections (c)(3), (d), 
15
(e), (i), (j), and (l)(1) apply with respect to a person 
16
(other than an individual) or an individual who is 
17
debarred under paragraph (1) to the same extent 
18
and in the same manner as such subsections apply 
19
with respect to a person who is debarred under sub-
20
section (a)(1), or an individual who is debarred 
21
under subsection (a)(2), respectively.’’. 
22
(e) JUDICIAL REVIEW.—Section 517(a) of the Fed-
23
eral Food, Drug, and Cosmetic Act (21 U.S.C. 360g(a)) 
24
is amended— 
25
02:14 Jul 08, 2021
H4128
201 
•HR 4128 IH
(1) in paragraph (8), by striking ‘‘or’’ at the 
1
end; 
2
(2) in paragraph (9), by inserting ‘‘or’’ after 
3
the comma at the end; and 
4
(3) before the matter that follows paragraph 
5
(9), by inserting the following: 
6
‘‘(10) an order issued pursuant to section 
7
587B, 587D, 587R, or 587S,’’. 
8
(f) EXPANDED ACCESS TO UNAPPROVED THERAPIES 
9
AND DIAGNOSTICS.—Section 561 of the Federal Food, 
10
Drug, and Cosmetic Act (21 U.S.C. 360bbb) is amend-
11
ed— 
12
(1) in subsections (a) through (d)— 
13
(A) by striking ‘‘or investigational devices’’ 
14
each place it appears and inserting ‘‘, investiga-
15
tional devices, or investigational in vitro clinical 
16
tests’’; and 
17
(B) by striking ‘‘or investigational device’’ 
18
each place it appears (other than the second 
19
such place in paragraph (3)(A)) and inserting 
20
‘‘, investigational device, or investigational in 
21
vitro clinical test’’; 
22
(2) in subsection (b)(4) by striking ‘‘or 520(g)’’ 
23
and inserting ‘‘, 520(g), or 587R’’ each place it ap-
24
pears; 
25
02:14 Jul 08, 2021
H4128
202 
•HR 4128 IH
(3) in subsection (c)— 
1
(A) by amending the subsection heading to 
2
read: ‘‘TREATMENT
INVESTIGATIONAL
NEW 
3
DRUG APPLICATIONS, TREATMENT INVESTIGA-
4
TIONAL DEVICE EXEMPTIONS, AND TREAT-
5
MENT INVESTIGATIONAL
IN VITRO CLINICAL 
6
TEST EXEMPTIONS’’; 
7
(B) in paragraph (3)(A), by striking ‘‘or 
8
investigational device exemption in effect under 
9
section 520(g)’’ and inserting ‘‘, investigational 
10
device exemption in effect under section 520(g), 
11
or investigational in vitro clinical test exemption 
12
under section 587R’’; 
13
(C) by striking ‘‘or treatment investiga-
14
tional device exemption’’ each place it appears 
15
and inserting ‘‘, treatment investigational device 
16
exemption, or treatment investigational in vitro 
17
clinical test exemption’’; and 
18
(D) in the matter following paragraph (7) 
19
by striking ‘‘or 520(g)’’ each place it appears 
20
and inserting ‘‘, 520(g) or 587R’’; and 
21
(4) by amending subsection (e) to read as fol-
22
lows: 
23
‘‘(e) DEFINITIONS.—In this section, the terms ‘inves-
24
tigational drug’, ‘investigational device’, ‘investigational in 
25
02:14 Jul 08, 2021
H4128
203 
•HR 4128 IH
vitro clinical test’, ‘treatment investigational new drug ap-
1
plication’, ‘treatment investigational device exemption’, 
2
and ‘treatment investigational in vitro clinical test exemp-
3
tion’ shall have the meanings given the terms in regula-
4
tions prescribed by the Secretary.’’. 
5
(g) OPTIMIZING GLOBAL CLINICAL TRIALS.—Section 
6
569A(b) of the Federal Food, Drug, and Cosmetic Act (21 
7
U.S.C. 360bbb–8a(b)) is amended by inserting ‘‘an in 
8
vitro clinical test, as defined in subsection (ss) of such sec-
9
tion,’’ before ‘‘or a biological product’’. 
10
(h) PATIENT PARTICIPATION IN MEDICAL PRODUCT 
11
DISCUSSION.—The heading of subsection (a) of section 
12
569C of the Federal Food, Drug, and Cosmetic Act (21 
13
U.S.C. 360bbb–8c) is amended by striking ‘‘DRUGS AND 
14
DEVICES’’ and inserting ‘‘DRUGS, DEVICES, AND IN 
15
VITRO CLINICAL TESTS’’. 
16
(i) 
REGULATIONS
AND
HEARINGS.—Section 
17
701(h)(1)(C)(ii) of the Federal Food, Drug, and Cosmetic 
18
Act (21 U.S.C. 371(h)(1)(C)(ii)) is amended by inserting 
19
‘‘and in vitro clinical tests’’ after ‘‘devices’’. 
20
(j) FACTORY INSPECTION.—Section 704 of the Fed-
21
eral Food, Drug, and Cosmetic Act (21 U.S.C. 374) (other 
22
than subsection (g)) is amended— 
23
02:14 Jul 08, 2021
H4128
204 
•HR 4128 IH
(1) by striking ‘‘drugs or devices’’ each place it 
1
appears and inserting ‘‘drugs, devices, or in vitro 
2
clinical tests’’; 
3
(2) in subsection (a)(1), in the third sentence, 
4
by striking ‘‘or chapter IX’’ and inserting ‘‘section 
5
587R or chapter IX’’; 
6
(3) in subsection (a)(2)(B)— 
7
(A) by inserting ‘‘or in vitro clinical tests’’ 
8
after ‘‘prescribe or use devices’’; and 
9
(B) by inserting ‘‘or in vitro clinical tests’’ 
10
after ‘‘process devices’’; 
11
(4) by inserting ‘‘in vitro clinical test,’’ after 
12
‘‘device,’’ each place it appears; 
13
(5) after making the amendments in para-
14
graphs (1) and (2), by inserting ‘‘in vitro clinical 
15
tests,’’ after ‘‘devices,’’ each place it appears; 
16
(6) in subsection (e), by inserting ‘‘, or section 
17
587L, 587M, or 587R,’’ after ‘‘section 519 or 
18
520(g)’’; and 
19
(7) in subsection (f)(3)— 
20
(A) in subparagraph (A), by striking ‘‘or’’ 
21
at the end; 
22
(B) in subparagraph (B), by striking the 
23
period at the end and inserting ‘‘; or’’; and 
24
02:14 Jul 08, 2021
H4128
205 
•HR 4128 IH
(C) after subparagraph (B), by inserting 
1
the following: 
2
‘‘(C) is accredited under section 587P.’’. 
3
(k) PUBLICITY.—Section 705(b) of the Federal Food, 
4
Drug, and Cosmetic Act (21 U.S.C. 375(b)) is amended 
5
by inserting ‘‘in vitro clinical tests,’’ after ‘‘devices,’’. 
6
(l) PRESUMPTION.—Section 709 of the Federal Food, 
7
Drug, and Cosmetic Act (21 U.S.C. 379a) is amended by 
8
inserting ‘‘in vitro clinical test,’’ after ‘‘device,’’. 
9
(m) IMPORTS AND EXPORTS.—Section 801 of the 
10
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 381) 
11
is amended— 
12
(1) in subsection (a)— 
13
(A) by inserting ‘‘in vitro clinical tests,’’ 
14
after ‘‘devices,’’ each place it appears; and 
15
(B) by inserting ‘‘in the case of an in vitro 
16
clinical test, the test does not conform to the 
17
applicable requirements of section 587J, or’’ 
18
after ‘‘requirements of section 520(f), or’’; 
19
(2) in subsection (d)(3)— 
20
(A) in subparagraph (A)— 
21
(i) in the matter preceding clause (i), 
22
by inserting ‘‘and no component of an in 
23
vitro clinical test or other article of in vitro 
24
02:14 Jul 08, 2021
H4128
206 
•HR 4128 IH
clinical test that requires further proc-
1
essing,’’ after ‘‘health-related purposes’’; 
2
(ii) in clause (i), by striking ‘‘drug or 
3
device’’ and inserting ‘‘drug, device, or in 
4
vitro clinical test’’; and 
5
(iii) in clause (i)(I), by inserting ‘‘in 
6
vitro clinical test,’’ after ‘‘device,’’; and 
7
(B) in subparagraph (B), by inserting ‘‘in 
8
vitro clinical test,’’ after ‘‘device,’’; and 
9
(3) in subsection (e)(1), by inserting ‘‘in vitro 
10
clinical test,’’ after ‘‘device,’’. 
11
(n) OFFICE OF INTERNATIONAL RELATIONS.—Sec-
12
tion 803 of the Federal Food, Drug, and Cosmetic Act 
13
(21 U.S.C. 383) is amended— 
14
(1) in subsection (b)— 
15
(A) in the matter preceding paragraph (1), 
16
by inserting ‘‘and in vitro clinical tests’’ after 
17
‘‘devices’’; and 
18
(B) in paragraph (1), by inserting ‘‘quality 
19
requirements established under section 587J; 
20
and’’ at the end; and 
21
(2) in subsection (c)— 
22
(A) in paragraph (2), by inserting ‘‘in vitro 
23
clinical tests,’’ after ‘‘devices,’’; and 
24
02:14 Jul 08, 2021
H4128
207 
•HR 4128 IH
(B) in paragraph (4), by inserting ‘‘or in 
1
vitro clinical tests’’ after ‘‘devices’’. 
2
(o) RECOGNITION OF FOREIGN GOVERNMENT IN-
3
SPECTIONS.—Section 809(a)(1) of the Federal Food, 
4
Drug, and Cosmetic Act (21 U.S.C. 384e(a)(1)) is amend-
5
ed by inserting ‘‘, or section 587I’’ after ‘‘510(h)’’. 
6
(p) FOOD
AND DRUG ADMINISTRATION.—Section 
7
1003(b)(2) of the Federal Food, Drug, and Cosmetic Act 
8
(21 U.S.C. 393(b)(2)) is amended— 
9
(1) in subparagraph (D), by striking ‘‘and’’ at 
10
the end; 
11
(2) in subparagraph (E), by striking the semi-
12
colon at the end and inserting ‘‘; and’’; and 
13
(3) by adding at the end the following: 
14
‘‘(F) in vitro clinical tests are analytically 
15
and clinically valid;’’. 
16
(q) OFFICE OF WOMEN’S HEALTH.—Section 1011(b) 
17
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
18
399b(b)) is amended— 
19
(1) in paragraph (1), by inserting ‘‘in vitro clin-
20
ical tests,’’ after ‘‘devices,’’; and 
21
(2) in paragraph (4), by striking ‘‘and device 
22
manufacturers’’ and inserting ‘‘device manufactur-
23
ers, and in vitro clinical test developers,’’. 
24
02:14 Jul 08, 2021
H4128
208 
•HR 4128 IH
(r) 
COUNTERMEASURE
PROVISIONS
OF
THE 
1
PHSA.—Title III of the PHSA is amended— 
2
(1) in section 319F–2(c)(1)(B) (42 U.S.C. 
3
247d–6b(c)(1)(B)) is amended— 
4
(A) by striking ‘‘or device’’ and inserting 
5
‘‘device’’; and 
6
(B) by inserting ‘‘or an in vitro clinical 
7
test (as that term is defined in section 201(ss) 
8
of the Federal Food, Drug, and Cosmetic Act 
9
(21 U.S.C. 321(ss)))’’ after ‘‘Act (21 U.S.C. 
10
321(h)))’’; 
11
(2) in section 319F–1(a)(2) (42 U.S.C. 247d– 
12
6a(a)(2)), by inserting ‘‘an in vitro clinical tests (as 
13
that term is defined in section 201(ss) of the Fed-
14
eral Food, Drug, and Cosmetic Act (21 U.S.C. 
15
321(ss))),’’ before ‘‘or device’’; and 
16
(3) in section 319F–3(i)(7) (42 U.S.C. 247d– 
17
6d(i)(7)), by inserting ‘‘an in vitro clinical tests (as 
18
that term is defined in section 201(ss) of the Fed-
19
eral Food, Drug, and Cosmetic Act (21 U.S.C. 
20
321(ss))),’’ before ‘‘or device’’. 
21
SEC. 5. TRANSITION. 
22
(a) IMPLEMENTATION.— 
23
(1) EFFECTIVE DATE.— 
24
02:14 Jul 08, 2021
H4128
209 
•HR 4128 IH
(A) IN
GENERAL.—Except as otherwise 
1
provided in this section, the amendments made 
2
by this Act apply 4 years after the date of en-
3
actment of this Act (in this section and in sub-
4
chapter J of chapter V of the Federal Food, 
5
Drug, and Cosmetic Act, as added by this Act, 
6
referred to in this section as the ‘‘effective date 
7
of this Act’’). 
8
(B) EXCEPTION.—The Secretary of Health 
9
and Human Services (in this section referred to 
10
as the ‘‘Secretary’’) may take the actions de-
11
scribed in paragraph (2), and may expend such 
12
funds as the Secretary determines necessary to 
13
ensure an orderly transition. 
14
(2) ACTIONS.—The Secretary shall, prior to the 
15
date on which the amendments made by this Act 
16
generally apply pursuant to paragraph (1)— 
17
(A) within 1 year of the date of enactment 
18
of this Act hold the public meetings described 
19
in subchapter J of chapter V of the Federal 
20
Food, Drug, and Cosmetic Act, as added by 
21
section 3; 
22
(B) within 2 years of the date of enact-
23
ment of this Act promulgate final regulations 
24
02:14 Jul 08, 2021
H4128
210 
•HR 4128 IH
required under sections 587B, 587D, 587L, 
1
587M, 587V, and 587W; and 
2
(C) within 2 years of the date of enact-
3
ment of this Act issue final guidance on appli-
4
cability requirements under section 587A. 
5
(3) APPLICABILITY
OF
REGULATIONS.—Not-
6
withstanding the date on which guidance or regula-
7
tions are issued under paragraph (2), no guidance or 
8
regulations issued pursuant to the amendments 
9
made by this Act shall take effect until the effective 
10
date of this Act, as described in paragraph (1), ex-
11
cept as otherwise provided for transitional tests 
12
under this section. 
13
(b) APPLICATION
OF AUTHORITIES
TO IN VITRO 
14
CLINICAL TESTS UNTIL AND AFTER EFFECTIVE DATE 
15
OF THIS ACT.—Except as provided in subsections (c) and 
16
(d), for any in vitro clinical test as defined in section 
17
201(ss) of the Federal Food, Drug, and Cosmetic Act, as 
18
added by this Act, the following authorities shall apply: 
19
(1) TESTS OFFERED PRIOR TO ENACTMENT.— 
20
An in vitro clinical test that meets the criteria for 
21
a grandfathered test as set forth in section 
22
587A(c)(2) of the Federal Food, Drug, and Cos-
23
metic Act, as added by section 3, may continue to 
24
be offered for clinical use and shall be subject only 
25
02:14 Jul 08, 2021
H4128
211 
•HR 4128 IH
to applicable provisions of section 353 of the Public 
1
Health Service Act and section 587A(a)(4) of the 
2
Federal Food, Drug, and Cosmetic Act, as added by 
3
section 3. 
4
(2) TESTS
APPROVED
OR
CLEARED
ON
OR 
5
AFTER THE DATE OF ENACTMENT BUT PRIOR TO 
6
THE EFFECTIVE DATE.—Before any in vitro clinical 
7
test as defined in section 201(ss) of the Federal 
8
Food, Drug, and Cosmetic Act, as added by this 
9
Act, is first offered, sold, or distributed after the 
10
date of enactment of this Act, but prior to the effec-
11
tive date of this Act, such product or test shall be 
12
considered a transitional test as described under 
13
subsection (c) and comply with the applicable device 
14
provisions of the Federal Food, Drug, and Cosmetic 
15
Act (21 U.S.C. 301 et seq.) and the Public Health 
16
Service Act (42 U.S.C. 201 et seq.). 
17
(3) TESTS UNDER FDA REVIEW BEGINNING ON 
18
OR AFTER THE DATE OF ENACTMENT OF THIS ACT 
19
BUT PRIOR TO IMPLEMENTATION.—For any in vitro 
20
clinical test as defined in section 201(ss) of the Fed-
21
eral Food, Drug, and Cosmetic Act, as added by this 
22
Act, for which a submission for marketing authoriza-
23
tion under section 515, clearance under section 
24
510(k), authorization under section 513(f)(2), ap-
25
02:14 Jul 08, 2021
H4128
212 
•HR 4128 IH
proval under section 520(m), or emergency use au-
1
thorization under section 564 of the Federal Food, 
2
Drug, and Cosmetic Act (21 U.S.C. 360e, 360(k), 
3
360c(f)(2), 360j(m), 360bbb–3) or approval under 
4
the Public Health Service Act (42 U.S.C. 201 et 
5
seq.) is pending on the effective date of this Act, the 
6
Secretary may review and take action on such sub-
7
mission after the effective date of this Act according 
8
to the statutory provision under which such submis-
9
sion was submitted. 
10
(c) APPLICATION
OF
AUTHORITIES
TO
TRANSI-
11
TIONAL
AND
GRANDFATHERED
IN
VITRO
CLINICAL 
12
TESTS.— 
13
(1) DEFINITION.—For purposes of this section, 
14
the term ‘‘transitional in vitro clinical test’’ means 
15
an in vitro clinical test, as defined in section 201(ss) 
16
of the Federal Food, Drug, and Cosmetic Act, as 
17
added by this Act, that— 
18
(A) is offered for clinical use during the 
19
period beginning on the date of enactment of 
20
this Act and ending on the date that is 90 days 
21
after the effective date of this Act; 
22
(B) is developed by a clinical laboratory 
23
certified by the Secretary under section 353 of 
24
the Public Health Service Act (42 U.S.C. 263a) 
25
02:14 Jul 08, 2021
H4128
213 
•HR 4128 IH
that meets the requirements for performing 
1
high-complexity testing for use only within that 
2
certified laboratory or another laboratory within 
3
the organization under common ownership; and 
4
(C) is not approved under section 515, 
5
cleared under section 510(k), authorized under 
6
section 513(f)(2), subject to an exemption 
7
under section 520(m), or authorized under sec-
8
tion 564 of the Federal Food, Drug, and Cos-
9
metic Act (21 U.S.C. 360e, 360(k), 360c(f)(2), 
10
360j(m), 360bbb–3) or approval under the Pub-
11
lic Health Service Act (42 U.S.C. 201 et seq.). 
12
(2) PREMARKET REVIEW OR TECHNOLOGY CER-
13
TIFICATION.—A transitional in vitro clinical test 
14
that is the subject of an application for premarket 
15
review under section 587B of the Federal Food, 
16
Drug, and Cosmetic Act or technology certification 
17
application under section 587D of such Act, as 
18
added by this Act, that is submitted prior to the ef-
19
fective date of this Act may continue to be offered, 
20
sold, or distributed until completion of the Sec-
21
retary’s review of the premarket application or tech-
22
nology certification application. 
23
(d) CONVERSION.— 
24
02:14 Jul 08, 2021
H4128
214 
•HR 4128 IH
(1) DEEMED PREMARKET APPROVAL.—Any in 
1
vitro clinical test (as defined in section 201(ss) of 
2
the Federal Food, Drug, and Cosmetic Act, as 
3
added by this Act) with a premarket approval under 
4
section 515, a clearance under section 510(k), an 
5
authorization under section 513(f), or a licensure 
6
under section 351 of the Public Health Service Act 
7
(42 U.S.C. 262) is deemed to have an approved ap-
8
plication under section 587B of the Federal Food, 
9
Drug, and Cosmetic Act, as added by this Act, be-
10
ginning on the later of— 
11
(A) the effective date of this Act; or 
12
(B) such other date, not later than 3 years 
13
after such effective date, as the person respon-
14
sible for the device selects. 
15
(2) 
DEEMED
INVESTIGATIONAL
USE
AP-
16
PROVAL.—Any in vitro clinical test (as defined in 
17
section 201(ss) of the Federal Food, Drug, and Cos-
18
metic Act, as added by this Act) that has an ap-
19
proved investigational device exemption under sec-
20
tion 520(g) of the Federal Food, Drug, and Cos-
21
metic Act (21 U.S.C. 360j(g)) is deemed to have an 
22
approved investigational use under section 587Q of 
23
such Act, as added by this Act, beginning on the ef-
24
fective date of this Act. 
25
02:14 Jul 08, 2021
H4128
215 
•HR 4128 IH
(e) INSTRUMENTS.—An instrument (as defined in 
1
section 587 of the Federal Food, Drug, and Cosmetic Act, 
2
as added by this Act) that was purchased prior to the date 
3
of enactment of this Act and was not cleared, authorized, 
4
or approved by the Food and Drug Administration or part 
5
of an instrument family that was cleared, authorized, or 
6
approved by the Food and Drug Administration at the 
7
time of purchase may continue to be used by the purchaser 
8
to develop and introduce into interstate commerce an in 
9
vitro clinical test during the period beginning on the date 
10
of enactment of this Act and ending 5 years after such 
11
date of enactment. Beginning at the end of such period, 
12
any new in vitro clinical test that is developed and intro-
13
duced into interstate commerce shall be based on an in-
14
strument (as defined in section 587(11) of the Federal 
15
Food, Drug, and Cosmetic Act, as added by section 3) 
16
that complies with the requirements of the Federal Food, 
17
Drug, and Cosmetic Act, as amended by this Act. 
18
(f) RELATION TO IN VITRO CLINICAL TEST PROVI-
19
SION.—This section applies notwithstanding section 
20
587A(a)(1)(C) of the Federal Food, Drug, and Cosmetic 
21
Act, as added by this Act. 
22
SEC. 6. EMERGENCY USE AUTHORIZATION. 
23
Section 564 of the Federal Food, Drug, and Cosmetic 
24
Act (21 U.S.C. 360bbb–3) is amended— 
25
02:14 Jul 08, 2021
H4128
216 
•HR 4128 IH
(1) in paragraphs (1) and (4)(C) of subsection 
1
(a), by inserting ‘‘in vitro clinical test,’’ before ‘‘or 
2
biological product’’ each place such term appears; 
3
and 
4
(2) in subsection (e)(3)— 
5
(A) in subparagraph (B), by striking 
6
‘‘and’’ at the end; 
7
(B) in subparagraph (C), by striking the 
8
period and inserting ‘‘; and’’; and 
9
(C) by adding at the end the following: 
10
‘‘(D) quality system requirements (with re-
11
spect to in vitro clinical tests) under section 
12
587J.’’. 
13
SEC. 7. ANTIMICROBIAL SUSCEPTIBILITY TESTS. 
14
Section 511A of the Federal Food, Drug, and Cos-
15
metic Act (21 U.S.C. 360a–2) is amended— 
16
(1) in subsection (a)(1)(C)— 
17
(A) by striking ‘‘or approve under section 
18
515’’ and inserting ‘‘approve under section 515, 
19
or approve, exempt, or issue a technology cer-
20
tification order under subchapter J’’; and 
21
(B) by striking ‘‘testing devices’’ and in-
22
serting ‘‘tests’’; 
23
02:14 Jul 08, 2021
H4128
217 
•HR 4128 IH
(2) in subsection (c)(5), by striking ‘‘drug or 
1
device’’ each place it appears and inserting ‘‘drug, 
2
device, or in vitro clinical test’’; 
3
(3) in subsection (e)— 
4
(A) in the heading, by striking ‘‘TESTING 
5
DEVICES’’ and inserting ‘‘IN VITRO CLINICAL 
6
TESTS’’; 
7
(B) in paragraph (1)— 
8
(i) by striking ‘‘and 515,’’ and insert-
9
ing ‘‘515, 587B, and 587D’’; 
10
(ii) by striking ‘‘antimicrobial suscep-
11
tibility testing device’’ and inserting ‘‘anti-
12
microbial susceptibility in vitro clinical 
13
test’’; and 
14
(iii) by striking ‘‘such device’’ and in-
15
serting ‘‘such test’’; 
16
(C) in paragraph (2)— 
17
(i) in the heading, by striking ‘‘TEST-
18
ING
DEVICES’’ and inserting ‘‘IN
VITRO 
19
CLINICAL TESTS’’; and 
20
(ii) by amending subparagraph (C) to 
21
read as follows: 
22
‘‘(C) The antimicrobial susceptibility in 
23
vitro clinical test meets all other requirements 
24
to be approved under section 587B or exempted 
25
02:14 Jul 08, 2021
H4128
218 
•HR 4128 IH
from premarket review under section 587D.’’; 
1
and 
2
(D) after making the amendments in sub-
3
paragraphs (B)(ii), (B)(iii), and (C)(ii), by 
4
striking ‘‘device’’ each place it appears and in-
5
serting ‘‘in vitro clinical test’’; 
6
(4) in subsection (f), by amending paragraph 
7
(1) to read as follows: 
8
‘‘(1) The term ‘antimicrobial susceptibility in 
9
vitro clinical test’ means an in vitro clinical test that 
10
utilizes susceptibility test interpretive criteria to de-
11
termine and report the in vitro susceptibility of cer-
12
tain microorganisms to a drug (or drugs).’’; and 
13
(5) in subsection (g)(2)— 
14
(A) by amending the matter preceding sub-
15
paragraph (A) to read as follows: 
16
‘‘(2) with respect to clearing under section 
17
510(k), classifying under section 513(f)(2), approv-
18
ing under section 515 or section 587B, or exempting 
19
from approval requirements under section 587D—’’; 
20
and 
21
(B) in subparagraph (A)— 
22
(i) by striking ‘‘device’’ and inserting 
23
‘‘in vitro clinical test’’; and 
24
02:14 Jul 08, 2021
H4128
219 
•HR 4128 IH
(ii) by striking ‘‘antimicrobial suscep-
1
tibility testing device’’ and inserting ‘‘anti-
2
microbial susceptibility in vitro clinical 
3
test’’. 
4
SEC. 8. COMBINATION PRODUCTS. 
5
(a) IN GENERAL.—Section 503(g) of the Federal 
6
Food, Drug, and Cosmetic Act (21 U.S.C. 353(g)) is 
7
amended— 
8
(1) in paragraph (1)— 
9
(A) in subparagraph (A)— 
10
(i) by inserting ‘‘(except for a com-
11
bination product constituted of a device 
12
and an in vitro clinical test)’’ after ‘‘agency 
13
center,’’; and 
14
(ii) by inserting ‘‘in vitro clinical 
15
test,’’ before ‘‘or biological product’’; and 
16
(B) in subparagraph (D)— 
17
(i) in the matter preceding clause (i), 
18
by striking ‘‘. If the Secretary determines’’ 
19
and inserting ‘‘, except for a combination 
20
product constituted of a device and an in 
21
vitro clinical test. For other combination 
22
products, if the Secretary determines’’; and 
23
(ii) in clause (ii)— 
24
02:14 Jul 08, 2021
H4128
220 
•HR 4128 IH
(I) by inserting ‘‘or in vitro clin-
1
ical test’’ after ‘‘device’’; and 
2
(II) by inserting ‘‘and in vitro 
3
clinical tests’’ before ‘‘shall’’; 
4
(2) in paragraph (3), by striking ‘‘safety and 
5
effectiveness or substantial equivalence’’ and insert-
6
ing ‘‘safety and effectiveness, substantial equiva-
7
lence, or analytical validity and clinical validity’’ be-
8
fore ‘‘for the approved constituent part’’; 
9
(3) in paragraph (4)— 
10
(A) in subparagraph (A), by striking ‘‘or 
11
513(f)(2) (submitted in accordance with para-
12
graph (5))’’ and inserting ‘‘513(f)(2) (sub-
13
mitted in accordance with paragraph (5)), 
14
587B, or an exempt test under section 587A, as 
15
applicable’’; and 
16
(B) in subparagraph (B), by inserting ‘‘or 
17
587B’’ after ‘‘section 515’’; 
18
(4) in paragraph (5)(A), by striking ‘‘or 
19
510(k)’’ and inserting ‘‘, 510(k), or 587B’’; 
20
(5) in paragraph (7), by striking ‘‘or substan-
21
tial equivalence’’ and inserting ‘‘, substantial equiva-
22
lence, or analytical validity and clinical validity’’; 
23
(6) in paragraph (8), by adding at the end the 
24
following: 
25
02:14 Jul 08, 2021
H4128
221 
•HR 4128 IH
‘‘(I) This paragraph shall not apply to a 
1
combination product constituted of a device and 
2
an in vitro clinical test.’’; and 
3
(7) in paragraph (9)— 
4
(A) in subparagraph (C)(i), by striking ‘‘or 
5
520(g)’’ and inserting ‘‘520(g), or 587B’’; and 
6
(B) in subparagraph (D), by striking ‘‘or 
7
520’’ and inserting ‘‘520, or 587B’’. 
8
(b) CLASSIFICATION OF PRODUCTS.—Section 563 of 
9
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
10
360bbb–2) is amended by adding at the end the following: 
11
‘‘(d) EXEMPTION.—This section shall not apply to a 
12
combination product constituted of a device and an in 
13
vitro clinical test.’’. 
14
SEC. 9. RESOURCES. 
15
(a) FINDINGS.—Congress finds that the fees author-
16
ized by this section will be dedicated to meeting the goals 
17
identified in the letters from the Secretary of Health and 
18
Human Services to the Committee on Health, Education, 
19
Labor, and Pensions of the Senate and the Committee on 
20
Energy and Commerce of the House of Representatives, 
21
as set forth in the Congressional Record. 
22
(b) ESTABLISHMENT OF USER FEE PROGRAM.— 
23
(1) DEVELOPMENT
OF
USER
FEES
FOR
IN 
24
VITRO CLINICAL TESTS.— 
25
02:14 Jul 08, 2021
H4128
222 
•HR 4128 IH
(A) IN
GENERAL.—Beginning not later 
1
than October 1, 2021, the Secretary of Health 
2
and Human Services (in this section referred to 
3
as the ‘‘Secretary’’) shall develop recommenda-
4
tions to present to Congress with respect to the 
5
goals, and plans for meeting the goals, for the 
6
process of the review of in vitro clinical test ap-
7
plications submitted under subchapter J of 
8
chapter V of the Federal Food, Drug, and Cos-
9
metic Act, as added by this Act, for the first 5 
10
fiscal years after fiscal year 2022. In developing 
11
such recommendations, the Secretary shall con-
12
sult with— 
13
(i) the Committee on Energy and 
14
Commerce of the House of Representa-
15
tives; 
16
(ii) the Committee on Health, Edu-
17
cation, Labor, and Pensions of the Senate; 
18
(iii) scientific and academic experts; 
19
(iv) health care professionals; 
20
(v) representatives of patient and con-
21
sumer advocacy groups; and 
22
(vi) the regulated industry. 
23
(B) PRIOR PUBLIC INPUT.—Prior to begin-
24
ning negotiations with the regulated industry 
25
02:14 Jul 08, 2021
H4128
223 
•HR 4128 IH
on the authorization of such subchapter J, the 
1
Secretary shall— 
2
(i) publish a notice in the Federal 
3
Register requesting public input on the au-
4
thorization of user fees; 
5
(ii) hold a public meeting at which the 
6
public may present its views on the author-
7
ization, including specific suggestions for 
8
the recommendations submitted under sub-
9
paragraph (E); 
10
(iii) provide a period of 30 days after 
11
the public meeting to obtain written com-
12
ments from the public suggesting changes 
13
to such subchapter J; and 
14
(iv) publish any comments received 
15
under clause (iii) on the website of the 
16
Food and Drug Administration. 
17
(C) PERIODIC
CONSULTATION.—Not less 
18
frequently than once every month during nego-
19
tiations with the regulated industry, the Sec-
20
retary shall hold discussions with representa-
21
tives of patient and consumer advocacy groups 
22
to continue discussions of the authorization 
23
under such subchapter J and to solicit sugges-
24
tions to be included in the recommendations 
25
02:14 Jul 08, 2021
H4128
224 
•HR 4128 IH
transmitted to Congress under subparagraph 
1
(E). 
2
(D) PUBLIC
REVIEW
OF
RECOMMENDA-
3
TIONS.—After negotiations with the regulated 
4
industry, the Secretary shall— 
5
(i) present the recommendations de-
6
veloped under subparagraph (A) to the 
7
Committee on Health, Education, Labor, 
8
and Pensions of the Senate and the Com-
9
mittee on Energy and Commerce of the 
10
House of Representatives; 
11
(ii) publish such recommendations in 
12
the Federal Register; 
13
(iii) provide for a period of 30 days 
14
for the public to provide written comments 
15
on such recommendations; 
16
(iv) hold a meeting at which the pub-
17
lic may present its views on such rec-
18
ommendations; and 
19
(v) after consideration of such public 
20
views and comments, revise such rec-
21
ommendations as necessary. 
22
(E) 
TRANSMITTAL
OF
RECOMMENDA-
23
TIONS.— 
24
02:14 Jul 08, 2021
H4128
225 
•HR 4128 IH
(i) IN
GENERAL.—Not later than 
1
June 1, 2021, the Secretary shall transmit 
2
to Congress the revised recommendations 
3
under subparagraph (A), a summary of the 
4
views and comments received under such 
5
subparagraph, and any changes made to 
6
the recommendations in response to such 
7
views and comments. 
8
(ii) 
RECOMMENDATION
REQUIRE-
9
MENTS.—The 
recommendations 
trans-
10
mitted under this subparagraph shall— 
11
(I) include the number of full- 
12
time equivalent employees per fiscal 
13
year that are agreed to be hired to 
14
carry out the goals included in such 
15
recommendations for each year of the 
16
5-year period; 
17
(II) provide that the amount of 
18
operating reserve balance in the user 
19
fee program established under this 
20
section is not more than the equiva-
21
lent of 10 weeks of operating reserve; 
22
(III) require the development of 
23
a strategic plan for any surplus within 
24
the operating reserve account above 
25
02:14 Jul 08, 2021
H4128
226 
•HR 4128 IH
the 10-week operating reserve within 
1
2 years of the establishment of the 
2
program; 
3
(IV) include an operating reserve 
4
adjustment such that, if the Secretary 
5
has an operating reserve balance in 
6
excess of 10 weeks of such operating 
7
reserves, the Secretary shall decrease 
8
such fee revenue and fees to provide 
9
for not more than 10 weeks of such 
10
operating reserves; 
11
(V) if an adjustment is made as 
12
described in subclause (IV), provide 
13
the rationale for the amount of the 
14
decrease in fee revenue and fees shall 
15
be contained in the Federal Register; 
16
and 
17
(VI) provide that the fees as-
18
sessed and collected for the full-time 
19
equivalent employees at the Center for 
20
Devices and Radiological Health, with 
21
respect to which the majority of time 
22
reporting data indicates are dedicated 
23
to the review of in vitro clinical tests, 
24
are not supported by the funds au-
25
02:14 Jul 08, 2021
H4128
227 
•HR 4128 IH
thorized to be collected and assessed 
1
under section 738 of the Federal 
2
Food, Drug, and Cosmetic Act (21 
3
U.S.C. 379j). 
4
(F) 
PUBLICATION
OF
RECOMMENDA-
5
TIONS.—The Secretary shall publish on the 
6
website of the Food and Drug Administration 
7
the revised recommendations under subpara-
8
graph (A), a summary of the views and com-
9
ments 
received 
under 
subparagraphs 
(B) 
10
through (D), and any changes made to the rec-
11
ommendations originally proposed by the Sec-
12
retary in response to such views and comments. 
13
(G) MINUTES
OF
NEGOTIATION
MEET-
14
INGS.— 
15
(i) 
PUBLIC
AVAILABILITY.—Before 
16
transmitting the recommendations devel-
17
oped under subparagraphs (A) through (F) 
18
to Congress, the Secretary shall make pub-
19
licly available, on the website of the Food 
20
and Drug Administration, minutes of all 
21
negotiation meetings conducted under this 
22
subsection between the Food and Drug Ad-
23
ministration and the regulated industry. 
24
02:14 Jul 08, 2021
H4128
228 
•HR 4128 IH
(ii) 
CONTENT.—The 
minutes 
de-
1
scribed under clause (i) shall summarize 
2
any substantive proposal made by any 
3
party to the negotiations, any significant 
4
controversies or differences of opinion dur-
5
ing the negotiations, and the resolution of 
6
any such controversy or difference of opin-
7
ion. 
8
(2) ESTABLISHMENT
OF
USER
FEE
PRO-
9
GRAM.—Effective on October 1, 2021, provided that 
10
the Secretary transmits the recommendations under 
11
paragraph (1)(E), the Secretary is authorized to col-
12
lect user fees relating to the submission of in vitro 
13
clinical test applications submitted under subchapter 
14
J of chapter V of the Federal Food, Drug, and Cos-
15
metic Act, as added by this Act. Fees under such 
16
program shall be assessed and collected only if the 
17
requirements under paragraph (4) are met. 
18
(3) AUDIT.— 
19
(A) IN GENERAL.—On the date that is 2 
20
years after first receiving a user fee applicable 
21
to submission of an in vitro clinical test applica-
22
tion submitted under subchapter J of chapter V 
23
of the Federal Food, Drug, and Cosmetic Act, 
24
as added by this Act, and on a biennial basis 
25
02:14 Jul 08, 2021
H4128
229 
•HR 4128 IH
thereafter until October 1, 2027, the Secretary 
1
shall perform an audit of the costs of reviewing 
2
such applications under such subchapter J. 
3
Such an audit shall compare the costs of re-
4
viewing such applications under such sub-
5
chapter J to the amount of the user fee applica-
6
ble to such applications. 
7
(B) ALTERATION OF USER FEE.—If the 
8
audit performed under subparagraph (A) indi-
9
cates that the user fees applicable to applica-
10
tions submitted under such subchapter J exceed 
11
30 percent of the costs of reviewing such appli-
12
cations, the Secretary shall alter the user fees 
13
applicable to applications submitted under such 
14
subchapter J such that the user fees do not ex-
15
ceed such percentage. 
16
(C) ACCOUNTING STANDARDS.—The Sec-
17
retary shall perform an audit under subpara-
18
graph (A) in conformance with the accounting 
19
principles, standards, and requirements pre-
20
scribed by the Comptroller General of the 
21
United States under section 3511 of title 31, 
22
United States Code, to ensure the validity of 
23
any potential variability. 
24
02:14 Jul 08, 2021
H4128
230 
•HR 4128 IH
(4) CONDITIONS.—The user fee program de-
1
scribed in this subsection shall take effect only if the 
2
Food and Drug Administration issues draft guidance 
3
related to the review requirements for in vitro diag-
4
nostic tests that would be subject to premarket re-
5
view under section 587B of the Federal Food, Drug, 
6
and Cosmetic Act, as added by section 3, the review 
7
requirements for test categories eligible for tech-
8
nology certification under section 587D of such Act, 
9
as added by section 3, and the parameters for the 
10
test categories that would be exempt from any re-
11
view under subchapter J of chapter V of such Act. 
12
(5) USER FEE PROGRAM DEFINITIONS AND RE-
13
SOURCE REQUIREMENTS.— 
14
(A) IN GENERAL.—The term ‘‘process for 
15
the review of in vitro clinical test applications’’ 
16
means the following activities of the Secretary 
17
with respect to the review of premarket applica-
18
tions under section 587B of the Federal Food, 
19
Drug, and Cosmetic Act (as added by section 
20
3), technology certification applications under 
21
section 587D of such Act (as added by section 
22
3), and supplements for such applications: 
23
(i) The activities necessary for the re-
24
view of premarket applications, premarket 
25
02:14 Jul 08, 2021
H4128
231 
•HR 4128 IH
reports, and supplements to such applica-
1
tions. 
2
(ii) The issuance of action letters that 
3
allow the marketing of in vitro clinical 
4
tests or which set forth in detail the spe-
5
cific deficiencies in such applications, re-
6
ports, supplements, or submissions and, 
7
where appropriate, the actions necessary to 
8
place them in condition for approval. 
9
(iii) The inspection of manufacturing 
10
establishments and other facilities under-
11
taken as part of the Secretary’s review of 
12
pending premarket applications, technology 
13
certifications, and supplements. 
14
(iv) Monitoring of research conducted 
15
in connection with the review of such appli-
16
cations, supplements, and submissions. 
17
(v) Review of in vitro clinical test ap-
18
plications subject to section 351 of the 
19
Public Health Service Act (42 U.S.C. 
20
262), investigational new drug applications 
21
under section 505(i) of the Federal Food, 
22
Drug, and Cosmetic Act (21 U.S.C. 
23
355(i)), or investigational test exemptions 
24
under section 587A(m) of the Federal 
25
02:14 Jul 08, 2021
H4128
232 
•HR 4128 IH
Food, Drug, and Cosmetic Act (as added 
1
by section 3), and activities conducted in 
2
anticipation of the submission of such ap-
3
plications under section 505(i) of the Fed-
4
eral Food, Drug, and Cosmetic Act or in-
5
vestigational use under section 587R of the 
6
Federal Food, Drug, and Cosmetic Act (as 
7
added by section 3). 
8
(vi) The development of guidance, pol-
9
icy documents, or regulations to improve 
10
the process for the review of premarket ap-
11
plications, technology certification applica-
12
tions, and supplements. 
13
(vii) The development of voluntary 
14
test methods, consensus standards, or 
15
mandatory performance standards in con-
16
nection with the review of such applica-
17
tions, supplements, or submissions and re-
18
lated activities. 
19
(viii) The provision of technical assist-
20
ance to in vitro clinical test developers in 
21
connection with the submission of such ap-
22
plications, reports, supplements, or submis-
23
sions. 
24
02:14 Jul 08, 2021
H4128
233 
•HR 4128 IH
(ix) Any activity undertaken in con-
1
nection with the initial classification or re-
2
classification of an in vitro clinical test in 
3
connection with any requirement for ap-
4
proval of an in vitro clinical test. 
5
(x) Evaluation of postmarket studies 
6
required as a condition of an approval of 
7
a premarket application of an in vitro clin-
8
ical test. 
9
(xi) Compiling, developing, and re-
10
viewing information on relevant in vitro 
11
clinical tests to identify issues with the ap-
12
plicable standard for premarket applica-
13
tions, technology certification applications, 
14
and supplements. 
15
(B) RESOURCE REQUIREMENTS.—Fees col-
16
lected and assessed under this section shall be 
17
used for the process for the review of in vitro 
18
clinical test applications, as described in sub-
19
paragraph (A), and shall— 
20
(i) be subject to the limitation under 
21
section 738(g)(3) of the Federal Food, 
22
Drug, and Cosmetic Act (21 U.S.C. 
23
379j(g)(3)), in the same manner that fees 
24
collected 
and 
assessed 
under 
section 
25
02:14 Jul 08, 2021
H4128
234 
•HR 4128 IH
737(9)(C) 
of 
such 
Act 
(21 
U.S.C. 
1
379i(9)(C)) are subject to such limitation; 
2
(ii) include travel expenses for officers 
3
and employees of the Food and Drug Ad-
4
ministration only if the Secretary deter-
5
mines that such travel is directly related to 
6
an activity described in subparagraph (A); 
7
and 
8
(iii) not be allocated to purposes de-
9
scribed under section 722(a) of the Con-
10
solidated Appropriations Act, 2018 (Public 
11
Law 115–141). 
12
(c) REPORTS.— 
13
(1) PERFORMANCE REPORT.— 
14
(A) IN GENERAL.— 
15
(i) GENERAL
REQUIREMENTS.—Be-
16
ginning with fiscal year 2021, for each fis-
17
cal year for which fees are collected under 
18
this section, the Secretary shall prepare 
19
and submit to the Committee on Health, 
20
Education, Labor, and Pensions of the 
21
Senate and the Committee on Energy and 
22
Commerce of the House of Representatives 
23
annual reports concerning the progress of 
24
the Food and Drug Administration in 
25
02:14 Jul 08, 2021
H4128
235 
•HR 4128 IH
achieving the goals identified in the rec-
1
ommendations transmitted to Congress by 
2
the Secretary pursuant to subsection 
3
(b)(1)(E) during such fiscal year and the 
4
future plans of the Food and Drug Admin-
5
istration for meeting the goals. 
6
(ii) ADDITIONAL INFORMATION.—Be-
7
ginning with fiscal year 2021, the annual 
8
report under this subparagraph shall in-
9
clude the progress of the Food and Drug 
10
Administration in achieving the goals, and 
11
future plans for meeting the goals, includ-
12
ing— 
13
(I) the number of premarket ap-
14
plications filed under section 587B of 
15
the Federal Food, Drug, and Cos-
16
metic Act during the applicable fiscal 
17
year; 
18
(II) the number of technology 
19
certification 
applications 
submitted 
20
under section 587D of the Federal 
21
Food, Drug, and Cosmetic Act during 
22
the applicable fiscal year for each re-
23
view division; and 
24
02:14 Jul 08, 2021
H4128
236 
•HR 4128 IH
(III) the number of breakthrough 
1
designations under section 587C of 
2
the Federal Food, Drug, and Cos-
3
metic Act during the applicable fiscal 
4
year. 
5
(iii) REAL-TIME REPORTING.— 
6
(I) IN GENERAL.—Not later than 
7
30 calendar days after the end of the 
8
second quarter of fiscal year 2021, 
9
and not later than 30 calendar days 
10
after the end of each quarter of each 
11
fiscal year thereafter, the Secretary 
12
shall post the data described in sub-
13
clause (II) on the website of the Food 
14
and Drug Administration for such 
15
quarter and on a cumulative basis for 
16
such fiscal year, and may remove du-
17
plicative data from the annual report 
18
under this subparagraph. 
19
(II) DATA.—The Secretary shall 
20
post the following data in accordance 
21
with subclause (I): 
22
(aa) The number and titles 
23
of draft and final guidance on 
24
topics related to the process for 
25
02:14 Jul 08, 2021
H4128
237 
•HR 4128 IH
the review of in vitro clinical 
1
tests, and whether such guid-
2
ances were issued as required by 
3
statute or pursuant to the rec-
4
ommendations 
transmitted 
to 
5
Congress by the Secretary pursu-
6
ant to subsection (b)(1)(E). 
7
(bb) The number and titles 
8
of public meetings held on topics 
9
related to the process for the re-
10
view of in vitro clinical tests, and 
11
if such meetings were required by 
12
statute or pursuant to the rec-
13
ommendations 
transmitted 
to 
14
Congress by the Secretary pursu-
15
ant to subsection (b)(1)(E). 
16
(iv) RATIONALE FOR IVCT USER FEE 
17
PROGRAM CHANGES.—Beginning with fis-
18
cal year 2022, the Secretary shall include 
19
in the annual performance report under 
20
paragraph (1)— 
21
(I) data, analysis, and discussion 
22
of the changes in the number of full- 
23
time equivalents hired as agreed upon 
24
in the recommendations transmitted 
25
02:14 Jul 08, 2021
H4128
238 
•HR 4128 IH
to Congress by the Secretary pursuant 
1
to subsection (b)(1)(E) and the num-
2
ber of full-time equivalents funded by 
3
budget authority at the Food and 
4
Drug Administration by each division 
5
within the Center for Devices and Ra-
6
diological Health, the Center for Bio-
7
logics Evaluation and Research, the 
8
Office of Regulatory Affairs, and the 
9
Office of the Commissioner; 
10
(II) data, analysis, and discus-
11
sion of the changes in the fee revenue 
12
amounts and costs for the process for 
13
the review of in vitro clinical tests, in-
14
cluding identifying drivers of such 
15
changes; and 
16
(III) for each of the Center for 
17
Devices and Radiological Health, the 
18
Center for Biologics Evaluation and 
19
Research, the Office of Regulatory Af-
20
fairs, and the Office of the Commis-
21
sioner, the number of employees for 
22
whom time reporting is required and 
23
the number of employees for whom 
24
time reporting is not required. 
25
02:14 Jul 08, 2021
H4128
239 
•HR 4128 IH
(v) ANALYSIS.—For each fiscal year, 
1
the Secretary shall include in the report 
2
under clause (i) an analysis of the fol-
3
lowing: 
4
(I) The difference between the 
5
aggregate number of premarket appli-
6
cations filed under section 587B or 
7
section 587D of the Federal Food, 
8
Drug, and Cosmetic Act and the ag-
9
gregate number of major deficiency 
10
letters, not approvable letters, and de-
11
nials for such applications issued by 
12
the agency, accounting for— 
13
(aa) the number of applica-
14
tions filed under each of sections 
15
587B and 587D of the Federal 
16
Food, Drug, and Cosmetic Act 
17
during one fiscal year for which a 
18
decision is not scheduled to be 
19
made until the following fiscal 
20
year; and 
21
(bb) the aggregate number 
22
of applications under each of sec-
23
tions 587B and 587D of the 
24
Federal Food, Drug, and Cos-
25
02:14 Jul 08, 2021
H4128
240 
•HR 4128 IH
metic Act for each fiscal year 
1
that did not meet the goals as 
2
identified by the recommenda-
3
tions transmitted to Congress by 
4
the Secretary pursuant to sub-
5
section (b)(1)(E). 
6
(II) Relevant data to determine 
7
whether the Center for Devices and 
8
Radiological Health has met perform-
9
ance enhancement goals identified by 
10
the recommendations transmitted to 
11
Congress by the Secretary pursuant to 
12
subsection (b)(1)(E). 
13
(III) The most common causes 
14
and trends for external or other cir-
15
cumstances affecting the ability of the 
16
Food and Drug Administration to 
17
meet review time and performance en-
18
hancement goals identified by the rec-
19
ommendations transmitted to Con-
20
gress by the Secretary pursuant to 
21
subsection (b)(1)(E). 
22
(B) PUBLICATION.—With regard to infor-
23
mation to be reported by the Food and Drug 
24
Administration to industry on a quarterly and 
25
02:14 Jul 08, 2021
H4128
241 
•HR 4128 IH
annual basis pursuant to recommendations 
1
transmitted to Congress by the Secretary pur-
2
suant to subsection (b)(1)(E), the Secretary 
3
shall make such information publicly available 
4
on the website of the Food and Drug Adminis-
5
tration not later than 60 days after the end of 
6
each quarter or 120 days after the end of each 
7
fiscal year, respectively, to which such informa-
8
tion applies. 
9
(C) UPDATES.—The Secretary shall in-
10
clude in each report under subparagraph (A) 
11
information on all previous cohorts for which 
12
the Secretary has not given a complete response 
13
on all in vitro clinical test premarket applica-
14
tions and technology certification orders and 
15
supplements, premarket, and technology certifi-
16
cation notifications in the cohort. 
17
(2) CORRECTIVE ACTION REPORT.—Beginning 
18
with fiscal year 2022, for each fiscal year for which 
19
fees are collected under this section, the Secretary 
20
shall prepare and submit a corrective action report 
21
to the Committee on Health, Education, Labor, and 
22
Pensions and the Committee on Appropriations of 
23
the Senate and the Committee on Energy and Com-
24
merce and the Committee on Appropriations of the 
25
02:14 Jul 08, 2021
H4128
242 
•HR 4128 IH
House of Representatives. The report shall include 
1
the following information, as applicable: 
2
(A) GOALS MET.—For each fiscal year, if 
3
the Secretary determines, based on the analysis 
4
under paragraph (1)(A)(v), that each of the 
5
goals identified by the recommendations trans-
6
mitted to Congress by the Secretary pursuant 
7
to subsection (b)(1)(E) for the applicable fiscal 
8
year have been met, the corrective action report 
9
shall include recommendations on ways in which 
10
the Secretary can improve and streamline the in 
11
vitro clinical test premarket application and 
12
technology certification review process. 
13
(B) GOALS MISSED.—For each of the goals 
14
identified by the letters described in rec-
15
ommendations transmitted to Congress by the 
16
Secretary pursuant to subsection (b)(1)(E) for 
17
the applicable fiscal year that the Secretary de-
18
termines to not have been met, the corrective 
19
action report shall include— 
20
(i) a justification for such determina-
21
tion; 
22
(ii) a description of the types of cir-
23
cumstances, in the aggregate, under which 
24
applications or reports submitted under 
25
02:14 Jul 08, 2021
H4128
243 
•HR 4128 IH
sections 587B and 587D of the Federal 
1
Food, Drug, and Cosmetic Act missed the 
2
review goal times but were approved dur-
3
ing the first cycle review, as applicable; 
4
(iii) a summary and any trends with 
5
regard to the circumstances for which a re-
6
view goal was missed; and 
7
(iv) the performance enhancement 
8
goals that were not achieved during the 
9
previous fiscal year and a description of ef-
10
forts the Food and Drug Administration 
11
has put in place for the fiscal year in 
12
which the report is submitted to improve 
13
the ability of such agency to meet each 
14
such goal for the such fiscal year. 
15
(3) FISCAL
REPORT.—For fiscal years 2021 
16
and annually thereafter, not later than 120 days 
17
after the end of each fiscal year during which fees 
18
are collected under this subpart, the Secretary shall 
19
prepare and submit to the Committee on Health, 
20
Education, Labor, and Pensions of the Senate and 
21
the Committee on Energy and Commerce of the 
22
House of Representatives, a report on the implemen-
23
tation of the authority for such fees during such fis-
24
cal year and the use, by the Food and Drug Admin-
25
02:14 Jul 08, 2021
H4128
244 
•HR 4128 IH
istration, of the fees collected during such fiscal year 
1
for which the report is made. 
2
(A) CONTENTS.—Such report shall include 
3
expenditures delineated by budget authority and 
4
user fee dollars related to administrative ex-
5
penses and information technology infrastruc-
6
ture contracts and expenditures. 
7
(B) OPERATING
RESERVE.—Such report 
8
shall provide the amount of operating reserve 
9
balance available each year, and any planned al-
10
locations or obligations of such balance that is 
11
above 10 weeks of operating reserve for the pro-
12
gram. 
13
(4) 
PUBLIC
AVAILABILITY.—The 
Secretary 
14
shall make the reports required under paragraphs 
15
(1) through (3) available to the public on the website 
16
of the Food and Drug Administration. 
17
(5) ENHANCED COMMUNICATION.— 
18
(A) COMMUNICATIONS WITH CONGRESS.— 
19
Each fiscal year, as applicable and requested, 
20
representatives from the Centers with expertise 
21
in the review of in vitro clinical tests shall meet 
22
with representatives from the Committee on 
23
Health, Education, Labor, and Pensions of the 
24
Senate and the Committee on Energy and Com-
25
02:14 Jul 08, 2021
H4128
245 
•HR 4128 IH
merce of the House of Representatives to report 
1
on the contents described in the reports under 
2
this section. 
3
(B) PARTICIPATION
IN
CONGRESSIONAL 
4
HEARING.—Each fiscal year, as applicable and 
5
requested, representatives from the Food and 
6
Drug Administration shall participate in a pub-
7
lic hearing before the Committee on Health, 
8
Education, Labor, and Pensions of the Senate 
9
and the Committee on Energy and Commerce 
10
of the House of Representatives, to report on 
11
the contents described in the reports under this 
12
section. Such hearing shall occur not later than 
13
120 days after the end of each fiscal year for 
14
which fees are collected under this section. 
15
Æ 
02:14 Jul 08, 2021
H4128
